00012807842024Q312-31falsehttp://www.htgc.com/20240930#OneMonthSecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember0200.3333.3333.3333171xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:GBPhtgc:Firmhtgc:equityInvestmenthtgc:creditFacilityhtgc:votePerShare00012807842024-01-012024-09-300001280784htgc:CommonStockParValueZeroPointZeroZeroOnePerShareMember2024-01-012024-09-300001280784htgc:SixPointTwoFiveNotesDueTwoThousandThirtyThreeMember2024-01-012024-09-3000012807842024-10-240001280784us-gaap:InvestmentUnaffiliatedIssuerMember2024-09-300001280784us-gaap:InvestmentUnaffiliatedIssuerMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2023-12-3100012807842024-09-3000012807842023-12-310001280784us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-09-300001280784us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001280784us-gaap:InvestmentUnaffiliatedIssuerMember2024-07-012024-09-300001280784us-gaap:InvestmentUnaffiliatedIssuerMember2023-07-012023-09-300001280784us-gaap:InvestmentUnaffiliatedIssuerMember2024-01-012024-09-300001280784us-gaap:InvestmentUnaffiliatedIssuerMember2023-01-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2024-07-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2023-07-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2024-01-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2023-01-012023-09-3000012807842024-07-012024-09-3000012807842023-07-012023-09-3000012807842023-01-012023-09-300001280784us-gaap:CommonStockMember2024-06-300001280784htgc:CapitalInExcessOfParValueMember2024-06-300001280784htgc:DistributableEarningsLossMember2024-06-3000012807842024-06-300001280784htgc:DistributableEarningsLossMember2024-07-012024-09-300001280784htgc:CapitalInExcessOfParValueMember2024-07-012024-09-300001280784us-gaap:CommonStockMember2024-07-012024-09-300001280784us-gaap:CommonStockMember2024-09-300001280784htgc:CapitalInExcessOfParValueMember2024-09-300001280784htgc:DistributableEarningsLossMember2024-09-300001280784us-gaap:CommonStockMember2023-12-310001280784htgc:CapitalInExcessOfParValueMember2023-12-310001280784htgc:DistributableEarningsLossMember2023-12-310001280784htgc:DistributableEarningsLossMember2024-01-012024-09-300001280784us-gaap:CommonStockMember2024-01-012024-09-300001280784htgc:CapitalInExcessOfParValueMember2024-01-012024-09-300001280784us-gaap:CommonStockMember2023-06-300001280784htgc:CapitalInExcessOfParValueMember2023-06-300001280784htgc:DistributableEarningsLossMember2023-06-3000012807842023-06-300001280784htgc:DistributableEarningsLossMember2023-07-012023-09-300001280784us-gaap:CommonStockMember2023-07-012023-09-300001280784htgc:CapitalInExcessOfParValueMember2023-07-012023-09-300001280784us-gaap:CommonStockMember2023-09-300001280784htgc:CapitalInExcessOfParValueMember2023-09-300001280784htgc:DistributableEarningsLossMember2023-09-3000012807842023-09-300001280784us-gaap:CommonStockMember2022-12-310001280784htgc:CapitalInExcessOfParValueMember2022-12-310001280784htgc:DistributableEarningsLossMember2022-12-3100012807842022-12-310001280784htgc:DistributableEarningsLossMember2023-01-012023-09-300001280784us-gaap:CommonStockMember2023-01-012023-09-300001280784htgc:CapitalInExcessOfParValueMember2023-01-012023-09-300001280784htgc:AdvisorFundsMember2024-01-012024-09-300001280784Debt Investments Biotechnology Tools and PathAI, Inc., Senior Secured, Maturity Date January 2027, Prime + 2.15%, Floor rate 9.15%, 7.85% Exit Fee2024-09-300001280784Debt Investments Biotechnology Tools (1.81%)2024-09-300001280784Debt Investments Communications & Networking and Aryaka Networks, Inc. Senior Secured, Maturity Date July 2026, Prime + 3.25%, Floor rate 6.75%, PIK Interest 1.05%, 3.55% Exit Fee2024-09-300001280784Debt Investments Communications & Networking (1.42%)2024-09-300001280784Debt Investments Consumer & Business Services and Altumint, Inc. Senior Secured, Maturity Date December 2027, Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services and Carwow LTD Senior Secured, Maturity Date December 2027, Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services and Houzz, Inc. Convertible Debt, Maturity Date May 2028, PIK Interest 10.00%2024-09-300001280784Debt Investments Consumer & Business Services and Jobandtalent USA, Inc. Senior Secured, Maturity Date August 2025, 1-month SOFR + 8.86, Floor rate 9.75%, 2.87% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services and Plentific Ltd. Senior Secured, Maturity Date October 2026, Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services and Provi, Senior Secured, Maturity Date December 2026, Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services and Riviera Partners LLC. Senior Secured, Maturity Date April 2027, 1-month SOFR + 8.27%, Floor rate 9.27%2024-09-300001280784Debt Investments Consumer & Business Services and RVShare, LLC, Senior Secured, Maturity Date December 2026, 3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%2024-09-300001280784Debt Investments Consumer & Business Services and SeatGeek, Inc., Senior Secured, Maturity Date May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services and SeatGeek, Inc. Senior Secured, Maturity Date July 2026, Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services and Total SeatGeek, Inc.2024-09-300001280784Debt Investments Consumer & Business Services and Skyword, Inc. Senior Secured, Maturity Date November 2026, Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services and Tectura Corporation, Senior Secured, Maturity Date January 2027, FIXED 8.25%2024-09-300001280784Debt Investments Consumer & Business Services and Thumbtack, Inc. Senior Secured, Maturity Date March 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.50%2024-09-300001280784Debt Investments Consumer & Business Services and Veem, Inc. Senior Secured, Maturity Date March 2025, Prime + 4.00%, Floor rate 7.25%, PIK Interest 1.25%, 4.50% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services and Veem, Inc. Senior Secured, Maturity Date March 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.50%, 4.50% Exit Fee2024-09-300001280784Debt Investments Consumer & Business Services, and Total Veem, Inc.2024-09-300001280784Debt Investments Consumer & Business Services and Worldremit Group Limited, Senior Secured, Maturity Date February 2026, 3-month SOFR + 9.40%, Floor rate 10.25%2024-09-300001280784Debt Investments Consumer & Business Services and Worldremit Group Limited, Senior Secured, Maturity Date February 2026, 1-month SOFR + 9.35%, Floor rate 10.25%2024-09-300001280784Debt Investments Consumer & Business Services and Total Worldremit Group Limited2024-09-300001280784Debt Investments Consumer & Business Services (18.52%)2024-09-300001280784Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Unsecured, Maturity Date September 2026, FIXED 3.45%, PIK Interest 8.05%2024-09-300001280784Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Unsecured, Maturity Date September 2026, Fixed 11.95%2024-09-300001280784Debt Investments Diversified Financial Services and Total Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC)2024-09-300001280784Debt Investments Diversified Financial Services and Hercules Adviser LLC, Unsecured, Maturity Date June 2025, FIXED 5.00%2024-09-300001280784Debt Investments Diversified Financial Services and Next Insurance, Inc, Senior Secured, Maturity Date February 2028, Prime -(1.50%), Floor rate 4.75%, PIK Interest 5.50%2024-09-300001280784Debt Investments Diversified Financial Services (3.17%)2024-09-300001280784Debt Investments Drug Discovery & Development and Adaptimmune Therapeutics plc. Senior Secured, Maturity Date June 2029, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.00%, 5.85% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Akero Therapeutics, Inc. Senior Secured, Maturity Date March 2027, Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Aldeyra Therapeutics, Inc. Senior Secured, Maturity Date April 2026, Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and AmplifyBio, LLC, Senior Secured, Maturity Date January 2027, Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Arcus Biosciences, Inc., Senior Secured Maturity Date September 2029, Prime + 1.95%, Floor rate 10.45%, 7.75% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and ATAI Life Sciences N.V. Senior Secured, Maturity Date August 2026, Prime + 4.30%, Floor rate 9.05%, 6.95% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Axsome Therapeutics, Inc. Senior Secured, Maturity Date January 2028 Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and bluebird bio, Inc. Senior Secured, Maturity Date April 2029, Prime + 1.45%, Floor rate 9.95%, PIK Interest 2.45%, 6.45% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Braeburn, Inc., Senior Secured, Maturity Date October 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and COMPASS Pathways plc Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Corium, Inc. Senior Secured, Maturity Date September 2026, Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Curevo, Inc. Senior Secured, Maturity Date June 2027, Prime + 1.70%, Floor rate 9.70%, 6.95% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Eloxx Pharmaceuticals, Inc. Senior Secured, Maturity Date April 2025, Prime + 6.25%, Floor rate 9.50%, 4.00% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and enGene, Inc. Senior Secured, Maturity Date January 2028, Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Geron Corporation, Senior Secured, Maturity Date October 2025, Prime + 4.50%, Floor rate 9.00%, 6.55% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Gritstone Bio, Inc. Senior Secured, Maturity Date July 2027, Prime + 3.15%, Floor rate 7.15%, Cap rate 8.65%, PIK Interest 2.00%, 5.75% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Heron Therapeutics, Inc.. Senior Secured, Maturity Date February 2026, Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Hibercell, Inc. Senior Secured, Maturity Date May 2025, Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Kura Oncology, Inc. Senior Secured, Maturity Date November 2027, Prime + 2.40%, Floor rate 8.65%, 15.13% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Locus Biosciences, Inc. Senior Secured, Maturity Date July 2025, Prime + 6.10%, Floor rate 9.35%, 4.95% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc. Senior Secured, Maturity Date May 2027, Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and NorthSea Therapeutics, Convertible Debt, Maturity Date December 2025, FIXED 6.00%2024-09-300001280784Debt Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc. Senior Secured, Maturity Date December 2027, Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 6.59% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Replimune Group, Inc. Senior Secured, Maturity Date October 2027, Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and SynOx Therapeutics Limited Senior Secured, Maturity Date May 2027, Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and uniQure B.V. Senior Secured, Maturity Date January 2027, Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and Viridian Therapeutics, Inc. Senior Secured, Maturity Date October 2026, Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc. Senior Secured, Maturity Date July 2027, Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee2024-09-300001280784Debt Investments Drug Discovery & Development (57.90%)2024-09-300001280784Debt Investments Electronics & Computer Hardware and Locus Robotics Corp. Senior Secured, Maturity Date June 2026, Prime + 4.50%, Floor rate 8.00%, 4.00% Exit Fee2024-09-300001280784Debt Investments Electronics & Computer Hardware and Shield AI, Inc. Senior Secured, Maturity Date February 2029, Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee2024-09-300001280784Debt Investments Electronics & Computer Hardware (5.13%)2024-09-300001280784Debt Investments Healthcare Services, Other and Blue Sprig Pediatrics, Inc. Senior Secured, Maturity Date November 2026, 1-month SOFR + 5.11%, Floor rate 6.00%, PIK Interest 4.45%2024-09-300001280784Debt Investments Healthcare Services, Other and Carbon Health Technologies, Inc. Senior Secured, Maturity Date June 2026, Prime - (1.50%), Floor rate 7.00%, PIK Interest 7.00%, 5.64% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other and Carbon Health Technologies, Inc. Convertible Debt, Maturity Date December 2025, FIXED 12.00%2024-09-300001280784Debt Investments Healthcare Services, Other and Total Carbon Health Technologies, Inc.2024-09-300001280784Debt Investments Healthcare Services, Other and Curana Health Holdings, LLC Senior Secured, Maturity Date January 2028, Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other and Equality Health, LLC, Senior Secured, Maturity Date February 2026, Prime + 6.25%, Floor rate 9.50%, PIK Interest 1.55%2024-09-300001280784Debt Investments Healthcare Services, Other and Main Street Rural, Inc. Senior Secured, Maturity Date July 2027, Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other and Marathon Health, LLC Senior Secured, Maturity Date February 2029, Prime - (0.90%), Floor rate 7.10%, PIK Interest 4.00%, 3.00% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other and Modern Life, Inc. Senior Secured, Maturity Date February 2027, Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other and NeueHealth, Inc. Senior Secured, Maturity Date June 2028, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other and Recover Together, Inc. Senior Secured, Maturity Date July 2027 Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other and Strive Health Holdings, LLC Senior Secured, Maturity Date September 2027, Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other and Vida Health, Inc. Senior Secured, Maturity Date July 2026, FIXED 8.50%, PIK Interest 2.05%, 4.95% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other and WellBe Senior Medical, LLC Senior Secured, Maturity Date May 2029, Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee2024-09-300001280784Debt Investments Healthcare Services, Other (30.59%)2024-09-300001280784Debt Investments Information Services and Checkr Group, Inc. Senior Secured, Maturity Date August 2028, Prime + 1.45%, Floor rate 8.00%, PIK Interest 2.00%, 2.75% Exit Fee2024-09-300001280784Debt Investments Information Services and Saama Technologies, LLC Senior Secured, Maturity Date July 2027, Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee2024-09-300001280784Debt Investments Information Services and Signal Media Limited, Senior Secured, Maturity Date June 2025, Prime + 5.50%, Floor rate 9.00%, Cap rate 12.00%, 3.45% Exit Fee2024-09-300001280784Debt Investments Information Services (4.18%)2024-09-300001280784Debt Investments Medical Devices & Equipment and Senseonics Holdings, Inc. Senior Secured, Maturity Date September 2027 Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee2024-09-300001280784Debt Investments Medical Devices & Equipment and Sight Sciences, Inc. Senior Secured, Maturity Date July 2028 Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee2024-09-300001280784Debt Investments Medical Devices & Equipment (2.99%) 2024-09-300001280784Debt Investments Software and 3GTMS, LLC, Senior Secured, Maturity Date February 2025, 3-month SOFR + 10.40%, Floor rate 11.30%2024-09-300001280784Debt Investments Software and 3GMTS, LLC, Senior Secured, Maturity Date February 2025, 3-month SOFR + 7.25%, Floor rate 8.15%2024-09-300001280784Debt Investments Software and Total 3GTMS, LLC2024-09-300001280784Debt Investments Software and Alchemer LLC, Senior Secured, Maturity Date May 2028, 1-month SOFR + 8.14%, Floor rate 9.14%2024-09-300001280784Debt Investments Software and Allvue Systems, LLC, Senior Secured, Maturity Date September 2029, 3-month SOFR + 7.25%, Floor rate 8.25%2024-09-300001280784Debt Investments Software and AlphaSense, Inc. Senior Secured, Maturity Date June 2029, 1-month SOFR + 6.25%, Floor rate 8.25%2024-09-300001280784Debt Investments Software and Annex Cloud, Senior Secured, Maturity Date February 2027, 1-month BSBY + 10.00%, Floor rate 11.00%2024-09-300001280784Debt Investments Software and Armis, Inc., Senior Secured, Maturity Date March 2028, Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee2024-09-300001280784Debt Investments Software and Armis, Inc., Senior Secured, Maturity Date March 2028, Prime + 1.25%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee2024-09-300001280784Debt Investments Software and Total Armis, Inc.2024-09-300001280784Debt Investments Software and Automation Anywhere, Inc. Senior Secured, Maturity Date September 2027, Prime + 4.25%, Floor rate 9.00%, 4.50% Exit Fee2024-09-300001280784Debt Investments Software and Babel Street, Senior Secured, Maturity Date December 2027, 3-month SOFR + 8.01%, Floor rate 9.01%2024-09-300001280784Debt Investments Software and Behavox Limited, Senior Secured, Maturity Date September 2027, Prime - (0.55%), Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee2024-09-300001280784Debt Investments Software and Brain Corporation, Senior Secured, Maturity Date September 2028, Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee2024-09-300001280784Debt Investments Software and Catchpoint Systems, Inc., Senior Secured, Maturity Date November 2025, 1-month SOFR + 9.41%, Floor rate 11.81%2024-09-300001280784Debt Investments Software and Ceros, Inc., Senior Secured, Maturity Date September 2026, 3-month SOFR+ 8.99%, Floor rate 9.89%2024-09-300001280784Debt Investments Software and Constructor io Corporation, Senior Secured, Maturity Date July 2027, 1-month SOFR + 8.44%, Floor rate 9.44%2024-09-300001280784Debt Investments Software and Convoy, Inc., Senior Secured, Maturity Date March 2026, Prime + 3.20%, Floor rate 6.45%, PIK Interest 1.95%, 4.55% Exit Fee2024-09-300001280784Debt Investments Software and Copper CRM, Inc, Senior Secured, Maturity Date March 2025, Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 4.50% Exit Fee2024-09-300001280784Debt Investments Software and Coronet Cyber Security Ltd., Senior Secured, Maturity Date October 2028, Prime - (2.95%), Floor rate 3.55%, PIK Interest 5.85%2024-09-300001280784Debt Investments Software and Cutover, Inc., Senior Secured, Maturity Date October 2025, Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee12024-09-300001280784Debt Investments Software and Cutover, Inc., Senior Secured, Maturity Date October 2025, Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee22024-09-300001280784Debt Investments Software and Total Cutover, Inc.2024-09-300001280784Debt Investments Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, Maturity Date August 2026, 6-month SOFR + 8.63%, Floor rate 9.38%, 0.58% Exit Fee2024-09-300001280784Debt Investments Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, Maturity Date August 2026, 6-month SOFR + 12.36%, Floor rate 13.11%, 0.58% Exit Fee2024-09-300001280784Debt Investments Software and Total Cybermaxx Intermediate Holdings, Inc.2024-09-300001280784Debt Investments Software and Dashlane, Inc., Senior Secured, Maturity Date December 2027, Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee2024-09-300001280784Debt Investments Software and Dispatch Technologies, Inc., Senior Secured, Maturity Date April 2028, 3-month SOFR + 8.01%, Floor rate 8.76%2024-09-300001280784Debt Investments Software and Dragos, Inc., Senior Secured, Maturity Date July 2027, Prime + 2.00%, Floor rate 8.75%, PIK Interest 2.00%, 1.00% Exit Fee2024-09-300001280784Debt Investments Software and DroneDeploy, Inc., Senior Secured, Maturity Date July 2026, Prime + 4.50%, Floor rate 8.75%, 4.00% Exit Fee2024-09-300001280784Debt Investments Software and Earnix, Inc., Senior Secured, Maturity Date June 2029, Prime - (1.15%), Floor rate 5.35%, PIK Interest 4.45%2024-09-300001280784Debt Investments Software and Elation Health, Inc., Senior Secured, Maturity Date March 2026, Prime + 4.25%, Floor rate 9.00%, PIK Interest 1.95%, 3.95% Exit Fee2024-09-300001280784Debt Investments Software and Flight Schedule Pro, LLC, Senior Secured, Maturity Date October 2027, 1-month SOFR + 7.80%, Floor rate 8.70%2024-09-300001280784Debt Investments Software and Fortified Health Security, Senior Secured, Maturity Date December 2027, 1-month SOFR + 7.64%, Floor rate 8.54%2024-09-300001280784Debt Investments Software and Harness, Inc., Senior Secured, Maturity Date March 2029, Prime - (2.25%), Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee2024-09-300001280784Debt Investments Software and iGrafx, LLC, Senior Secured, Maturity Date May 2027, 1-month SOFR + 8.61%, Floor rate 9.51%, 0.47% Exit Fee2024-09-300001280784Debt Investments Software and Ikon Science Limited, Senior Secured, Maturity Date October 2024, 3-month SOFR + 9.26%, Floor rate 10.00%2024-09-300001280784Debt Investments Software and Khoros (p.k.a Lithium Technologies), Senior Secured, Maturity Date January 2025, PIK 3-month SOFR + 4.50%, Floor rate 5.50%2024-09-300001280784Debt Investments Software and Leapwork ApS., Senior Secured, Maturity Date February 2026, Prime + 0.25%, Floor rate 7.00%, PIK Interest 1.95%, 2.70% Exit Fee2024-09-300001280784Debt Investments Software and LinenMaster, LLC., Senior Secured, Maturity Date August 2028 1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%2024-09-300001280784Debt Investments Software and Loftware, Inc., Senior Secured, Maturity Date March 2028, 3-month SOFR + 7.88%, Floor rate 8.88%2024-09-300001280784Debt Investments Software and LogicSource, Senior Secured, Maturity Date July 2027, 1-month SOFR + 8.93%, Floor rate 9.93%2024-09-300001280784Debt Investments Software and LogRhythm, Inc., Senior Secured, Maturity Date July 2029, 3-month SOFR + 7.50%, Floor rate 8.50%2024-09-300001280784Debt Investments Software and Marigold Group, Inc. (p.k.a. Campaign Monitor Limited), Senior Secured, Maturity Date November 2026, PIK Interest 6-month SOFR + 10.55%, Floor rate 11.55%2024-09-300001280784Debt Investments Software and Mobile Solutions Services, Senior Secured, Maturity Date December 2025, 6-month SOFR + 9.31%, Floor rate 10.06%2024-09-300001280784Debt Investments Software and New Relic, Inc., Senior Secured, Maturity Date November 2030, 3-month SOFR + 6.75%, Floor rate 7.75%2024-09-300001280784Debt Investments Software and Omeda Holdings, LLC, Senior Secured, Maturity Date July 2027, 3-month SOFR + 8.05%, Floor rate 9.05%2024-09-300001280784Debt Investments Software and Pindrop Security, Inc., Senior Secured, Maturity Date June 2029, Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee2024-09-300001280784Debt Investments Software and Reveleer, Senior Secured, Maturity Date February 2027, Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee2024-09-300001280784Debt Investments Software and Semperis Technologies Inc., Senior Secured, Maturity Date April 2028, Prime - (1.75%), Floor rate 6.75%, PIK Interest 3.25%2024-09-300001280784Debt Investments Software and ShadowDragon, LLC, Senior Secured, Maturity Date December 2026, 3-month SOFR + 8.92%, Floor rate 9.82%2024-09-300001280784Debt Investments Software and Simon Data, Inc., Senior Secured, Maturity Date March 2027, Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.95% Exit Fee2024-09-300001280784Debt Investments Software and Sisense Ltd., Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee2024-09-300001280784Debt Investments Software and Streamline Healthcare Solutions, Senior Secured, Maturity Date March 2028, 3-month SOFR + 7.25%, Floor rate 8.25%2024-09-300001280784Debt Investments Software and Sumo Logic, Inc., Senior Secured, Maturity Date May 2030, 3-month SOFR + 6.50%, Floor rate 7.50%2024-09-300001280784Debt Investments Software and Suzy, Inc.., Senior Secured, Maturity Date August 2027, Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee2024-09-300001280784Debt Investments Software and ThreatConnect, Inc., Senior Secured, Maturity Date May 2026, 3-month SOFR + 9.15%, Floor rate 10.00%2024-09-300001280784Debt Investments Software and Tipalti Solutions Ltd., Senior Secured, Maturity Date April 2027, Prime + 0.45%, Floor rate 7.95%, PIK Interest 2.00%, 3.75% Exit Fee2024-09-300001280784Debt Investments Software and Zappi, Inc., Senior Secured, Maturity Date December 2027, 3-month SOFR + 8.03%, Floor rate 9.03%2024-09-300001280784Debt Investments Software and Zimperium, Inc., Senior Secured, Maturity Date May 2027, 3-month SOFR + 8.31%, Floor rate 9.31%2024-09-300001280784Debt Investments Software (53.06%)2024-09-300001280784Debt Investments Space Technologies and Voyager Space Holdings, Inc., Senior Secured, Maturity Date July 2028, Prime + 1.25%, Floor rate 9.75%, PIK Interest 2.50%, 5.50% Exit Fee2024-09-300001280784Debt Investments Space Technologies (2.42%)2024-09-300001280784Debt Investments Sustainable and Renewable Technology and Ampion, PBC, Senior Secured, Maturity Date May 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 3.95% Exit Fee2024-09-300001280784Debt Investments Sustainable and Renewable Technology and Electric Hydrogen Co., Senior Secured, May 2028, Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.89% Exit Fee2024-09-300001280784Debt Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Senior Secured, Maturity Date June 2027, FIXED 10.00%2024-09-300001280784Debt Investments Sustainable and Renewable Technology (1.35%)2024-09-300001280784Debt Investments (182.56%)2024-09-300001280784Equity Investments Biotechnology Tools and Alamar Biosciences, Inc., Equity, Acquisition Date 2/21/2024, Series Preferred Series C2024-01-012024-09-300001280784Equity Investments Biotechnology Tools and Alamar Biosciences, Inc., Equity, Acquisition Date 2/21/2024, Series Preferred Series C2024-09-300001280784Equity Investments Biotechnology Tools (0.08%)2024-09-300001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2024-01-012024-09-300001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2024-09-300001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 7/16/2013, Series Preferred Series B2024-01-012024-09-300001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 7/16/2013, Series Preferred Series B2024-09-300001280784Equity Investments Consumer & Business Products and Total Fabletics, Inc.2024-09-300001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock2024-01-012024-09-300001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock2024-09-300001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units2024-01-012024-09-300001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units2024-09-300001280784Equity Investments Consumer & Business Products (0.04%)2024-09-300001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42024-09-300001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2024-09-300001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2024-09-300001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2024-09-300001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-12024-01-012024-09-300001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-12024-09-300001280784Equity Investments Consumer & Business Services and Total OfferUp, Inc.2024-09-300001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2024-09-300001280784Equity Investments Consumer & Business Services and Reischling Press, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Reischling Press, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2024-09-300001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2024-09-300001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2024-09-300001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2024-09-300001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2024-09-300001280784Equity Investments Consumer & Business Services and Total Tectura Corporation2024-09-300001280784Equity Investments Consumer & Business Services and Worldremit Group Limited, Equity, Acquisition Date 6/24/2024, Series Preferred Series X2024-01-012024-09-300001280784Equity Investments Consumer & Business Services and Worldremit Group Limited, Equity, Acquisition Date 6/24/2024, Series Preferred Series X2024-09-300001280784Equity Investments Consumer & Business Services (0.39%)2024-09-300001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Equity, Acquisition Date 3/1/2018, Series Member Units2024-01-012024-09-300001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Equity, Acquisition Date 3/1/2018, Series Member Units2024-09-300001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2024-01-012024-09-300001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2024-09-300001280784Equity Investments Diversified Financial Services and Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22024-01-012024-09-300001280784Equity Investments Diversified Financial Services and Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22024-09-300001280784Equity Investments Diversified Financial Services (2.89%)2024-09-300001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2024-09-300001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2024-01-012024-09-300001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2024-09-300001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2024-09-300001280784Equity Investments Drug Delivery and Talphera, Inc, Equity, Acquisition Date 12/10/2018, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Delivery and Talphera, Inc, Equity, Acquisition Date 12/10/2018, Series Common Stock2024-09-300001280784Equity Investments Drug Delivery (0.00%)2024-09-300001280784Equity Investments Drug Discovery & Development and Akero Therapeutics, Inc., Equity, Acquisition Date 3/8/2024, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Akero Therapeutics, Inc., Equity, Acquisition Date 3/8/2024, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc., Equity, Acquisition Date 5/9/2022, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc., Equity, Acquisition Date 5/9/2022, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/5/2020, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/5/2020, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Cyclo Therapeutics, Inc., Equity, Acquisition Date 4/6/2021, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Cyclo Therapeutics, Inc., Equity, Acquisition Date 4/6/2021, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Gritstone Bio, Inc., Equity, Acquisition Date 10/26/2022, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Gritstone Bio, Inc., Equity, Acquisition Date 10/26/2022, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2024-09-300001280784Equity Investments Drug Discovery & Development and HilleVax, Inc, Equity, Acquisition Date 5/3/2022, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and HilleVax, Inc, Equity, Acquisition Date 5/3/2022, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Equity, Acquisition Date 9/29/2023, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Equity, Acquisition Date 9/29/2023, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2024-09-300001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Tarsus Pharmaceuticals, Inc., Equity, Acquisition Date 5/5/2022, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Tarsus Pharmaceuticals, Inc., Equity, Acquisition Date 5/5/2022, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2024-09-300001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2024-09-300001280784Equity Investments Drug Discovery & Development, Total Valo Health LLC2024-09-300001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2024-09-300001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2024-01-012024-09-300001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2024-09-300001280784Equity Investments Drug Discovery & Development (2.03%)2024-09-300001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2024-01-012024-09-300001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2024-09-300001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2024-01-012024-09-300001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2024-09-300001280784Equity Investments Electronics & Computer Hardware (0.05%)2024-09-300001280784Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock2024-01-012024-09-300001280784Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock2024-09-300001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C2024-01-012024-09-300001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C2024-09-300001280784Equity Investments Healthcare Services, Other and Click Therapeutics, Inc., Equity, Acquisition Date 5/20/2024, Series Common Stock2024-01-012024-09-300001280784Equity Investments Healthcare Services, Other and Click Therapeutics, Inc., Equity, Acquisition Date 5/20/2024, Series Common Stock2024-09-300001280784Equity Investments Healthcare Services, Other and Curana Health Holdings, LLC, Equity, Acquisition Date 5/13/2024, Series Common Units2024-01-012024-09-300001280784Equity Investments Healthcare Services, Other and Curana Health Holdings, LLC, Equity, Acquisition Date 5/13/2024, Series Common Units2024-09-300001280784Equity Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Equity, Acquisition Date 6/10/2024, Series Common Units2024-01-012024-09-300001280784Equity Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Equity, Acquisition Date 6/10/2024, Series Common Units2024-09-300001280784Equity Investments Healthcare Services, Other (0.36%)2024-09-300001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2024-01-012024-09-300001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2024-09-300001280784Equity Investments Information Services (0.21%)2024-09-300001280784Equity Investments Manufacturing Technology and Xometry, Inc., Equity, Acquisition Date 5/9/2018, Series Common Stock2024-01-012024-09-300001280784Equity Investments Manufacturing Technology and Xometry, Inc., Equity, Acquisition Date 5/9/2018, Series Common Stock2024-09-300001280784Equity Investments Manufacturing Technology (0.05%) 2024-09-300001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2024-01-012024-09-300001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2024-09-300001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22024-01-012024-09-300001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22024-09-300001280784Equity Investments Medical Devices & Equipment, Total Coronado Aesthetics, LLC2024-09-300001280784Equity Investments Medical Devices & Equipment (0.02%)2024-09-300001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2024-01-012024-09-300001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2024-09-300001280784Equity Investments Semiconductors (0.01%)2024-09-300001280784Equity Investments Software and 3GTMS, LLC, Equity, Acquisition Date 8/9/2021, Series Common Stock2024-01-012024-09-300001280784Equity Investments Software and 3GTMS, LLC, Equity, Acquisition Date 8/9/2021, Series Common Stock2024-09-300001280784Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note2024-01-012024-09-300001280784Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note2024-09-300001280784Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-32024-01-012024-09-300001280784Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-32024-09-300001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2024-01-012024-09-300001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2024-09-300001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2024-01-012024-09-300001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2024-09-300001280784Equity Investments Software, Total Contentful Global, Inc.2024-09-300001280784Equity Investments Software and DNAnexus, Inc, Equity, Acquisition Date 3/21/2014, Series Preferred Series C2024-01-012024-09-300001280784Equity Investments Software and DNAnexus, Inc, Equity, Acquisition Date 3/21/2014, Series Preferred Series C2024-09-300001280784Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2024-01-012024-09-300001280784Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2024-09-300001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22024-01-012024-09-300001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22024-09-300001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32024-01-012024-09-300001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32024-09-300001280784Equity Investments Software, Total Druva Holdings, Inc.2024-09-300001280784Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock2024-01-012024-09-300001280784Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock2024-09-300001280784Equity Investments Software and Leapwork ApS., Equity, Acquisition Date 8/25/2023, Series Preferred Series B22024-01-012024-09-300001280784Equity Investments Software and Leapwork ApS., Equity, Acquisition Date 8/25/2023, Series Preferred Series B22024-09-300001280784Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2024-01-012024-09-300001280784Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2024-09-300001280784Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock2024-01-012024-09-300001280784Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock2024-09-300001280784Equity Investments Software and Palantir Technologies, Equity, Acquisition Date 9/23/2020, Series Common Stock2024-01-012024-09-300001280784Equity Investments Software and Palantir Technologies, Equity, Acquisition Date 9/23/2020, Series Common Stock2024-09-300001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E2024-01-012024-09-300001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E2024-09-300001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F2024-01-012024-09-300001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F2024-09-300001280784Equity Investments Software, Total SingleStore, Inc.2024-09-300001280784Equity Investments Software and Sirion Labs, Inc., Equity, Acquisition Date 6/30/2024, Series Preferred Series F12024-01-012024-09-300001280784Equity Investments Software and Sirion Labs, Inc., Equity, Acquisition Date 6/30/2024, Series Preferred Series F12024-09-300001280784Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Preferred Series E2024-01-012024-09-300001280784Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Preferred Series E2024-09-300001280784Equity Investments Software (1.40%)2024-09-300001280784Equity Investments Space Technologies and Planet Labs, Inc., Equity, Acquisition Date 6/21/2019, Series Common Stock2024-01-012024-09-300001280784Equity Investments Space Technologies and Planet Labs, Inc., Equity, Acquisition Date 6/21/2019, Series Common Stock2024-09-300001280784Equity Investments Space Technologies (0.07%) 2024-09-300001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12024-01-012024-09-300001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12024-09-300001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2024-01-012024-09-300001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2024-09-300001280784Equity Investments Sustainable and Renewable Technology and NantEnergy, LLC, Equity, Acquisition Date 8/31/2013, Series Common Units2024-01-012024-09-300001280784Equity Investments Sustainable and Renewable Technology and NantEnergy, LLC, Equity, Acquisition Date 8/31/2013, Series Common Units2024-09-300001280784Equity Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Equity, Acquisition Date 12/10/2020, Series Common Stock2024-01-012024-09-300001280784Equity Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Equity, Acquisition Date 12/10/2020, Series Common Stock2024-09-300001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2024-01-012024-09-300001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2024-09-300001280784Equity Investments Sustainable and Renewable Technology (0.13%)2024-09-300001280784Equity Investments (7.72%)2024-09-300001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series C2024-01-012024-09-300001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series C2024-09-300001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2024-09-300001280784Warrant Investments and Biotechnology Tools (0.01%)2024-09-300001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2024-09-300001280784Warrant Investments and Communications & Networking (0.00%)2024-09-300001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2024-09-300001280784Warrant Investments and Consumer & Business Products (0.03%)2024-09-300001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 2/13/2024, Series Preferred Series D-42024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 2/13/2024, Series Preferred Series D-42024-09-300001280784Warrant Investments and Consumer & Business Services , Total Carwow LTD2024-09-300001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2024-09-300001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary Shares2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary Shares2024-09-300001280784Warrant Investments and Consumer & Business Services and Provi, Warrant, Acquisition Date 12/22/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Provi, Warrant, Acquisition Date 12/22/2022, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2024-09-300001280784Warrant Investments and Consumer & Business Services and Total Skyword, Inc.2024-09-300001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2024-09-300001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2024-09-300001280784Warrant Investments and Consumer & Business Services and Total Snagajob.com, Inc.2024-09-300001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2024-09-300001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2024-09-300001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2024-01-012024-09-300001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2024-09-300001280784Warrant Investments and Consumer & Business Services and Total Worldremit Group Limited2024-09-300001280784Warrant Investments and Consumer & Business Services (0.30%)2024-09-300001280784Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock2024-09-300001280784Warrant Investments and Diversified Financial Services (0.03%)2024-09-300001280784Warrant Investments and Drug Delivery and BioQ Pharma Incorporated, Warrant, Acquisition Date 10/27/2014, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Delivery and BioQ Pharma Incorporated, Warrant, Acquisition Date 10/27/2014, Series Common Stock2024-09-300001280784Warrant Investments and Drug Delivery (0.00%)2024-09-300001280784Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Series Common Stock2024-09-300001280784 Warrant Investments and Drug Discovery & Development and AmplifyBio, LLC, Warrant, Acquisition Date 12/27/2022, Series Class A Units2024-01-012024-09-300001280784 Warrant Investments and Drug Discovery & Development and AmplifyBio, LLC, Warrant, Acquisition Date 12/27/2022, Series Class A Units2024-09-300001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and blubird bio, Inc., Warrant, Acquisition Date 3/15/2024, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and blubird bio, Inc., Warrant, Acquisition Date 3/15/2024, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2024-09-300001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2024-09-300001280784Warrant Investments and Drug Discovery & Development and Curevo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Curevo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Dermavant Sciences Ltd., Warrant, Acquisition Date 5/31/2019, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Dermavant Sciences Ltd., Warrant, Acquisition Date 5/31/2019, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2023, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Fresh Tracks Therapeutics, Inc., Warrant, Acquisition Date 2/18/2016, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Fresh Tracks Therapeutics, Inc., Warrant, Acquisition Date 2/18/2016, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2024-09-300001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and SynOx Therapeutics Limited, Warrant, Acquisition Date 4/18/2024, Series Preferred Series B2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and SynOx Therapeutics Limited, Warrant, Acquisition Date 4/18/2024, Series Preferred Series B2024-09-300001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 2/28/2019, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 2/28/2019, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Units2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Units2024-09-300001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/18/2019, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/18/2019, Series Common Stock2024-09-300001280784Warrant Investments and Drug Discovery & Development (0.51%)2024-09-300001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2024-09-300001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2024-09-300001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2024-09-300001280784Warrant Investments and Electronics & Computer Hardware (0.02%)2024-09-300001280784Warrant Investments and Healthcare Services, Other and Curana Health Holdings, LLC., Warrant, Acquisition Date 1/4/2024, Series Common Units2024-01-012024-09-300001280784Warrant Investments and Healthcare Services, Other and Curana Health Holdings, LLC., Warrant, Acquisition Date 1/4/2024, Series Common Units2024-09-300001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc., Warrant, Acquisition Date 3/30/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc., Warrant, Acquisition Date 3/30/2023, Series Common Stock2024-09-300001280784Warrant Investments and Healthcare Services, Other and NeueHealth, Inc., Warrant, Acquisition Date 6/21/2024, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Healthcare Services, Other and NeueHealth, Inc., Warrant, Acquisition Date 6/21/2024, Series Common Stock2024-09-300001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc.., Warrant, Acquisition Date 7/3/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc.., Warrant, Acquisition Date 7/3/2023, Series Common Stock2024-09-300001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC., Warrant, Acquisition Date 9/28/2023, Series Common Units2024-01-012024-09-300001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC., Warrant, Acquisition Date 9/28/2023, Series Common Units2024-09-300001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Series Preferred Series E2024-01-012024-09-300001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Series Preferred Series E2024-09-300001280784Warrant Investments and Healthcare Services, Other (0.09%)2024-09-300001280784Warrant Investments and Information Services and INMOBI Inc., Warrant, Acquisition Date 11/19/2014, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Information Services and INMOBI Inc., Warrant, Acquisition Date 11/19/2014, Series Common Stock2024-09-300001280784Warrant Investments and Information Services and NetBase Quid, Inc. (p.k.a NetBase Solutions), Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12024-01-012024-09-300001280784Warrant Investments and Information Services and NetBase Quid, Inc. (p.k.a NetBase Solutions), Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12024-09-300001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2024-09-300001280784Warrant Investments and Information Services (0.00%)2024-09-300001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2024-09-300001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2024-09-300001280784Warrant Investments and Manufacturing Technology (0.06%)2024-09-300001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12024-01-012024-09-300001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12024-09-300001280784Warrant Investments and Media/Content/Info (0.00%)2024-09-300001280784Warrant Investments and Medical Devices & Equipment and Outset Medical, Inc., Warrant, Acquisition Date 9/27/2013, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Medical Devices & Equipment and Outset Medical, Inc., Warrant, Acquisition Date 9/27/2013, Series Common Stock2024-09-300001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc., Warrant, Acquisition Date 9/8/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc., Warrant, Acquisition Date 9/8/2023, Series Common Stock2024-09-300001280784Warrant Investments and Medical Devices & Equipment and Sight Sciences, Inc., Warrant, Acquisition Date 1/22/2024, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Medical Devices & Equipment and Sight Sciences, Inc., Warrant, Acquisition Date 1/22/2024, Series Common Stock2024-09-300001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2024-09-300001280784Warrant Investments and Medical Devices & Equipment (0.02%)2024-09-300001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Series Preferred Series D-22024-01-012024-09-300001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Series Preferred Series D-22024-09-300001280784Warrant Investments and Semiconductors (0.02%)2024-09-300001280784Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Series Preferred Series G2024-01-012024-09-300001280784Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Series Preferred Series G2024-09-300001280784Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2024-09-300001280784Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2024-09-300001280784Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2024-09-300001280784Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2024-09-300001280784Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Series Common Stock2024-09-300001280784Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2024-01-012024-09-300001280784Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2024-09-300001280784Warrant Investments and Software and Coronet Cyber Security Ltd., Warrant, Acquisition Date 9/26/2024, Ordinary Shares2024-01-012024-09-300001280784Warrant Investments and Software and Coronet Cyber Security Ltd., Warrant, Acquisition Date 9/26/2024, Ordinary Shares2024-09-300001280784Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Series Common Stock2024-09-300001280784Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2024-09-300001280784Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2024-09-300001280784Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2024-09-300001280784Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Series Common Stock2024-09-300001280784Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2024-09-300001280784Warrant Investments and Software and Earnix, Inc., Warrant, Acquisition Date 6/6/2024, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Earnix, Inc., Warrant, Acquisition Date 6/6/2024, Series Common Stock2024-09-300001280784Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2024-09-300001280784Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2024-01-012024-09-300001280784Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2024-09-300001280784Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2024-09-300001280784Warrant Investments and Software and Harness, Inc., Warrant, Acquisition Date 3/12/2024, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Harness, Inc., Warrant, Acquisition Date 3/12/2024, Series Common Stock2024-09-300001280784Warrant Investments and Software and Kore.ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2024-01-012024-09-300001280784Warrant Investments and Software and Kore.ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2024-09-300001280784Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2024-09-300001280784Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series LB-22024-01-012024-09-300001280784Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series LB-22024-09-300001280784Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2024-09-300001280784Warrant Investments and Software and Pindrop Security, Inc., Warrant, Acquisition Date 6/26/2024, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Pindrop Security, Inc., Warrant, Acquisition Date 6/26/2024, Series Common Stock2024-09-300001280784Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2024-09-300001280784Warrant Investments and Software and Semperis Technologies Inc., Warrant, Acquisition Date 4/23/2024, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Semperis Technologies Inc., Warrant, Acquisition Date 4/23/2024, Series Common Stock2024-09-300001280784Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2024-09-300001280784Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Series Preferred Series D2024-01-012024-09-300001280784Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Series Preferred Series D2024-09-300001280784Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/28/2023, Series Ordinary Shares2024-01-012024-09-300001280784Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/28/2023, Series Ordinary Shares2024-09-300001280784Warrant Investments and Software and Suzy, Inc. Warrant, Acquisition Date 8/24/2023, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and Suzy, Inc. Warrant, Acquisition Date 8/24/2023, Series Common Stock2024-09-300001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2024-01-012024-09-300001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2024-09-300001280784Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2024-09-300001280784Warrant Investments and Software (0.50%)2024-09-300001280784Warrant Investments and Space Technologies and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Space Technologies and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock2024-09-300001280784Warrant Investments and Space Technologies (0.00%)2024-09-300001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2024-01-012024-09-300001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2024-09-300001280784Warrant Investments and Sustainable and Renewable Technology and Electric Hydrogen Co., Warrant, Acquisition Date 3/27/2024, Series Common stock2024-01-012024-09-300001280784Warrant Investments and Sustainable and Renewable Technology and Electric Hydrogen Co., Warrant, Acquisition Date 3/27/2024, Series Common stock2024-09-300001280784Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/7/2015, Series Common stock2024-01-012024-09-300001280784Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/7/2015, Series Common stock2024-09-300001280784Warrant Investments and Sustainable and Renewable Technology (0.02%)2024-09-300001280784Warrant Investments (1.62%)2024-09-300001280784Investments in Securities (191.90%)2024-09-300001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202024-01-012024-09-300001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202024-09-300001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222024-01-012024-09-300001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222024-09-300001280784Investment Funds & Vehicles Investments and Drug Discovery & Development (0.35%)2024-09-300001280784Investment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222024-01-012024-09-300001280784Investment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222024-09-300001280784Investment Funds & Vehicles Investments and Software (0.02%)2024-09-300001280784Investment Funds & Vehicles Investments (0.37%)2024-09-300001280784Investments (192.27%)2024-09-300001280784Foreign Currency Exchange Contracts Counterparty Goldman Sachs Bank USA Settlement Date 6/3/20252024-01-012024-09-300001280784Foreign Currency Exchange Contracts Counterparty Goldman Sachs Bank USA Settlement Date 6/3/20252024-09-300001280784Total Foreign Currency Forward ((0.06%))2024-09-300001280784htgc:OneMonthSOFRMember2024-09-300001280784htgc:ThreeMonthSOFRMember2024-09-300001280784htgc:SixMonthSOFRMember2024-09-300001280784us-gaap:FairValueInputsLevel2Memberus-gaap:WarrantMember2024-09-300001280784us-gaap:FairValueInputsLevel1Memberus-gaap:CommonStockMember2024-09-300001280784htgc:BlackCrowAIIncMemberhtgc:PromissoryNotesMember2024-09-300001280784htgc:RoyaltyContractMemberhtgc:PhathomPharmaceuticalsIncMember2024-09-300001280784Debt Investment Biotechnology Tools and Alamar Biosciences, Inc., Senior Secured, June 2026, Prime + 3.00%, Floor rate 6.50%, PIK Interest 1.00%, 5.95% Exit Fee2023-12-310001280784Debt Investment Biotechnology Tools and PathAI, Inc., Senior Secured, January 2027, Prime + 2.15%, Floor rate 9.15%, 9.81% Exit Fee2023-12-310001280784Debt Investment Biotechnology Tools (2.66%)2023-12-310001280784Debt Investment Communications & Networking and Aryaka Networks, Inc., Senior Secured, July 2026, Prime + 3.25%, Floor rate 6.75%, PIK Interest 1.05%, 3.55% Exit Fee2023-12-310001280784Debt Investment Communications & Networking and Cytracom Holdings LLC, Senior Secured, February 2025, 3-month SOFR + 9.72%, Floor rate 10.62%2023-12-310001280784Debt Investment Communications & Networking and (1.62%)2023-12-310001280784Debt Investment Consumer & Business Services and Altumint, Inc., Senior Secured, December 2027, Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and AppDirect, Inc., Senior Secured, April 2026, Prime + 5.50%, Floor rate 8.75%, 7.12% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Carwow LTD, Senior Secured, December 2024, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 4.95% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Houzz, Inc., Convertible Debt, May 2028, PIK Interest 8.50%2023-12-310001280784Debt Investment Consumer & Business Services and Jobandtalent USA, Inc., Senior Secured, February 2025, 1-month SOFR + 8.86%, Floor rate 9.75%, 3.00% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Plentific Ltd, Senior Secured, October 2026, Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Provi, Senior Secured, December 2026, Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Rhino Labs, Inc., Senior Secured, June 2024, Prime + 5.50%, Floor rate 8.75%, PIK Interest 2.25%2023-12-310001280784Debt Investment Consumer & Business Services and Riviera Partners LLC, Senior Secured, April 2027, 3-month SOFR + 8.26%, Floor rate 9.26%2023-12-310001280784Debt Investment Consumer & Business Services and RVShare, LLC, Senior Secured, December 2026, 3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%2023-12-310001280784Debt Investment Consumer & Business Services and SeatGeek, Inc., Senior Secured, May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and SeatGeek, Inc., Senior Secured, July 2026, Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Total SeatGeek, Inc2023-12-310001280784Debt Investment Consumer & Business Services and Skyword, Inc., Senior Secured, November 2026, Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Tectura Corporation, Senior Secured, July 2024, FIXED 8.25%2023-12-310001280784Debt Investment Consumer & Business Services and Thumbtack, Inc., Senior Secured, April 2026, Prime + 4.95%, Floor rate 8.20%, PIK Interest 1.50%, 3.95% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Udacity, Inc., Senior Secured, September 2024, Prime + 4.50%, Floor rate 7.75%, PIK Interest 2.00%, 3.00% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Veem, Inc., Senior Secured, March 2025, Prime + 4.00%, Floor rate 7.25%, PIK Interest 1.25%, 4.50% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Veem, Inc., Senior Secured, March 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.50%, 4.50% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Total Veem, Inc.,2023-12-310001280784Debt Investment Consumer & Business Services and Worldremit Group Limited, Senior Secured, February 2025, 3-month SOFR + 9.40%, Floor rate 10.25%, 3.20% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Worldremit Group Limited, Senior Secured, February 2025, 1-month SOFR + 9.35%, Floor rate 10.25%, 3.20% Exit Fee2023-12-310001280784Debt Investment Consumer & Business Services and Total Worldremit Group Limited2023-12-310001280784Debt Investment Consumer & Business Services (28.24%)2023-12-310001280784Debt Investment Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Unsecured, September 2026, FIXED 11.50%2023-12-310001280784Debt Investment Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Unsecured, September 2026, FIXED 11.95%2023-12-310001280784Debt Investment Diversified Financial Services and Total Gibraltar Acquisition, LLC2023-12-310001280784Debt Investment Diversified Financial Services and Hercules Adviser LLC, Unsecured, June 2025, FIXED 5.00%2023-12-310001280784Debt Investment Diversified Financial Services and Next Insurance, Inc., Senior Secured, February 2028, Prime - (1.50%), Floor rate 4.75%, PIK Interest 5.50%2023-12-310001280784Debt Investment Diversified Financial Services (3.17%)2023-12-310001280784Debt Investment Drug Discovery & Development and Akero Therapeutics, Inc., Senior Secured, January 2027, Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Aldeyra Therapeutics, Inc., Senior Secured, October 2024, Prime + 3.10%, Floor rate 8.60%, 8.90% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Alladapt Immunotherapeutics Inc., Senior Secured, September 2026, Prime + 3.65%, Floor rate 8.40%, Cap rate 10.90%, 5.30% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and AmplifyBio, LLC, Senior Secured, January 2027, Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and ATAI Life Sciences N.V., Senior Secured, August 2026, Prime + 4.55%, Floor rate 8.55%, 6.95% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Axsome Therapeutics, Inc., Senior Secured, January 2028, Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Bicycle Therapeutics PLC, Senior Secured, July 2025, Prime + 4.55%, Floor rate 8.05%, Cap rate 9.05%, 5.00% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and BiomX, INC, Senior Secured, September 2025, Prime + 5.70%, Floor rate 8.95%, 6.55% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Braeburn, Inc., Senior Secured, October 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and BridgeBio Pharma, Inc., Senior Secured, November 2026, FIXED 9.00%, 2.00% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Cellarity, Inc., Senior Secured, June 2026, Prime + 5.70%, Floor rate 8.95%, 3.75% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and COMPASS Pathways plc, Senior Secured, July 2027, Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Corium, Inc., Senior Secured, September 2026, Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Curevo, Inc., Senior Secured, June 2027, Prime + 1.70%, Floor rate 9.70%, 6.95% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Eloxx Pharmaceuticals, Inc., Senior Secured, April 2025, Prime + 6.25%, Floor rate 9.50%, 6.55% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and enGene, Inc., Senior Secured, July 2028, Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and G1 Therapeutics, Inc., Senior Secured, November 2026, Prime + 5.65%, Floor rate 9.15%, 11.41% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Geron Corporation, Senior Secured, April 2025, Prime + 4.50%, Floor rate 9.00%, 6.55% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Gritstone Bio, Inc., Senior Secured, July 2027, Prime + 3.15%, Floor rate 7.15%, Cap rate 8.65%, PIK Interest 2.00%, 5.75% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Heron Therapeutics, Inc., Senior Secured, February 2026, Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Hibercell, Inc., Senior Secured, May 2025, Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and HilleVax, Inc., Senior Secured, May 2027, Prime + 1.05%, Floor rate 4.55%, Cap rate 6.05%, PIK Interest 2.85%, 7.15% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Kura Oncology, Inc., Senior Secured, November 2027, Prime + 2.40%, Floor rate 8.65%, 15.13% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Locus Biosciences, Inc., Senior Secured, July 2025, Prime + 6.10%, Floor rate 9.35%, 4.95% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Senior Secured, May 2026, Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Senior Secured, December 2027, Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.15%, 7.29% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Redshift Bioanalytics, Inc., Senior Secured, January 2026, Prime + 4.25%, Floor rate 7.50%, 3.80% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Replimune Group, Inc., Senior Secured, October 2027, Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Tarsus Pharmaceuticals, Inc., Senior Secured, February 2027, Prime + 4.45%, Floor rate 8.45%, Cap rate 11.45%, 4.75% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and TG Therapeutics, Inc., Senior Secured, January 2026, Prime + 1.20%, Floor rate 8.95%, PIK Interest 2.25%, 5.69% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and uniQure B.V., Senior Secured, January 2027, Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Valo Health, LLC, Senior Secured, May 2024, Prime + 6.45%, Floor rate 9.70%, 3.85% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Verona Pharma, Inc., Senior Secured, December 2028, 1-month SOFR + 5.85%, Floor rate 11.19%, Cap rate 13.19%, 3.50% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and Viridian Therapeutics, Inc., Senior Secured, October 2026, Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development and X4 Pharmaceuticals, Inc., Senior Secured, October 2026, Prime + 3.15%, Floor rate 10.15%, 3.80% Exit Fee2023-12-310001280784Debt Investment Drug Discovery & Development (66.60%)2023-12-310001280784Debt Investment Electronics & Computer Hardware and Locus Robotics Corp., Senior Secured, June 2026, Prime + 4.50%, Floor rate 8.00%, 4.00% Exit Fee2023-12-310001280784Debt Investment Electronics & Computer Hardware (1.05%)2023-12-310001280784Debt Investment Healthcare Services, Other and Better Therapeutics, Inc., Senior Secured, August 2025, Prime + 5.70%, Floor rate 8.95%, 5.95% Exit Fee2023-12-310001280784Debt Investment Healthcare Services, Other and Blue Sprig Pediatrics, Inc., Senior Secured, November 2026, 1-month SOFR + 5.11% , Floor rate 6.00%, PIK Interest 4.45%2023-12-310001280784Debt Investment Healthcare Services, Other and Carbon Health Technologies, Inc., Senior Secured, March 2025, Prime + 5.60%, Floor rate 8.85%, 4.61% Exit Fee2023-12-310001280784Debt Investment Healthcare Services, Other and Equality Health, LLC, Senior Secured, February 2026, Prime + 6.25%, Floor rate 9.50%, PIK Interest 1.55%2023-12-310001280784Debt Investment Healthcare Services, Other and Main Street Rural, Inc., Senior Secured, July 2027, Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee2023-12-310001280784Debt Investment Healthcare Services, Other and Modern Life, Inc., Senior Secured, February 2027, Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee2023-12-310001280784Debt Investment Healthcare Services, Other and Recover Together, Inc., Senior Secured, July 2027, Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee2023-12-310001280784Debt Investment Healthcare Services, Other and Strive Health Holdings, LLC, Senior Secured, September 2027, Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee2023-12-310001280784Debt Investment Healthcare Services, Other and Vida Health, Inc., Senior Secured, March 2026, 9.20% + Lower of (Prime - 3.25%) or 1.00%, Floor rate 9.20%, Cap rate 10.20%, 4.95% Exit Fee2023-12-310001280784Debt Investment Healthcare Services, Other (16.56%)2023-12-310001280784Debt Investment Information Services and Capella Space Corp., Senior Secured, November 2025, Prime + 5.00%, Floor rate 8.25%, PIK Interest 1.10%, 7.00% Exit Fee2023-12-310001280784Debt Investment Information Services and Checkr Group, Inc., Senior Secured, August 2028, Prime + 1.45%, Floor rate 8.00%, PIK Interest 2.00%, 2.75% Exit Fee2023-12-310001280784Debt Investment Information Services and Saama Technologies, LLC, Senior Secured, July 2027, Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee2023-12-310001280784Debt Investment Information Services and Signal Media Limited, Senior Secured, June 2025, Prime + 5.50%, Floor rate 9.00%, Cap rate 12.00%, 3.45% Exit Fee2023-12-310001280784Debt Investment Information Services and Yipit, LLC, Senior Secured, September 2026, 1-month SOFR + 8.45%, Floor rate 9.35%2023-12-310001280784Debt Investment Information Services (6.65%)2023-12-310001280784Debt Investment Manufacturing Technology and Bright Machines, Inc., Senior Secured, May 2025, Prime + 4.00%, Floor rate 9.50%, 5.00% Exit Fee2023-12-310001280784Debt Investment Manufacturing Technology (0.44%)2023-12-310001280784Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, September 2026, Prime + 3.50%, Floor rate 9.00%, 4.00% Exit Fee2023-12-310001280784Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, September 2025, Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee2023-12-310001280784Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, December 2025, Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee2023-12-310001280784Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, March 2026, Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee2023-12-310001280784Debt Investment Media/Content/Info and Fever Labs, Inc., Senior Secured, June 2026, Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee2023-12-310001280784Debt Investment Media/Content/Info and Total Fever Labs, Inc.2023-12-310001280784Debt Investment Media/Content/Info (0.69%)2023-12-310001280784Debt Investment Medical Devices & Equipment and Senseonics Holdings, Inc., Senior Secured, September 2027, Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee2023-12-310001280784Debt Investment Medical Devices & Equipment (1.20%)2023-12-310001280784Debt Investment Software and 3GTMS, LLC, Senior Secured, February 2025, 3-month SOFR + 9.70%, Floor rate 10.60%2023-12-310001280784Debt Investment Software and 3GTMS, LLC, Senior Secured, February 2025, 3-month SOFR + 6.88%, Floor rate 7.78%2023-12-310001280784Debt Investment Software and Total 3GTMS, LLC2023-12-310001280784Debt Investment Software and Agilence, Inc., Senior Secured, October 2026, 1-month BSBY + 9.00%, Floor rate 10.00%2023-12-310001280784Debt Investment Software and Alchemer LLC, Senior Secured, May 2028, 1-month SOFR + 8.14%, Floor rate 9.14%2023-12-310001280784Debt Investment Software and Allvue Systems, LLC, Senior Secured, September 2029, 6-month SOFR + 7.25%, Floor rate 8.25%2023-12-310001280784Debt Investment Software and Annex Cloud, Senior Secured, February 2027, 1-month BSBY + 9.41%, Floor rate 10.41%2023-12-310001280784Debt Investment Software and Automation Anywhere, Inc., Senior Secured, September 2027, Prime + 4.25%, Floor rate 9.00%, 4.50% Exit Fee2023-12-310001280784Debt Investment Software and Babel Street, Senior Secured, December 2027, 3-month SOFR + 7.89%, Floor rate 8.89%2023-12-310001280784Debt Investment Software and Brain Corporation, Senior Secured, April 2026, Prime + 3.70%, Floor rate 9.20%, PIK Interest 1.00%, 3.95% Exit Fee2023-12-310001280784Debt Investment Software and Campaign Monitor Limited, Senior Secured, November 2025, 3-month SOFR + 9.05%, Floor rate 9.90%2023-12-310001280784Debt Investment Software and Catchpoint Systems, Inc., Senior Secured, November 2025, 3-month SOFR + 9.41%, Floor rate 11.81%2023-12-310001280784Debt Investment Software and Ceros, Inc., Senior Secured, September 2026, 6-month SOFR + 8.99%, Floor rate 9.89%2023-12-310001280784Debt Investment Software and Constructor.io Corporation, Senior Secured, July 2027, 1-month SOFR + 8.44%, Floor rate 9.44%2023-12-310001280784Debt Investment Software and Convoy, Inc., Senior Secured, March 2026, Prime + 3.20%, Floor rate 6.45%, PIK Interest 1.95%, 4.55% Exit Fee2023-12-310001280784Debt Investment Software and Copper CRM, Inc, Senior Secured, March 2025, Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 3.96% Exit Fee2023-12-310001280784Debt Investment Software and Cutover, Inc., Senior Secured, October 2025, Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee2023-12-310001280784Debt Investment Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, August 2026, 6-month SOFR + 8.63%, Floor rate 9.38%2023-12-310001280784Debt Investment Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, August 2026, 6-month SOFR + 12.36%, Floor rate 13.11%2023-12-310001280784Debt Investment Software and Total Cybermaxx Intermediate Holdings, Inc., 2023-12-310001280784Debt Investment Software and Dashlane, Inc., Senior Secured, December 2027, Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 7.26% Exit Fee2023-12-310001280784Debt Investment Software and Dispatch Technologies, Inc., Senior Secured, April 2028, 3-month SOFR + 8.01%, Floor rate 8.76%2023-12-310001280784Debt Investment Software and DroneDeploy, Inc., Senior Secured, July 2026, Prime + 4.50%, Floor rate 8.75%, 4.00% Exit Fee2023-12-310001280784Debt Investment Software and Eigen Technologies Ltd., Senior Secured, April 2025, Prime + 5.10%, Floor rate 8.35%, 2.95% Exit Fee2023-12-310001280784Debt Investment Software and Elation Health, Inc., Senior Secured, March 2026, Prime + 4.25%, Floor rate 9.00%, PIK Interest 1.95%, 3.95% Exit Fee2023-12-310001280784Debt Investment Software and Enmark Systems, Inc., Senior Secured, September 2026, 3-month SOFR + 6.73%, Floor rate 7.73%, PIK Interest 2.13%2023-12-310001280784Debt Investment Software and Flight Schedule Pro, LLC, Senior Secured, October 2027, 1-month SOFR + 7.80%, Floor rate 8.70%2023-12-310001280784Debt Investment Software and Fortified Health Security, Senior Secured, December 2027, 1-month SOFR + 7.64%, Floor rate 8.54%2023-12-310001280784Debt Investment Software and iGrafx, LLC, Senior Secured, May 2027, 1-month SOFR + 8.66%, Floor rate 9.56%2023-12-310001280784Debt Investment Software and Ikon Science Limited, Senior Secured, October 2024, 3-month SOFR + 9.26%, Floor rate 10.00%2023-12-310001280784Debt Investment Software and Khoros (p.k.a Lithium Technologies), Senior Secured, January 2025, 3-month SOFR + 4.50%, Floor rate 5.50%, PIK Interest 4.50%2023-12-310001280784Debt Investment Software and Leapwork ApS, Senior Secured, February 2026, Prime + 0.25%, Floor rate 7.25%, PIK Interest 1.95%, 2.70% Exit Fee2023-12-310001280784Debt Investment Software and LinenMaster, LLC, Senior Secured, August 2028, 1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%2023-12-310001280784Debt Investment Software and Loftware, Inc., Senior Secured, March 2028, 3-month SOFR + 7.88%, Floor rate 8.88%2023-12-310001280784Debt Investment Software and LogicSource, Senior Secured, July 2027, 3-month SOFR + 8.93%, Floor rate 9.93%2023-12-310001280784Debt Investment Software and Mobile Solutions Services, Senior Secured, December 2025, 6-month SOFR + 9.31%, Floor rate 10.06%2023-12-310001280784Debt Investment Software and New Relic, Inc., Senior Secured, November 2030, 3-month SOFR + 6.75%, Floor rate 7.75%2023-12-310001280784Debt Investment Software and Omeda Holdings, LLC, Senior Secured, July 2027, 3-month SOFR + 8.05%, Floor rate 9.05%2023-12-310001280784Debt Investment Software and Onna Technologies, Inc., Senior Secured, March 2026, Prime + 1.35%, Floor rate 8.85%, PIK Interest 1.75%, 4.45% Exit Fee2023-12-310001280784Debt Investment Software and Salary.com, LLC, Senior Secured, September 2027, 3-month SOFR + 8.00%, Floor rate 9.00%2023-12-310001280784Debt Investment Software and ShadowDragon, LLC, Senior Secured, December 2026, 1-month SOFR + 9.01%, Floor rate 9.91%2023-12-310001280784Debt Investment Software and Simon Data, Inc., Senior Secured, March 2027, Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.92% Exit Fee2023-12-310001280784Debt Investment Software and Sisense Ltd., Senior Secured, July 2027, Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee2023-12-310001280784Debt Investment Software and Streamline Healthcare Solutions, Senior Secured, March 2028, 3-month SOFR + 7.25%, Floor rate 8.25%2023-12-310001280784Debt Investment Software and Sumo Logic, Inc., Senior Secured, May 2030, 3-month SOFR + 6.50%, Floor rate 7.50%2023-12-310001280784Debt Investment Software and Suzy, Inc., Senior Secured, August 2027, Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee2023-12-310001280784Debt Investment Software and ThreatConnect, Inc., Senior Secured, May 2026, 6-month SOFR + 9.25%, Floor rate 10.00%2023-12-310001280784Debt Investment Software and Tipalti Solutions Ltd., Senior Secured, April 2027, Prime + 0.45%, Floor rate 7.95%, PIK Interest 2.00%, 3.75% Exit Fee2023-12-310001280784Debt Investment Software and Zappi, Inc., Senior Secured, December 2027, 3-month SOFR + 8.03%, Floor rate 9.03%2023-12-310001280784Debt Investment Software and Zimperium, Inc., Senior Secured, May 2027, 3-month SOFR + 8.31%, Floor rate 9.31%2023-12-310001280784Debt Investment Software (40.39%)2023-12-310001280784Debt Investment Sustainable and Renewable Technology and Ampion, PBC, Senior Secured, May 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 3.78% Exit Fee2023-12-310001280784Debt Investment Sustainable and Renewable Technology and Pineapple Energy LLC, Senior Secured, June 2027, FIXED 10.00%2023-12-310001280784Debt Investment Sustainable and Renewable Technology (0.31%)2023-12-310001280784Total Debt Investments (169.59%)2023-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2023-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc. Equity, Acquisition Date 7/16/2013, Preferred Series B2023-01-012023-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc. Equity, Acquisition Date 7/16/2013, Preferred Series B2023-12-310001280784Equity Investments Consumer & Business Products and Total Fabletics, Inc.2023-12-310001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Equity, Acquisition Date 4/30/2021, Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Equity, Acquisition Date 4/30/2021, Common Stock2023-12-310001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Equity, Acquisition Date 4/30/2010, Class A Units2023-01-012023-12-310001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Equity, Acquisition Date 4/30/2010, Class A Units2023-12-310001280784Equity Investments Consumer & Business Products and TFG Holding, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Products and TFG Holding, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2023-12-310001280784Equity Investments Consumer & Business Products (0.13%)2023-12-310001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42023-01-012023-12-310001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42023-12-310001280784Equity Investments Consumer & Business Services and DoorDash, Inc., Equity, Acquisition Date 12/20/2018, Series Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and DoorDash, Inc., Equity, Acquisition Date 12/20/2018, Series Common Stock2023-12-310001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2023-12-310001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2023-12-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2023-12-310001280784Equity, Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date10/25/2016, Series Preferred Series A-12023-01-012023-12-310001280784Equity, Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date10/25/2016, Series Preferred Series A-12023-12-310001280784Equity Investments Consumer & Business Services and Total OfferUp, Inc.2023-12-310001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2023-12-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2023-12-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2023-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2023-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2023-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2023-01-012023-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2023-12-310001280784Equity Investments Consumer & Business Services and Total Tectura Corporation2023-12-310001280784Equity Investments Consumer & Business Services (0.70%)2023-12-310001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Equity, Acquisition Date 3/1/2018, Series Member Units2023-01-012023-12-310001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), Equity, Acquisition Date 3/1/2018, Series Member Units2023-12-310001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2023-01-012023-12-310001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2023-12-310001280784Equity Investments Diversified Financial Services, Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22023-01-012023-12-310001280784Equity Investments Diversified Financial Services, Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22023-12-310001280784Equity Investments Diversified Financial Services (3.17%)2023-12-310001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2023-12-310001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2023-01-012023-12-310001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2023-12-310001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2023-12-310001280784Equity Investments Drug Delivery and Talphera, Inc. (p.k.a. AcelRx Pharmaceuticals, Inc.), Equity, Acquisition Date 12/10/2018, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Delivery and Talphera, Inc. (p.k.a. AcelRx Pharmaceuticals, Inc.), Equity, Acquisition Date 12/10/2018, Series Common Stock2023-12-310001280784Equity Investments Drug Delivery (0.00%)2023-12-310001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc.., Equity, Acquisition Date 5/9/2022, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc.., Equity, Acquisition Date 5/9/2022, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/05/2020, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/05/2020, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Cyclo Therapeutics, Inc. (p.k.a. Applied Molecular Transport)., Equity, Acquisition Date 4/06/2021, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Cyclo Therapeutics, Inc. (p.k.a. Applied Molecular Transport)., Equity, Acquisition Date 4/06/2021, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 5/9/2022, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 5/9/2022, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Gritstone Bio, Inc., Equity, Acquisition Date 10/26/2022, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Gritstone Bio, Inc., Equity, Acquisition Date 10/26/2022, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2023-12-310001280784Equity Investments Drug Discovery & Development and HilleVax, Inc., Equity, Acquisition Date 5/3/2022, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and HilleVax, Inc., Equity, Acquisition Date 5/3/2022, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Humanigen, Inc., Equity, Acquisition Date 3/31/2021, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Humanigen, Inc., Equity, Acquisition Date 3/31/2021, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Equity, Acquisition Date 9/29/2023, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Equity, Acquisition Date 9/29/2023, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2023-12-310001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Sio Gene Therapies, Inc., Equity, Acquisition Date 2/2/2017, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Sio Gene Therapies, Inc., Equity, Acquisition Date 2/2/2017, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Tarsus Pharmaceuticals, Inc., Equity, Acquisition Date 5/5/2022, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Tarsus Pharmaceuticals, Inc., Equity, Acquisition Date 5/5/2022, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2023-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2023-12-310001280784Equity Investments Drug Discovery & Development and Total Valo Health, LLC2023-12-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2023-12-310001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2023-01-012023-12-310001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2023-12-310001280784Equity Investments Drug Discovery & Development (2.47%)2023-12-310001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2023-01-012023-12-310001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2023-12-310001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2023-01-012023-12-310001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2023-12-310001280784Equity Investments Electronics & Computer Hardware (0.05%)2023-12-310001280784Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock2023-01-012023-12-310001280784Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock2023-12-310001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C2023-01-012023-12-310001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C2023-12-310001280784Equity Investments Healthcare Services, Other (0.05%)2023-12-310001280784Equity Investments Information Services and Planet Labs, Inc., Equity, Acquisition Date 6/21/2019, Series Common Stock2023-01-012023-12-310001280784Equity Investments Information Services and Planet Labs, Inc., Equity, Acquisition Date 6/21/2019, Series Common Stock2023-12-310001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2023-01-012023-12-310001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2023-12-310001280784Equity Investments Information Services (0.35%)2023-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2023-01-012023-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2023-12-310001280784Equity Investments and Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22023-01-012023-12-310001280784Equity Investments and Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22023-12-310001280784Equity Investments Medical Devices & Equipment, Coronado Aesthetics, LLC2023-12-310001280784Equity Investments Medical Devices & Equipment (0.01%)2023-12-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2023-01-012023-12-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2023-12-310001280784Equity Investments Semiconductors (0.02%)2023-12-310001280784Equity Investments Software and 3GTMS, LLC, Equity, Acquisition Date 8/9/2021, Series Common Stock2023-01-012023-12-310001280784Equity Investments Software and 3GTMS, LLC, Equity, Acquisition Date 8/9/2021, Series Common Stock2023-12-310001280784Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note2023-01-012023-12-310001280784Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note2023-12-310001280784Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-32023-01-012023-12-310001280784Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-32023-12-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2023-01-012023-12-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2023-12-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2023-01-012023-12-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2023-12-310001280784Equity Investments Software and Total Contentful Global, Inc.2023-12-310001280784Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2023-01-012023-12-310001280784Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2023-12-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22023-01-012023-12-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22023-12-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32023-01-012023-12-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32023-12-310001280784Equity Investments Software and Total Druva Holdings, Inc.2023-12-310001280784Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock2023-01-012023-12-310001280784Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock2023-12-310001280784Equity Investments Software and Leapwork ApS, Equity, Acquisition Date 8/25/2023, Preferred Series B22023-01-012023-12-310001280784Equity Investments Software and Leapwork ApS, Equity, Acquisition Date 8/25/2023, Preferred Series B22023-12-310001280784Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2023-01-012023-12-310001280784Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2023-12-310001280784Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock2023-01-012023-12-310001280784Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock2023-12-310001280784Equity Investments Software and Palantir Technologies, Equity, Acquisition Date 9/23/2020, Series Common Stock2023-01-012023-12-310001280784Equity Investments Software and Palantir Technologies, Equity, Acquisition Date 9/23/2020, Series Common Stock2023-12-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E2023-01-012023-12-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E2023-12-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F2023-01-012023-12-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F2023-12-310001280784Equity Investments Software and Total SingleStore, Inc.2023-12-310001280784Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Preferred Series E2023-01-012023-12-310001280784Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Preferred Series E2023-12-310001280784Equity Investments Software and ZeroFox, Inc., Equity, Acquisition Date 5/7/2020, Series Common Stock2023-01-012023-12-310001280784Equity Investments Software and ZeroFox, Inc., Equity, Acquisition Date 5/7/2020, Series Common Stock2023-12-310001280784Equity Investments Software (1.27%)2023-12-310001280784Equity Investments Sustainable and Renewable Technology and Fulcrum Bioenergy, Inc., Equity, Acquisition Date 9/13/2012, Series Preferred Series C-12023-01-012023-12-310001280784Equity Investments Sustainable and Renewable Technology and Fulcrum Bioenergy, Inc., Equity, Acquisition Date 9/13/2012, Series Preferred Series C-12023-12-310001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12023-01-012023-12-310001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12023-12-310001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2023-01-012023-12-310001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2023-12-310001280784Equity Investments Sustainable and Renewable Technology and NantEnergy, LLC, Equity, Acquisition Date 8/31/2013, Series Common Units2023-01-012023-12-310001280784Equity Investments Sustainable and Renewable Technology and NantEnergy, LLC, Equity, Acquisition Date 8/31/2013, Series Common Units2023-12-310001280784Equity Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Equity, Acquisition Date 12/10/2020, Series Common Stock2023-01-012023-12-310001280784Equity Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Equity, Acquisition Date 12/10/2020, Series Common Stock2023-12-310001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2023-01-012023-12-310001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2023-12-310001280784Equity Investments Sustainable and Renewable Technology and Proterra, Inc., Equity, Acquisition Date 5/28/2015, Series Common Stock2023-01-012023-12-310001280784Equity Investments Sustainable and Renewable Technology and Proterra, Inc., Equity, Acquisition Date 5/28/2015, Series Common Stock2023-12-310001280784Equity Investments Sustainable and Renewable Technology (0.22%)2023-12-310001280784Equity Investments (8.44%)2023-12-310001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series B2023-01-012023-12-310001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series B2023-12-310001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2023-12-310001280784Warrant Investments and Biotechnology Tools (0.02%)2023-12-310001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2023-12-310001280784Warrant Investments and Communications & Networking (0.01%)2023-12-310001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Products and The Neat Company, Warrant, Acquisition Date 8/13/2014, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Products and The Neat Company, Warrant, Acquisition Date 8/13/2014, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2023-12-310001280784Warrant Investments and Consumer & Business Products (0.02%)2023-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2023-12-310001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary shares2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary shares2023-12-310001280784Warrant Investments and Consumer & Business Services and Provi., Warrant, Acquisition Date 12/22/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Provi., Warrant, Acquisition Date 12/22/2022, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2023-12-310001280784Warrant Investments and Consumer & Business Services and Total Skyword, Inc.2023-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2023-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2023-12-310001280784Warrant Investments and Consumer & Business Services and Total Snagajob.com, Inc.2023-12-310001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Udacity, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Udacity, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2023-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2023-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2023-01-012023-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2023-12-310001280784Warrant Investments and Consumer & Business Services and Total Worldremit Group Limited2023-12-310001280784Warrant Investments and Consumer & Business Services (0.23%)2023-12-310001280784Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock2023-12-310001280784Warrant Diversified Financial Services (0.03%)2023-12-310001280784Warrant Investments and Drug Delivery and Aerami Therapeutics Holdings, Inc., Warrant, Acquisition Date 6/1/2016, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Delivery and Aerami Therapeutics Holdings, Inc., Warrant, Acquisition Date 6/1/2016, Series Common Stock2023-12-310001280784Warrant Investments and Drug Delivery and BioQ Pharma Incorporated, Warrant, Acquisition Date 10/27/2014, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Delivery and BioQ Pharma Incorporated, Warrant, Acquisition Date 10/27/2014, Series Common Stock2023-12-310001280784Warrant Investments and Drug Delivery and PDS Biotechnology Corporation, Warrant, Acquisition Date 8/28/2014, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Delivery and PDS Biotechnology Corporation, Warrant, Acquisition Date 8/28/2014, Series Common Stock2023-12-310001280784Warrant Investments and Drug Delivery (0.00%)2023-12-310001280784Warrant Investments and Drug Discovery & Development and ADMA Biologics, Inc.., Warrant, Acquisition Date 2/24/2014 Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and ADMA Biologics, Inc.., Warrant, Acquisition Date 2/24/2014 Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and AmplifyBio, Warrant, Acquisition Date 12/27/2022, Series Class A Units2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and AmplifyBio, Warrant, Acquisition Date 12/27/2022, Series Class A Units2023-12-310001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2023-12-310001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2023-12-310001280784Warrant Investments and Drug Discovery & Development and Cuervo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Cuervo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Dermavant Sciences Ltd., Warrant, Acquisition Date 5/31/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Dermavant Sciences Ltd., Warrant, Acquisition Date 5/31/2019, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2019, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Evofem Biosciences, Inc., Warrant, Acquisition Date 6/11/2014, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Evofem Biosciences, Inc., Warrant, Acquisition Date 6/11/2014, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Fresh Tracks Therapeutics, Inc. (p.k.a. Brickell Biotech, Inc.), Warrant, Acquisition Date 2/18/2016, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Fresh Tracks Therapeutics, Inc. (p.k.a. Brickell Biotech, Inc.), Warrant, Acquisition Date 2/18/2016, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2023-12-310001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 2/28/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 2/28/2019, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/218/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/218/2019, Series Common Stock2023-12-310001280784Warrant Investments and Drug Discovery & Development (0.46%)2023-12-310001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2023-12-310001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2023-12-310001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2023-12-310001280784Warrant Investments and Electronics & Computer Hardware (0.02%)2023-12-310001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc, Warrant, Acquisition Date 3/30/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc, Warrant, Acquisition Date 3/30/2023, Series Common Stock2023-12-310001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc., , Warrant, Acquisition Date 7/3/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc., , Warrant, Acquisition Date 7/3/2023, Series Common Stock2023-12-310001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC, Warrant, Warrant, Acquisition Date 9/28/2023, Series Common Units2023-01-012023-12-310001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC, Warrant, Warrant, Acquisition Date 9/28/2023, Series Common Units2023-12-310001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Warrant, Acquisition Date 3/28/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Warrant, Acquisition Date 3/28/2022, Series Common Stock2023-12-310001280784Warrant Investments and Healthcare Services, Other (0.03%)2023-12-310001280784Warrant Investments and Information Services and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Information Services and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock2023-12-310001280784Warrant Investments and Information Services and INMOBI Inc., Warrant, Acquisition Date 11/19/2014, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Information Services and INMOBI Inc., Warrant, Acquisition Date 11/19/2014, Series Common Stock2023-12-310001280784Warrant Investments and Information Services and NetBase Solutions, Inc., Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12023-01-012023-12-310001280784Warrant Investments and Information Services and NetBase Solutions, Inc., Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12023-12-310001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2023-12-310001280784Warrant Investments and Information Services (0.03%)2023-12-310001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2023-12-310001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2023-12-310001280784Warrant Investments and Manufacturing Technology and Xometry, Inc., Warrant, Acquisition Date 5/9/2018, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Manufacturing Technology and Xometry, Inc., Warrant, Acquisition Date 5/9/2018, Series Common Stock2023-12-310001280784Warrant Investments and Manufacturing Technology (0.17%)2023-12-310001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12023-01-012023-12-310001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12023-12-310001280784Warrant Investments and Media/Content/Info (0.01%)2023-12-310001280784Warrant Investments and Medical Devices & Equipment and Intuity Medical, Inc., Warrant, Acquisition Date 12/29/2017, Series Preferred Series B-12023-01-012023-12-310001280784Warrant Investments and Medical Devices & Equipment and Intuity Medical, Inc., Warrant, Acquisition Date 12/29/2017, Series Preferred Series B-12023-12-310001280784Warrant Investments and Medical Devices & Equipment and Outset Medical Inc, Warrant, Acquisition Date 9/27/2013, Series Common stock2023-01-012023-12-310001280784Warrant Investments and Medical Devices & Equipment and Outset Medical Inc, Warrant, Acquisition Date 9/27/2013, Series Common stock2023-12-310001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc, Warrant, Acquisition Date 9/8/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc, Warrant, Acquisition Date 9/8/2023, Series Common Stock2023-12-310001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2023-12-310001280784Warrant Investments and Medical Devices & Equipment (0.01%)2023-12-310001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Series Preferred Series D-22023-01-012023-12-310001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Series Preferred Series D-22023-12-310001280784Warrant Investments and Semiconductors (0.04%)2023-12-310001280784Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Series Preferred Series G2023-01-012023-12-310001280784Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Series Preferred Series G2023-12-310001280784Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2023-12-310001280784Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2023-12-310001280784Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2023-12-310001280784Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2023-12-310001280784Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Series Common Stock2023-12-310001280784Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2023-01-012023-12-310001280784Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2023-12-310001280784Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Series Common Stock2023-12-310001280784Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2023-12-310001280784Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2023-12-310001280784Warrant Investments and Software and Delphix Corp., Warrant, Acquisition Date 10/8/2019, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Delphix Corp., Warrant, Acquisition Date 10/8/2019, Series Common Stock2023-12-310001280784Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2023-12-310001280784Warrant Investments and Software and DNAnexus, Inc., Warrant, Acquisition Date 3/21/2014, Series Preferred Series C2023-01-012023-12-310001280784Warrant Investments and Software and DNAnexus, Inc., Warrant, Acquisition Date 3/21/2014, Series Preferred Series C2023-12-310001280784Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Series Common Stock2023-12-310001280784Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2023-12-310001280784Warrant Investments and Software and Eigen Technologies Ltd., Warrant, Acquisition Date 4/13/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Eigen Technologies Ltd., Warrant, Acquisition Date 4/13/2022, Series Common Stock2023-12-310001280784Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2023-12-310001280784Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2023-01-012023-12-310001280784Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2023-12-310001280784Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2023-12-310001280784Warrant Investments and Software and Kore, ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2023-01-012023-12-310001280784Warrant Investments and Software and Kore, ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2023-12-310001280784Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2023-12-310001280784Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series D2023-01-012023-12-310001280784Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series D2023-12-310001280784Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2023-12-310001280784Warrant Investments and Software and Onna TechnologiesInc, Warrant, Acquisition Date 7/5/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Onna TechnologiesInc, Warrant, Acquisition Date 7/5/2023, Series Common Stock2023-12-310001280784Warrant Investments and Software and Poplicus, Inc., Warrant, Acquisition Date 5/28/2014, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Poplicus, Inc., Warrant, Acquisition Date 5/28/2014, Series Common Stock2023-12-310001280784Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2023-12-310001280784Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2023-12-310001280784Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Series Preferred Series D2023-01-012023-12-310001280784Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Series Preferred Series D2023-12-310001280784Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/8/2023, Series Ordinary Shares2023-01-012023-12-310001280784Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/8/2023, Series Ordinary Shares2023-12-310001280784Warrant Investments and Software and Suzy Inc, Warrant, Acquisition Date 8/24/2023, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and Suzy Inc, Warrant, Acquisition Date 8/24/2023, Series Common Stock2023-12-310001280784Warrant Investments and Software and The Faction Group LLC, Warrant, Acquisition Date 11/3/2014, Series Preferred Series AA2023-01-012023-12-310001280784Warrant Investments and Software and The Faction Group LLC, Warrant, Acquisition Date 11/3/2014, Series Preferred Series AA2023-12-310001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2023-01-012023-12-310001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2023-12-310001280784Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2023-12-310001280784Warrant Investments and Software (0.75%)2023-12-310001280784Warrant Investments and Surgical Devices and TransMedics Group, Inc., Warrant, Acquisition Date 9/11/2015, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Surgical Devices and TransMedics Group, Inc., Warrant, Acquisition Date 9/11/2015, Series Common Stock2023-12-310001280784Warrant Investments and Surgical Devices (0.04%)2023-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2023-01-012023-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2023-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/22/2014, Series Preferred Series A2023-01-012023-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/22/2014, Series Preferred Series A2023-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/7/2015, Series Preferred Series B2023-01-012023-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/7/2015, Series Preferred Series B2023-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Total Halio, Inc., 2023-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Warrant, Polyera Corporation Acquisition Date 3/24/2015, Series Preferred Series C2023-01-012023-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Warrant, Polyera Corporation Acquisition Date 3/24/2015, Series Preferred Series C2023-12-310001280784Warrant Investments and Sustainable and Renewable Technology (0.00%)2023-12-310001280784Total Warrant Investments (1.88%)2023-12-310001280784Investments in Securities (179.92%)2023-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202023-01-012023-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202023-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222023-01-012023-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222023-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development (0.23%)2023-12-310001280784nvestment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222023-01-012023-12-310001280784nvestment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222023-12-310001280784Investment Funds & Vehicles Investments and Software (0.02%)2023-12-310001280784Investment Funds & Vehicles Investments (0.26%)2023-12-310001280784Investments (180.18%)2023-12-310001280784Investment Fund Cash & Cash Equivalent and GS Financial Square Government Fund, Series FGTXX/38141W2732023-12-310001280784Investment Fund In Cash & Cash Equivalents (3.11%)2023-12-310001280784Investment Fund After Cash & Cash Equivalents (183.28%)2023-12-310001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/3/20242023-01-012023-12-310001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/3/20242023-12-310001280784Total Foreign Currency Forward ((0.04%))2023-12-310001280784htgc:OneMonthSOFRMember2023-12-310001280784htgc:ThreeMonthSOFRMember2023-12-310001280784htgc:SixMonthSOFRMember2023-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:WarrantMember2023-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:CommonStockMember2023-12-310001280784htgc:BlackCrowAIIncMemberhtgc:PromissoryNotesMember2023-12-310001280784htgc:RoyaltyContractMemberhtgc:PhathomPharmaceuticalsIncMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:EscrowAndOtherInvestmentReceivableMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberhtgc:EscrowAndOtherInvestmentReceivableMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:SeniorSecuredDebtMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberhtgc:SeniorSecuredDebtMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:UnsecuredDebtMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:UnsecuredDebtMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2024-09-300001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-09-300001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMember2024-09-300001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrivateEquityFundsForeignMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:InvestmentsExcludingDerivativeInstrumentsIncludingCashAndCashEquivalentsAndOtherAssetsMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:DerivativeInstrumentMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:IncludingCashAndCashEquivalentsAndDerivativeInstrumentsMember2024-09-300001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:EscrowAndOtherInvestmentReceivableMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberhtgc:EscrowAndOtherInvestmentReceivableMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:SeniorSecuredDebtMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberhtgc:SeniorSecuredDebtMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:UnsecuredDebtMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:UnsecuredDebtMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2023-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrivateEquityFundsForeignMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:InvestmentsExcludingDerivativeInstrumentsIncludingCashAndCashEquivalentsAndOtherAssetsMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:DerivativeInstrumentMember2023-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:IncludingCashAndCashEquivalentsAndDerivativeInstrumentsMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:PreferredStockInvestmentMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:PreferredStockInvestmentMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:CommonStockInvestmentMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:CommonStockInvestmentMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:WarrantInvestmentMember2024-01-012024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:WarrantInvestmentMember2023-01-012023-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberus-gaap:IncomeApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:ValuationTechniqueLiquidationMemberhtgc:DebtInvestmentsMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsImminentPayoffsMemberhtgc:DebtInvestmentsMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtMaturingWithinOneYearMemberhtgc:DebtInvestmentsMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsInWhollyOwnedSubsidiariesMemberhtgc:DebtInvestmentsMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberhtgc:ValuationTechniqueLiquidationMember2024-09-300001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-09-300001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-09-300001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMembersrt:WeightedAverageMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsAndOtherInvestmentReceivablesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:ValuationTechniqueLiquidationMemberhtgc:DebtInvestmentsMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberus-gaap:IncomeApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:ValuationTechniqueLiquidationMemberhtgc:DebtInvestmentsMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsImminentPayoffsMemberhtgc:DebtInvestmentsMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtMaturingWithinOneYearMemberhtgc:DebtInvestmentsMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:OtherInvestmentReceivableMemberhtgc:ValuationTechniqueLiquidationMemberhtgc:OtherInvestmentReceivablesMember2023-12-310001280784srt:MinimumMemberhtgc:OtherInvestmentReceivablesMemberus-gaap:FairValueInputsLevel3Memberhtgc:OtherInvestmentReceivableMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2023-12-310001280784srt:MaximumMemberhtgc:OtherInvestmentReceivablesMemberus-gaap:FairValueInputsLevel3Memberhtgc:OtherInvestmentReceivableMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2023-12-310001280784srt:WeightedAverageMemberhtgc:OtherInvestmentReceivablesMemberus-gaap:FairValueInputsLevel3Memberhtgc:OtherInvestmentReceivableMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsAndOtherInvestmentReceivablesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:EquitySecuritiesMember2024-09-300001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:EquitySecuritiesMember2024-09-300001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMember2024-09-300001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMemberus-gaap:EquitySecuritiesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:WarrantMember2024-09-300001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:WarrantMember2024-09-300001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberhtgc:EquityAndWarrantInvestmentsMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:EquitySecuritiesMember2023-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:EquitySecuritiesMember2023-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMember2023-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMemberus-gaap:EquitySecuritiesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:WarrantMember2023-12-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputEbitdaMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:WarrantMember2023-12-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMemberus-gaap:WarrantMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EquityAndWarrantInvestmentsMember2023-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2024-09-300001280784htgc:TwoThousandThirtyThreeNotesMember2023-12-310001280784htgc:UnderwritingMemberhtgc:TwoThousandThirtyThreeNotesMember2023-12-310001280784htgc:UnderwritingMemberhtgc:TwoThousandThirtyThreeNotesMember2024-09-300001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2024-09-300001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SBADebenturesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2024-09-300001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2024-09-300001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SMBCFacilityMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300001280784us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SBADebenturesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JulyTwoThousandTwentyFourNotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JulyTwoThousandTwentyFourNotesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JulyTwoThousandTwentyFourNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2023-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2023-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SMBCFacilityMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2023-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2024-07-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2024-01-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2024-07-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2024-01-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2024-07-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2024-01-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2024-07-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2024-01-012024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2023-07-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2023-01-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2023-07-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2023-01-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2023-07-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2023-01-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2023-07-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2023-01-012023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2023-09-300001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-09-300001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-01-012023-12-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-09-300001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-09-300001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-12-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-01-012023-12-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-09-300001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-09-300001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-12-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-01-012023-12-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-09-300001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-09-300001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-12-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-09-300001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-12-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-09-300001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-12-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-09-300001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-12-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2023-01-012023-12-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784country:DKus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784country:DKus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784country:DKus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784country:DKus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-09-300001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-09-300001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-12-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DrugDiscoveryAndDevelopmentMember2024-09-300001280784htgc:DrugDiscoveryAndDevelopmentMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DrugDiscoveryAndDevelopmentMember2023-12-310001280784htgc:DrugDiscoveryAndDevelopmentMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SoftwareMember2024-09-300001280784htgc:SoftwareMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SoftwareMember2023-12-310001280784htgc:SoftwareMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:HealthcareServicesOtherMember2024-09-300001280784htgc:HealthcareServicesOtherMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:HealthcareServicesOtherMember2023-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ConsumerAndBusinessServicesMember2024-09-300001280784htgc:ConsumerAndBusinessServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ConsumerAndBusinessServicesMember2023-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DiversifiedFinancialServicesMember2024-09-300001280784htgc:DiversifiedFinancialServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DiversifiedFinancialServicesMember2023-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ElectronicsComputerHardwareMember2024-09-300001280784htgc:ElectronicsComputerHardwareMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ElectronicsComputerHardwareMember2023-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:InformationServicesMember2024-09-300001280784htgc:InformationServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:InformationServicesMember2023-12-310001280784htgc:InformationServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:MedicalDevicesAndEquipmentMember2024-09-300001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:MedicalDevicesAndEquipmentMember2023-12-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SpaceTechnologiesMember2024-09-300001280784htgc:SpaceTechnologiesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SpaceTechnologiesMember2023-12-310001280784htgc:SpaceTechnologiesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:BiotechnologyToolsMember2024-09-300001280784htgc:BiotechnologyToolsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:BiotechnologyToolsMember2023-12-310001280784htgc:BiotechnologyToolsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SustainableAndRenewableTechnologyMember2024-09-300001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SustainableAndRenewableTechnologyMember2023-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:CommunicationsAndNetworkingMember2024-09-300001280784htgc:CommunicationsAndNetworkingMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:CommunicationsAndNetworkingMember2023-12-310001280784htgc:CommunicationsAndNetworkingMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ManufacturingTechnologyMember2024-09-300001280784htgc:ManufacturingTechnologyMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ManufacturingTechnologyMember2023-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ConsumerAndBusinessProductsMember2024-09-300001280784htgc:ConsumerAndBusinessProductsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ConsumerAndBusinessProductsMember2023-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SemiconductorsMember2024-09-300001280784htgc:SemiconductorsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SemiconductorsMember2023-12-310001280784htgc:SemiconductorsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:MediaContentInfoMember2024-09-300001280784htgc:MediaContentInfoMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:MediaContentInfoMember2023-12-310001280784htgc:MediaContentInfoMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DrugDeliveryMember2024-09-300001280784htgc:DrugDeliveryMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DrugDeliveryMember2023-12-310001280784htgc:DrugDeliveryMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SurgicalDevicesMember2024-09-300001280784htgc:SurgicalDevicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SurgicalDevicesMember2023-12-310001280784htgc:SurgicalDevicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:TotalIndustrySectorsMember2024-09-300001280784htgc:TotalIndustrySectorsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:TotalIndustrySectorsMember2023-12-310001280784htgc:TotalIndustrySectorsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySubSectorInvestmentsBenchmarkMember2023-01-012023-12-310001280784us-gaap:CreditConcentrationRiskMember2024-09-300001280784us-gaap:CreditConcentrationRiskMember2023-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsIncludingIntellectualPropertyMemberhtgc:TotalDebtInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsIncludingIntellectualPropertyMemberhtgc:TotalDebtInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsWithNegativePledgeOnIntellectualPropertyMemberhtgc:TotalDebtInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsWithNegativePledgeOnIntellectualPropertyMemberhtgc:TotalDebtInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:LastOutWithSecurityInterestInAllOfTheAssetsMemberhtgc:TotalDebtInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:LastOutWithSecurityInterestInAllOfTheAssetsMemberhtgc:TotalDebtInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:TotalDebtInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:TotalDebtInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:SecondLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:TotalDebtInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:SecondLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:TotalDebtInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:UnsecuredMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:TotalDebtInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:UnsecuredMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:TotalDebtInvestmentsBenchmarkMember2023-01-012023-12-310001280784htgc:CollateralTypeConcentrationRiskMemberhtgc:TotalDebtInvestmentsBenchmarkMember2024-01-012024-09-300001280784htgc:CollateralTypeConcentrationRiskMemberhtgc:TotalDebtInvestmentsBenchmarkMember2023-01-012023-12-310001280784us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMember2024-09-300001280784us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMember2023-12-310001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2024-09-300001280784us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2023-12-310001280784us-gaap:ForeignExchangeForwardMember2024-09-300001280784us-gaap:ForeignExchangeForwardMember2023-12-310001280784us-gaap:ForeignExchangeForwardMember2024-07-012024-09-300001280784us-gaap:ForeignExchangeForwardMember2023-07-012023-09-300001280784us-gaap:ForeignExchangeForwardMember2024-01-012024-09-300001280784us-gaap:ForeignExchangeForwardMember2023-01-012023-09-300001280784htgc:ContractualInterestIncomeMember2024-07-012024-09-300001280784htgc:ContractualInterestIncomeMember2023-07-012023-09-300001280784htgc:ContractualInterestIncomeMember2024-01-012024-09-300001280784htgc:ContractualInterestIncomeMember2023-01-012023-09-300001280784htgc:ExitFeeMember2024-07-012024-09-300001280784htgc:ExitFeeMember2023-07-012023-09-300001280784htgc:ExitFeeMember2024-01-012024-09-300001280784htgc:ExitFeeMember2023-01-012023-09-300001280784htgc:PIKInterestMember2024-07-012024-09-300001280784htgc:PIKInterestMember2023-07-012023-09-300001280784htgc:PIKInterestMember2024-01-012024-09-300001280784htgc:PIKInterestMember2023-01-012023-09-300001280784htgc:DividendIncomeMember2024-07-012024-09-300001280784htgc:DividendIncomeMember2023-07-012023-09-300001280784htgc:DividendIncomeMember2024-01-012024-09-300001280784htgc:DividendIncomeMember2023-01-012023-09-300001280784htgc:OtherInterestIncomeMember2024-07-012024-09-300001280784htgc:OtherInterestIncomeMember2023-07-012023-09-300001280784htgc:OtherInterestIncomeMember2024-01-012024-09-300001280784htgc:OtherInterestIncomeMember2023-01-012023-09-300001280784htgc:RecurringFeeIncomeMember2024-07-012024-09-300001280784htgc:RecurringFeeIncomeMember2023-07-012023-09-300001280784htgc:RecurringFeeIncomeMember2024-01-012024-09-300001280784htgc:RecurringFeeIncomeMember2023-01-012023-09-300001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2024-07-012024-09-300001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2023-07-012023-09-300001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2024-01-012024-09-300001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2023-01-012023-09-300001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2024-07-012024-09-300001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2023-07-012023-09-300001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2024-01-012024-09-300001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2023-01-012023-09-300001280784htgc:IncludedInCostMember2024-09-300001280784htgc:IncludedInCostMember2023-12-310001280784htgc:DeferredFeesMember2024-09-300001280784htgc:DeferredFeesMember2023-12-310001280784htgc:SBADebenturesMember2024-09-300001280784htgc:SBADebenturesMember2023-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2024-09-300001280784htgc:JulyTwoThousandTwentyFourNotesMember2023-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2024-09-300001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2023-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2024-09-300001280784htgc:JuneTwoThousandTwentyFiveNotesMember2023-12-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-09-300001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2023-12-310001280784htgc:MarchTwoThousandTwentySixANotesMember2024-09-300001280784htgc:MarchTwoThousandTwentySixANotesMember2023-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2024-09-300001280784htgc:MarchTwoThousandTwentySixBNotesMember2023-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2024-09-300001280784htgc:SeptemberTwoThousandTwentySixNotesMember2023-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2024-09-300001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2023-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2024-09-300001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2023-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2024-09-300001280784htgc:TwoThousandThirtyThreeNotesMember2023-12-310001280784htgc:MUFGBankFacilityMember2024-09-300001280784htgc:MUFGBankFacilityMember2023-12-310001280784htgc:SMBCFacilityMember2024-09-300001280784htgc:SMBCFacilityMember2023-12-310001280784htgc:SmbcLcFacilityMember2023-12-310001280784htgc:SmbcLcFacilityMember2024-09-300001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2023-12-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2024-09-300001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2024-07-090001280784htgc:DebtIssuanceCostsNetAndOtherAssetsMember2024-09-300001280784htgc:DebtIssuanceCostsNetAndOtherAssetsMember2023-12-310001280784htgc:SBADebenturesMember2024-07-012024-09-300001280784htgc:SBADebenturesMember2024-01-012024-09-300001280784htgc:JulyTwoThousandTwentyFourNotesMember2024-07-012024-09-300001280784htgc:JulyTwoThousandTwentyFourNotesMember2024-01-012024-09-300001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2024-07-012024-09-300001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2024-01-012024-09-300001280784htgc:JuneTwoThousandTwentyFiveNotesMember2024-07-012024-09-300001280784htgc:JuneTwoThousandTwentyFiveNotesMember2024-01-012024-09-300001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-07-012024-09-300001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-01-012024-09-300001280784htgc:MarchTwoThousandTwentySixANotesMember2024-07-012024-09-300001280784htgc:MarchTwoThousandTwentySixANotesMember2024-01-012024-09-300001280784htgc:MarchTwoThousandTwentySixBNotesMember2024-07-012024-09-300001280784htgc:MarchTwoThousandTwentySixBNotesMember2024-01-012024-09-300001280784htgc:SeptemberTwoThousandTwentySixNotesMember2024-07-012024-09-300001280784htgc:SeptemberTwoThousandTwentySixNotesMember2024-01-012024-09-300001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2024-07-012024-09-300001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2024-01-012024-09-300001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2024-07-012024-09-300001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2024-01-012024-09-300001280784htgc:TwoThousandThirtyThreeNotesMember2024-07-012024-09-300001280784htgc:TwoThousandThirtyThreeNotesMember2024-01-012024-09-300001280784htgc:MUFGBankFacilityMember2024-07-012024-09-300001280784htgc:MUFGBankFacilityMember2024-01-012024-09-300001280784htgc:SMBCFacilityMember2024-07-012024-09-300001280784htgc:SMBCFacilityMember2024-01-012024-09-300001280784htgc:SBADebenturesMember2023-07-012023-09-300001280784htgc:SBADebenturesMember2023-01-012023-09-300001280784htgc:JulyTwoThousandTwentyFourNotesMember2023-07-012023-09-300001280784htgc:JulyTwoThousandTwentyFourNotesMember2023-01-012023-09-300001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2023-07-012023-09-300001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2023-01-012023-09-300001280784htgc:JuneTwoThousandTwentyFiveNotesMember2023-07-012023-09-300001280784htgc:JuneTwoThousandTwentyFiveNotesMember2023-01-012023-09-300001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2023-07-012023-09-300001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2023-01-012023-09-300001280784htgc:MarchTwoThousandTwentySixANotesMember2023-07-012023-09-300001280784htgc:MarchTwoThousandTwentySixANotesMember2023-01-012023-09-300001280784htgc:MarchTwoThousandTwentySixBNotesMember2023-07-012023-09-300001280784htgc:MarchTwoThousandTwentySixBNotesMember2023-01-012023-09-300001280784htgc:SeptemberTwoThousandTwentySixNotesMember2023-07-012023-09-300001280784htgc:SeptemberTwoThousandTwentySixNotesMember2023-01-012023-09-300001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2023-07-012023-09-300001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2023-01-012023-09-300001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2023-07-012023-09-300001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2023-01-012023-09-300001280784htgc:TwoThousandThirtyThreeNotesMember2023-07-012023-09-300001280784htgc:TwoThousandThirtyThreeNotesMember2023-01-012023-09-300001280784htgc:MUFGBankFacilityMember2023-07-012023-09-300001280784htgc:MUFGBankFacilityMember2023-01-012023-09-300001280784htgc:SMBCFacilityMember2023-07-012023-09-300001280784htgc:SMBCFacilityMember2023-01-012023-09-300001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2024-09-300001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2023-12-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2024-09-300001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2023-12-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2024-01-012024-09-300001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2024-09-300001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2023-12-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2024-01-012024-09-300001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2020-10-272020-10-270001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2020-10-270001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2024-01-012024-09-300001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2024-07-092024-07-090001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2024-09-300001280784htgc:HerculesCapitalFourLPMember2024-09-300001280784htgc:HerculesSBICVL.P.Member2024-09-300001280784htgc:HerculesCapitalFourLPMember2023-12-310001280784htgc:HerculesSBICVL.P.Member2023-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2019-07-160001280784htgc:JulyTwoThousandTwentyFourNotesMember2024-07-162024-07-160001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2020-02-050001280784htgc:JuneTwoThousandTwentyFiveNotesMember2020-06-030001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2022-06-230001280784htgc:MarchTwoThousandTwentySixANotesMember2020-11-040001280784htgc:MarchTwoThousandTwentySixBNotesMember2021-03-040001280784htgc:SeptemberTwoThousandTwentySixNotesMember2021-09-160001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2022-01-200001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2022-06-220001280784htgc:TwoThousandThirtyOneAssetBackedNotesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-09-300001280784htgc:TwoThousandThirtyOneAssetBackedNotesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2018-09-240001280784us-gaap:RevolvingCreditFacilityMember2024-01-012024-09-300001280784us-gaap:RevolvingCreditFacilityMember2023-01-012023-12-310001280784htgc:MUFGBankFacilityMember2024-09-300001280784srt:MaximumMemberhtgc:MUFGBankFacilityMember2024-09-300001280784htgc:MUFGBankFacilityMember2024-01-012024-09-300001280784htgc:SMBCFacilityMember2024-09-300001280784srt:MaximumMemberhtgc:SMBCFacilityMember2024-09-300001280784htgc:SMBCFacilityMember2024-01-012024-09-300001280784htgc:SmbcLcFacilityMember2023-01-310001280784srt:MaximumMemberhtgc:SmbcLcFacilityMember2024-09-300001280784srt:MinimumMemberhtgc:SMBCFacilityMember2024-01-012024-09-300001280784srt:MaximumMemberhtgc:SMBCFacilityMember2024-01-012024-09-300001280784us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-01-012023-12-310001280784us-gaap:CommonStockMemberhtgc:TwoThousandTwentyThreeEquityDistributionAgreementMember2023-05-050001280784us-gaap:CommonStockMember2023-08-072023-08-070001280784htgc:CommonGrossProceedsMember2024-01-012024-09-300001280784htgc:CommonOfferingExpensesMember2024-01-012024-09-300001280784htgc:CommonGrossProceedsMember2023-01-012023-09-300001280784htgc:CommonOfferingExpensesMember2023-01-012023-09-300001280784htgc:O2023Q1DividendsMember2023-01-012023-03-310001280784htgc:S2023Q1DividendsMember2023-01-012023-03-310001280784htgc:O2023Q2DividendsMember2023-04-012023-06-300001280784htgc:S2023Q2DividendsMember2023-04-012023-06-300001280784htgc:O2023Q3DividendsMember2023-07-012023-09-300001280784htgc:S2023Q3DividendsMember2023-07-012023-09-300001280784htgc:O2023Q4DividendsMember2023-10-012023-12-310001280784htgc:S2023Q4DividendsMember2023-10-012023-12-3100012807842023-01-012023-12-310001280784htgc:O2024Q1DividendsMember2024-01-012024-03-310001280784htgc:S2024Q1DividendsMember2024-01-012024-03-310001280784htgc:O2024Q2DividendsMember2024-04-012024-06-300001280784htgc:S2024Q2DividendsMember2024-04-012024-06-300001280784htgc:O2024Q3DividendsMember2024-07-012024-09-300001280784htgc:S2024Q3DividendsMember2024-07-012024-09-300001280784htgc:SpilloveramountpershareMember2024-09-300001280784us-gaap:CommonStockMemberhtgc:TwoThousandEighteenPlanMember2018-06-280001280784us-gaap:CommonStockMemberhtgc:DirectorPlanMember2018-06-280001280784us-gaap:CommonStockMemberhtgc:TwoThousandEighteenPlanMember2024-09-300001280784us-gaap:CommonStockMemberhtgc:DirectorPlanMember2024-09-300001280784htgc:ServiceVestingAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001280784htgc:ServiceVestingAwardsMemberhtgc:ShareBasedPaymentArrangementTrancheTwoAndThreeMember2024-01-012024-09-300001280784htgc:ServiceVestingAwardsMembersrt:MaximumMember2024-01-012024-09-300001280784htgc:ServiceVestingAwardsMember2024-01-012024-09-300001280784htgc:ServiceVestingAwardsMember2023-01-012023-09-300001280784us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001280784us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001280784htgc:PerformanceVestingAwardsMember2024-01-012024-09-300001280784htgc:PerformanceVestingAwardsMembersrt:MinimumMember2024-01-012024-09-300001280784htgc:PerformanceVestingAwardsMember2023-01-012023-09-300001280784htgc:PerformanceDeuMember2024-01-012024-09-300001280784htgc:PerformanceDeuMember2023-01-012023-09-300001280784htgc:PerformanceVestingAwardsMember2024-09-300001280784htgc:PerformanceVestingAwardsMember2023-09-300001280784htgc:LiabilityClassifiedAwardsMember2024-01-012024-09-300001280784htgc:OtherLiabilityClassifiedAwardsMember2024-01-012024-09-300001280784htgc:LiabilityClassifiedAwardsMember2023-01-012023-09-300001280784htgc:LiabilityClassifiedAwardsMember2023-09-300001280784srt:MinimumMember2024-01-012024-09-300001280784srt:MaximumMember2024-01-012024-09-300001280784htgc:ServiceVestingAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-09-300001280784htgc:ServiceVestingAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300001280784us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001280784us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001280784us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001280784us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001280784us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001280784us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001280784us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001280784us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001280784htgc:UnvestedRestrictedStockAwardsMember2024-07-012024-09-300001280784htgc:UnvestedRestrictedStockAwardsMember2023-07-012023-09-300001280784htgc:UnvestedRestrictedStockAwardsMember2024-01-012024-09-300001280784htgc:UnvestedRestrictedStockAwardsMember2023-01-012023-09-300001280784us-gaap:SubsequentEventMember2024-10-270001280784us-gaap:SubsequentEventMember2024-10-280001280784htgc:NetInvestmentIncomeMember2024-01-012024-09-300001280784htgc:NetInvestmentIncomeMember2023-01-012023-09-300001280784htgc:RealizedGainLossMember2024-01-012024-09-300001280784htgc:RealizedGainLossMember2023-01-012023-09-300001280784htgc:UnrealizedGainLossMember2024-01-012024-09-300001280784htgc:UnrealizedGainLossMember2023-01-012023-09-300001280784htgc:EarnixLtdMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:EarnixLtdMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ArcusBiosciencesInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ArcusBiosciencesInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ShieldAIInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ShieldAIInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ThumbtackInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ThumbtackInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ArmisInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ArmisInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:CheckrGroupInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:CheckrGroupInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:SkydioInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:SkydioInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:PindropSecurityInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:PindropSecurityInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:BraeburnPharmaceuticalsMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:BraeburnPharmaceuticalsMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:CoronetCyberSecurityLtd.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:CoronetCyberSecurityLtd.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:PhathomPharmaceuticalsInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:PhathomPharmaceuticalsInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:AkeroTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:AkeroTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:MainStreetRuralInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:MainStreetRuralInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:HarnessInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:HarnessInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:MarathonHealthLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:MarathonHealthLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ViridianTherapeuticsMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ViridianTherapeuticsMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:SuzyInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:SuzyInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:WellBeSeniorMedicalLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:WellBeSeniorMedicalLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:GeronCorporationMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:GeronCorporationMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:SemperisTechnologiesInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:SemperisTechnologiesInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ElationHealthInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ElationHealthInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:CuranaHealthHoldingsLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:CuranaHealthHoldingsLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ATAILifeSciencesN.V.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ATAILifeSciencesN.V.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:BehavoxLimitedMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:BehavoxLimitedMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:DragosMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:DragosMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:LeapworkApSMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:LeapworkApSMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:EnGeneInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:EnGeneInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:BabelStreetMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:BabelStreetMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:HeronTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:HeronTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:AlphaSenseInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:AlphaSenseInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:SaamaTechnologiesLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:SaamaTechnologiesLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:AllvueSystemsLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:AllvueSystemsLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:SightSciencesInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:SightSciencesInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:LogRhythmInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:LogRhythmInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:RecoverTogetherInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:RecoverTogetherInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:DronedeployInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:DronedeployInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:RivieraPartnersLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:RivieraPartnersLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ZappiInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ZappiInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:LoftwareInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:LoftwareInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:StreamlineHealthcareSolutionsMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:StreamlineHealthcareSolutionsMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:NewRelicInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:NewRelicInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:SumoLogicInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:SumoLogicInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:CerosInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:CerosInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ThreatConnectInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ThreatConnectInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:LogicSourceMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:LogicSourceMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:A3GTMSLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:A3GTMSLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ZimperiumInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ZimperiumInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:FlightScheduleProLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:FlightScheduleProLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:IkonScienceLimitedMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:IkonScienceLimitedMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:LinenMasterLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:LinenMasterLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:FortifiedHealthSecurityMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:FortifiedHealthSecurityMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:OmedaHoldingsLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:OmedaHoldingsLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:DispatchTechnologiesInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:DispatchTechnologiesInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:Constructor.ioCorporationMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:Constructor.ioCorporationMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ShadowDragonLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ShadowDragonLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:CybermaxxIntermediateHoldingsInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:CybermaxxIntermediateHoldingsInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:AutomationAnywhereInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:AutomationAnywhereInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:TarsusPharmaceuticalsInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:TarsusPharmaceuticalsInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:KuraOncologyInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:KuraOncologyInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:TipaltiSolutionsLtd.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:TipaltiSolutionsLtd.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:NextInsuranceInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:NextInsuranceInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:SenseonicsHoldingsInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:SenseonicsHoldingsInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:ModernLifeInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:ModernLifeInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:BrainCorporationMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:BrainCorporationMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:CutoverInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:CutoverInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:PlentificLtdMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:PlentificLtdMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:AltumintInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:AltumintInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:YipitLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:YipitLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:DashlaneInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:DashlaneInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:AnnexCloudMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:AnnexCloudMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:AgilenceInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:AgilenceInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:EnmarkSystemsInc.Memberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:EnmarkSystemsInc.Memberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:AlchemerLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:AlchemerLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:CytracomHoldingsLLCMemberhtgc:DebtInvestmentsMember2024-09-300001280784htgc:CytracomHoldingsLLCMemberhtgc:DebtInvestmentsMember2023-12-310001280784htgc:DebtInvestmentsMember2024-09-300001280784htgc:DebtInvestmentsMember2023-12-310001280784htgc:ForbionGrowthOpportunitiesFundICVMemberhtgc:InvestmentFundsAndVehiclesMember2024-09-300001280784htgc:ForbionGrowthOpportunitiesFundICVMemberhtgc:InvestmentFundsAndVehiclesMember2023-12-310001280784htgc:ForbionGrowthOpportunitiesFundIICVMemberhtgc:InvestmentFundsAndVehiclesMember2024-09-300001280784htgc:ForbionGrowthOpportunitiesFundIICVMemberhtgc:InvestmentFundsAndVehiclesMember2023-12-310001280784htgc:InvestmentFundsAndVehiclesMember2024-09-300001280784htgc:InvestmentFundsAndVehiclesMember2023-12-310001280784htgc:AdviserFundsMember2024-09-300001280784htgc:AdviserFundsMember2023-12-310001280784htgc:LeaseAndLicenseObligationsMember2024-09-300001280784htgc:LeaseAndLicenseObligationsMember2023-12-310001280784htgc:SMBCFacilityMember2024-09-300001280784htgc:MUFGBankFacilityMember2024-09-300001280784htgc:SMBCFacilityMember2023-12-310001280784htgc:MUFGBankFacilityMember2023-12-310001280784htgc:AdviserSubsidiaryMember2024-07-012024-09-300001280784htgc:AdviserSubsidiaryMember2024-01-012024-09-300001280784htgc:AdviserSubsidiaryMember2023-07-012023-09-300001280784htgc:AdviserSubsidiaryMember2023-01-012023-09-300001280784htgc:AdviserSubsidiaryMember2024-09-300001280784htgc:AdviserSubsidiaryMember2023-12-310001280784htgc:AdviserFundsMember2024-01-012024-09-300001280784htgc:AdviserFundsMember2023-01-012023-09-300001280784us-gaap:SubsequentEventMemberhtgc:O2024Q4DividendsMember2024-10-240001280784us-gaap:SubsequentEventMemberhtgc:S2024ADividendsMember2024-01-012024-12-310001280784us-gaap:SubsequentEventMemberhtgc:S2024Q4DividendsMember2024-10-012024-12-310001280784us-gaap:SubsequentEventMemberhtgc:S2024Q4DividendsMember2024-10-240001280784htgc:S2024Q1DividendsMember2024-03-062024-03-060001280784htgc:S2024Q3DividendsMember2024-08-132024-08-130001280784htgc:S2024Q2DividendsMember2024-05-142024-05-140001280784htgc:S2024ADividendsMember2024-02-082024-02-080001280784htgc:SignificantPortfolioInvestmentMember2024-01-012024-09-300001280784htgc:ScottBluesteinMember2024-01-012024-09-300001280784htgc:ScottBluesteinMember2024-04-012024-06-300001280784htgc:ScottBluesteinMember2024-06-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2024-01-012024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2024-01-012024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2024-01-012024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMember2024-01-012024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2024-01-012024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2024-01-012024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-01-012024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2024-01-012024-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2023-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2024-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2024-01-012024-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2023-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2024-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2024-01-012024-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2023-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2024-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-01-012024-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2023-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2023-01-012023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2022-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2023-01-012023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2022-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2023-01-012023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2022-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:PreferredStockMember2023-01-012023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:PreferredStockMember2022-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:PreferredStockMember2023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2023-01-012023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2022-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2023-01-012023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2022-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2023-01-012023-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2022-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2023-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2023-01-012023-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2022-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2023-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2023-01-012023-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2022-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2023-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2023-01-012023-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2022-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2023-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2023-01-012023-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2022-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2023-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2022-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:SeriesAPreferredStockMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:PreferredStockMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:CommonStockMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MedicalDevicesAndEquipmentMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtOneMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtTwoMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:MemberUnitsMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:DiversifiedFinancialServicesMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:UnsecuredDebtMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:MemberUnitsMember2024-09-300001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:DiversifiedFinancialServicesMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:CommonStockMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:PreferredSeriesBBMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:PreferredStockMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:SeriesCPreferredStockMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:PreferredStockMember2024-09-300001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:ConsumerAndBusinessServicesMember2024-09-300001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:SeriesAPreferredStockMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:PreferredStockMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:CommonStockMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MedicalDevicesAndEquipmentMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtOneMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtTwoMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:MemberUnitsMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:DiversifiedFinancialServicesMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:UnsecuredDebtMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:MemberUnitsMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:DiversifiedFinancialServicesMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:CommonStockMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:PreferredSeriesBBMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:PreferredStockMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:SeriesCPreferredStockMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:PreferredStockMember2023-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:ConsumerAndBusinessServicesMember2023-12-31

美國

證券交易委員會

華盛頓特區20549

_________________________________________________

形式 10-Q

_________________________________________________

(Mark一）

x 根據1934年《證券交易法》第13或15（d）條的季度報告

截至季度 2024年9月30日

或

o 根據1934年《證券交易所法》第13或15（d）條提交的過渡報告

委員會文件號： 814-00702

_________________________________________________

赫庫爾斯資本公司

（註冊人章程中規定的確切名稱）

_________________________________________________

馬里蘭						74-3113410
（州或管轄區 公司或組織）						(IRS僱主 識別號）
北b街1號., 2000套房 聖馬特奧, 加州 （主要行政辦公室地址）						94401 (Zip代碼）

(650) 289-3060

（註冊人的電話號碼，包括地區代碼）

根據該法第12（b）條登記的證券：

每個班級的標題

交易符號

註冊的每個交易所的名稱

普通股，面值每股0.001美金

HTGC

紐約證券交易所

6.25% 2033年到商業本票據

HCXY

紐約證券交易所

通過複選標記確定登記人是否（1）在過去12個月內（或在登記人被要求提交此類報告的較短期限內）提交了1934年證券交易法第13或15（d）條要求提交的所有報告，以及（2）在過去90天內一直遵守此類提交要求。 是的 x 沒有 o

通過勾選標記檢查註冊人是否已在過去12個月內（或在註冊人被要求提交此類文件的較短期限內）以電子方式提交了根據S-t法規第405條（本章第232.405條）要求提交的所有交互數據文件。 是的 x 沒有 o

通過複選標記來確定註冊人是大型加速申報人、加速申報人、非加速申報人、小型報告公司還是新興成長型公司。請參閱《交易法》第120條第2條中「大型加速申報人」、「加速申報人」、「小型報告公司」和「新興成長型公司」的定義。

大型加速文件夾

x

加速編報公司

o

非加速歸檔

o

小型上市公司

o

新興成長型公司

o

如果是新興成長型公司，請通過勾選標記表明註冊人是否選擇不利用延長的過渡期來遵守根據《交易法》第13（a）條規定的新的或修訂的財務會計準則。

通過勾選標記檢查註冊人是否是空殼公司（定義見《交易法》第120條第2款）。是的 o 沒有 x

2024年10月24日，有 162,449,710 註冊人普通股的流通股，面值0.001美金。

---

赫庫爾斯資本公司

Form 10-Q目錄

第一部分.財務資料						3
項目1.			綜合財務報表			3
			截至2011年的合併資產負債表 九月 2024年30日（未經審計）和2023年12月31日			3
			這三者的合併運營報表 九 截至 九月 2024年和2023年（未經審計）			4
			三者合併淨資產變動表 九 截至 九月 2024年和2023年（未經審計）			5
			合併現金流量表 九 截至 九月 2024年和2023年（未經審計）			6
			截至日期的綜合投資計劃 九月 2024年30日（未經審計）			7
			截至2023年12月31日的合併投資計劃			21
			合併財務報表附註（未經審計）			35
項目2.			管理層對財務狀況和經營成果的討論和分析			71
項目3.			關於市場風險的定量和定性披露			87
項目4.			控制和程式			88
第二部分.其他信息						89
項目1.			法律訴訟			89
項目1A.			危險因素			89
項目2.			股權證券的未登記銷售、收益的使用和發行人購買股權證券			90
項目3.			優先證券			90
項目4.			礦山安全披露			90
項目5.			其他信息			90
項目6.			展品和財務報表附表			91
簽名						96

---

目錄

第一部分：財務信息

在本季度報告中，「公司」、「Hercules」、「我們」、「我們」和「我們的」是指Hercules Capital，Inc.，其全資子公司及其附屬證券化信託，除非上下文另有要求。

項目1. 綜合財務報表

赫庫爾斯資本公司

資產和負債合併報表

(in數千人，每股數據除外）			2024年9月30日 （未經審計）						2023年12月31日
資產
投資，按公允價值計算：
非控制/非附屬投資（成本為美金3,505,649 和$3,143,851，分別）			$	3,447,416					$	3,133,042
控制投資（成本為美金104,337 和$103,182，分別）			113,097						115,004
投資總額，按公允價值計算（成本為美金3,609,986 和$3,247,033分別;與VIE $相關的公允價值金額272,611 和$254,868，分別）			3,560,513						3,248,046
現金及現金等價物			38,904						98,899
受限制現金（與VIE $相關的金額5,113 和$17,114，分別）			5,113						17,114
收利息			31,450						32,741
使用權資產			17,249						4,787
其他資產			3,130						15,339
總資產			$	3,656,359					$	3,416,926
負債
債務（扣除債務發行成本美金11,791 和$15,131，分別;與VIE $相關的金額148,985 和$148,544，分別）			$	1,739,209					$	1,554,869
應付款項和應計負債			46,860						54,156
經營租賃負債			18,480						5,195
總負債			$	1,804,549					$	1,614,220
淨資產包括：
普通股，面值			$	163					$	158
超過面值的資本			1,741,975						1,662,535
可分配收益總額			109,672						140,013
淨資產總額			$	1,851,810					$	1,802,706
負債總額和淨資產			$	3,656,359					$	3,416,926
流通普通股股份（美金0.001 票面金額及 200,000 授權）			162,505						157,758
每股資產淨值			$	11.40					$	11.43

參見合併財務報表附註

3

---

目錄

赫庫爾斯資本公司

綜合經營報表

（未經審計）

(in數千人，每股數據除外）			截至9月30日的三個月，												截至9月30日的九個月，
			2024						2023						2024						2023
投資收益：
利息和股息收入：
非控制/非附屬投資			$	115,563					$	109,240					$	342,457					$	315,952
控制投資			3,487						1,099						9,901						3,270
利息和股息收入總額			119,050						110,339						352,358						319,222
費用收入：
非控制/非附屬投資			6,162						6,383						19,341						18,783
控制投資			36						22						108						60
總費用收入			6,198						6,405						19,449						18,843
總投資收益			125,248						116,744						371,807						338,065
運營費用：
興趣			20,370						16,428						57,156						50,237
貸款費用			1,993						2,524						6,736						7,317
一般及行政			4,596						4,591						14,135						13,868
稅費用			1,986						1,882						4,451						5,249
員工薪酬：
薪酬福利			12,159						13,604						42,917						41,062
股票補償			3,194						3,337						9,671						9,848
員工薪酬總額			15,353						16,941						52,588						50,910
總運營費用			44,298						42,366						135,066						127,581
分配給顧問子公司的費用			(2,214)						(2,416)						(7,943)						(7,509)
淨運營費用總額			42,084						39,950						127,123						120,072
淨投資收入			83,164						76,794						244,684						217,993
已實現淨收益（損失）和未實現增值（折舊）淨變化：
已實現淨收益（虧損）：
非控制/非附屬投資			(559)						(2,587)						1,825						5,590
已實現淨收益（損失）總額			(559)						(2,587)						1,825						5,590
未實現增值（折舊）淨變化：
非控制/非附屬投資			(15,167)						(45,141)						(41,920)						(18,597)
控制投資			1,273						(1,099)						(3,062)						12,320
未實現增值（折舊）淨變化總額			(13,894)						(46,240)						(44,982)						(6,277)
已實現淨收益（損失）和未實現增值（折舊）淨變化總額			(14,453)						(48,827)						(43,157)						(687)
經營淨資產淨增加（減少）			$	68,711					$	27,967					$	201,527					$	217,306
每股普通股損益前的淨投資收益：
基本			$	0.51					$	0.52					$	1.52					$	1.53
每股普通股運營導致的淨資產變化：
基本			$	0.42					$	0.19					$	1.25					$	1.52
稀釋			$	0.42					$	0.19					$	1.24					$	1.51
加權平均發行股數：
基本			161,019						146,899						159,742						141,223
稀釋			161,515						147,110						160,253						142,126
每股普通股支付的分配：
基本			$	0.48					$	0.48					$	1.44					$	1.42

See notes to consolidated financial statements

4

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

(unaudited)

(in thousands)			Common Stock												Capital in excess of par value						Distributable Earnings (loss)						Net Assets
For the Three Months Ended September 30, 2024			Shares						Par Value
Balance as of June 30, 2024			162,428						$	163					$	1,737,478					$	118,904					$	1,856,545
Net increase (decrease) in net assets resulting from operations			—						—						—						68,711						68,711
Public offering, net of offering expenses			—						—						(88)						—						(88)
Issuance of common stock under equity-based award plans			10						—						75						—						75
Shares retired on vesting of equity-based awards			(69)						—						(1,165)						—						(1,165)
Distributions reinvested in common stock			136						—						2,445						—						2,445
Distributions			—						—						—						(77,943)						(77,943)
Stock-based compensation(1)			—						—						3,230						—						3,230
Balance as of September 30, 2024			162,505						$	163					$	1,741,975					$	109,672					$	1,851,810
For the Nine Months Ended September 30, 2024
Balance as of December 31, 2023			157,758						$	158					$	1,662,535					$	140,013					$	1,802,706
Net increase (decrease) in net assets resulting from operations			—						—						—						201,527						201,527
Public offering, net of offering expenses			3,725						4						66,280						—						66,284
Issuance of common stock under equity-based award plans			1,032						1						2,975						—						2,976
Shares retired on vesting of equity-based awards			(351)						—						(5,371)						—						(5,371)
Distributions reinvested in common stock			341						—						6,277						—						6,277
Distributions			—						—						—						(231,868)						(231,868)
Stock-based compensation(1)			—						—						9,279						—						9,279
Balance as of September 30, 2024			162,505						$	163					$	1,741,975					$	109,672					$	1,851,810

(1)Stock-based compensation includes $36 thousand and $107 thousand of restricted stock and option expense related to director compensation for the three and nine months ended September 30, 2024, respectively.

(in thousands)			Common Stock												Capital in excess of par value						Distributable Earnings (loss)						Net Assets
For the Three Months Ended September 30, 2023			Shares						Par Value
Balance as of June 30, 2023			144,641						$	145					$	1,468,270					$	117,095					$	1,585,510
Net increase (decrease) in net assets resulting from operations			—						—						—						27,967						27,967
Public offering, net of offering expenses			6,500						7						107,555						—						107,562
Issuance of common stock under equity-based award plans			21						—						163						—						163
Shares retired on vesting of equity-based awards			(48)						—						(675)						—						(675)
Distributions reinvested in common stock			65						—						1,057						—						1,057
Distributions			—						—						—						(72,534)						(72,534)
Stock-based compensation(1)			—						—						3,007						—						3,007
Balance as of September 30, 2023			151,179						$	152					$	1,579,377					$	72,528					$	1,652,057
For the Nine Months Ended September 30, 2023
Balance as of December 31, 2022			133,045						$	134					$	1,341,416					$	59,909					$	1,401,459
Net increase (decrease) in net assets resulting from operations			—						—						—						217,306						217,306
Public offering, net of offering expenses			16,221						16						238,294						—						238,310
Issuance of common stock under equity-based award plans			1,923						2						376						—						378
Shares retired on vesting of equity-based awards			(208)						—						(12,503)						—						(12,503)
Distributions reinvested in common stock			198						—						2,936						—						2,936
Distributions			—						—						—						(204,687)						(204,687)
Stock-based compensation(1)			—						—						8,858						—						8,858
Balance as of September 30, 2023			151,179						$	152					$	1,579,377					$	72,528					$	1,652,057

(1)Stock-based compensation includes $31 thousand and $81 thousand of restricted stock and option expense related to director compensation for the three and nine months ended September 30, 2023, respectively.

See notes to consolidated financial statements

5

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)			For the Nine Months Ended September 30,
			2024						2023
Cash flows provided by (used in) operating activities:
Net increase (decrease) in net assets resulting from operations			$	201,527					$	217,306
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchases of investments (1)			(1,180,071)						(1,291,627)
Fundings assigned to Adviser Funds (1)			118,379						294,468
Principal and fee repayments received and proceeds from the sale of debt investments			721,944						685,103
Proceeds from the sale of equity and warrant investments			23,423						34,877
Net change in unrealized (appreciation) depreciation			44,982						6,277
Net realized (gain) loss			(1,825)						(5,590)
Payments of derivative instruments			(849)						—
Accretion of paid-in-kind interest			(37,870)						(17,999)
Accretion of loan discounts			(3,160)						(5,344)
Accretion of loan exit fees			(19,761)						(14,140)
Change in loan income, net of collections			14,899						15,349
Unearned fees related to unfunded commitments			(159)						(279)
Amortization of debt fees and issuance costs			5,229						5,227
Depreciation and amortization			373						167
Stock-based compensation and amortization of restricted stock grants (2)			9,278						8,858
Change in operating assets and liabilities:
Interest receivable			1,191						(366)
Other assets			7,607						6,533
Accrued liabilities			6,019						(1,419)
Net cash (used in) operating activities			(88,844)						(62,599)
Cash flows provided by (used in) investing activities:
Purchases of capital equipment			(700)						(390)
Net cash (used in) investing activities			(700)						(390)
Cash flows provided by (used in) financing activities:
Issuance of common stock			67,275						243,609
Offering expenses			(991)						(5,299)
Retirement of employee shares, net			(2,395)						(12,125)
Distributions paid			(225,591)						(201,751)
Issuance of debt			939,000						533,000
Repayment of debt			(758,000)						(478,000)
Fees paid for credit facilities and debentures			(1,750)						(5,090)
Net cash provided by financing activities			17,548						74,344
Net increase (decrease) in cash, cash equivalents, and restricted cash			(71,996)						11,355
Cash, cash equivalents, and restricted cash at beginning of period			116,013						25,876
Cash, cash equivalents, and restricted cash at end of period			$	44,017					$	37,231
Supplemental disclosures of cash flow information and non-cash investing and financing activities:
Interest paid			$	64,221					$	57,410
Income tax, including excise tax, paid			$	5,185					$	5,205
Distributions reinvested			$	6,277					$	2,936

(1)Excluded from the amounts presented are certain investment funding allocations of $158.7 million, which were directly funded by the Adviser Funds during the nine month period ended September 30, 2024. Refer to Note 12 – Related Party Transaction for additional information.

(2)Stock-based compensation includes $107 thousand and $81 thousand of restricted stock and option expense related to director compensation for the nine months ended September 30, 2024 and 2023, respectively.

The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Assets and Liabilities that sum to the total of the same such amounts in the Consolidated Statements of Cash Flows:

(in thousands)			For the Nine Months Ended September 30,
			2024						2023
Cash and cash equivalents			$	38,904					$	31,979
Restricted cash			5,113						5,252
Total cash, cash equivalents, and restricted cash presented in the Consolidated Statements of Cash Flows			$	44,017					$	37,231

See “Note 2 – Summary of Significant Accounting Policies” for a description of cash, cash equivalents, and restricted cash.

See notes to consolidated financial statements

6

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
Debt Investments
Biotechnology Tools
PathAI, Inc.			Senior Secured			January 2027			Prime + 2.15%, Floor rate 9.15%, 7.85% Exit Fee			$	32,000					$	32,572					$	33,600					(12)(13)
Subtotal: Biotechnology Tools (1.81%)*																		32,572						33,600
Communications & Networking
Aryaka Networks, Inc.			Senior Secured			July 2026			Prime + 3.25%, Floor rate 6.75%, PIK Interest 1.05%, 3.55% Exit Fee			$	25,351					25,427						26,373						(12)(14)(19)
Subtotal: Communications & Networking (1.42%)*																		25,427						26,373
Consumer & Business Services
Altumint, Inc.			Senior Secured			December 2027			Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee			$	10,000					9,958						10,107						(15)
Carwow LTD			Senior Secured			December 2027			Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee			£	20,287					27,650						27,128						(5)(10)(14)
Houzz, Inc.			Convertible Debt			May 2028			PIK Interest 10.00%			$	25,011					25,011						25,745						(9)(14)
Jobandtalent USA, Inc.			Senior Secured			August 2025			1-month SOFR + 8.86%, Floor rate 9.75%, 2.87% Exit Fee			$	13,123					13,345						13,345						(5)(10)
Plentific Ltd			Senior Secured			October 2026			Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee			$	3,325					3,264						3,324						(5)(10)(13)
Provi			Senior Secured			December 2026			Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee			$	15,000					15,043						15,229						(15)
Riviera Partners LLC			Senior Secured			April 2027			1-month SOFR + 8.27%, Floor rate 9.27%			$	36,587					36,161						34,807						(17)(18)
RVShare, LLC			Senior Secured			December 2026			3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%			$	29,771					29,442						29,753						(13)(14)(15)
SeatGeek, Inc.			Senior Secured			May 2026			Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee			$	25,295					25,313						25,736						(11)(14)(16)
			Senior Secured			July 2026			Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee			$	77,939					77,594						78,952						(12)(14)(16)
Total SeatGeek, Inc.												$	103,234					102,907						104,688
Skyword, Inc.			Senior Secured			November 2026			Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee			$	7,271					7,375						7,482						(13)(14)
Tectura Corporation			Senior Secured			January 2027			FIXED 8.25%			$	8,250					8,250						8,250						(7)
Thumbtack, Inc.			Senior Secured			March 2028			Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.50%			$	20,839					20,460						21,069						(11)(14)(17)
Veem, Inc.			Senior Secured			March 2025			Prime + 4.00%, Floor rate 7.25%, PIK Interest 1.25%, 4.50% Exit Fee			$	5,156					5,322						5,322						(13)(14)
			Senior Secured			March 2025			Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.50%, 4.50% Exit Fee			$	5,169					5,338						5,338						(12)(14)
Total Veem, Inc.												$	10,325					10,660						10,660
Worldremit Group Limited			Senior Secured			February 2026			3-month SOFR + 9.40%, Floor rate 10.25%			$	24,617					24,485						24,863						(5)(10)(11)(12)(19)
			Senior Secured			February 2026			1-month SOFR + 9.35%, Floor rate 10.25%			$	6,466					6,424						6,530						(5)(10)(19)
Total Worldremit Group Limited												$	31,083					30,909						31,393
Subtotal: Consumer & Business Services (18.52%)*																		340,435						342,980
Diversified Financial Services
Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC)			Unsecured			September 2026			FIXED 3.45%, PIK Interest 8.05%			$	26,033					25,774						25,774						(7)(14)(20)
			Unsecured			September 2026			FIXED 11.95%			$	10,000					9,859						9,859						(7)(20)
Total Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC)												$	36,033					35,633						35,633
Hercules Adviser LLC			Unsecured			June 2025			FIXED 5.00%			$	12,000					12,000						12,000						(7)(23)
Next Insurance, Inc.			Senior Secured			February 2028			Prime - (1.50%), Floor rate 4.75%, PIK Interest 5.50%			$	10,918					10,757						11,149						(13)(14)(19)
Subtotal: Diversified Financial Services (3.17%)*																		58,390						58,782
Drug Discovery & Development
Adaptimmune Therapeutics plc			Senior Secured			June 2029			Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.00%, 5.85% Exit Fee			$	30,108					29,878						29,878						(5)(10)(14)

See notes to consolidated financial statements

7

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
Akero Therapeutics, Inc.			Senior Secured			March 2027			Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee			$	17,500					$	17,603					$	17,897					(10)(13)(17)
Aldeyra Therapeutics, Inc.			Senior Secured			April 2026			Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee			$	15,000					15,292						15,293						(11)
AmplifyBio, LLC			Senior Secured			January 2027			Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee			$	24,000					24,502						24,891						(15)
Arcus Biosciences, Inc.			Senior Secured			September 2029			Prime + 1.95%, Floor rate 10.45%, 7.75% Exit Fee			$	37,500					37,248						37,248						(6)(10)(15)(17)
ATAI Life Sciences N.V.			Senior Secured			August 2026			Prime + 4.30%, Floor rate 9.05%, 6.95% Exit Fee			$	14,000					14,347						14,253						(5)(10)(17)
Axsome Therapeutics, Inc.			Senior Secured			January 2028			Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee			$	143,350					144,974						152,241						(10)(11)(12)(16)
bluebird bio, Inc.			Senior Secured			April 2029			Prime + 1.45%, Floor rate 9.95%, PIK Interest 2.45%, 6.45% Exit Fee			$	65,250					63,337						63,682						(14)
Braeburn, Inc.			Senior Secured			October 2028			Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee			$	53,045					53,079						54,450						(14)(17)
COMPASS Pathways plc			Senior Secured			July 2027			Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee			$	24,404					24,401						25,280						(5)(10)(14)
Corium, Inc.			Senior Secured			September 2026			Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee			$	105,225					109,041						110,394						(13)(16)
Curevo, Inc.			Senior Secured			June 2027			Prime + 1.70%, Floor rate 9.70%, 6.95% Exit Fee			$	10,000					10,039						9,639						(15)
Eloxx Pharmaceuticals, Inc.			Senior Secured			April 2025			Prime + 6.25%, Floor rate 9.50%, 4.00% Exit Fee			$	489					988						988						(15)
enGene, Inc.			Senior Secured			January 2028			Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee			$	15,878					15,897						16,337						(5)(10)(14)(17)
Geron Corporation			Senior Secured			October 2025			Prime + 4.50%, Floor rate 9.00%, 6.55% Exit Fee			$	30,200					31,690						32,353						(10)(12)(13)(17)
Gritstone Bio, Inc.			Senior Secured			July 2027			Prime + 3.15%, Floor rate 7.15%, Cap rate 8.65%, PIK Interest 2.00%, 5.75% Exit Fee			$	30,995					31,523						30,472						(13)(14)
Heron Therapeutics, Inc.			Senior Secured			February 2026			Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee			$	20,327					20,303						20,761						(14)(15)(17)
Hibercell, Inc.			Senior Secured			May 2025			Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee			$	6,233					6,980						6,980						(13)(15)
Kura Oncology, Inc.			Senior Secured			November 2027			Prime + 2.40%, Floor rate 8.65%, 15.13% Exit Fee			$	5,500					5,599						5,694						(10)(15)
Locus Biosciences, Inc.			Senior Secured			July 2025			Prime + 6.10%, Floor rate 9.35%, 4.95% Exit Fee			$	3,009					3,343						3,343						(15)
Madrigal Pharmaceutical, Inc.			Senior Secured			May 2027			Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee			$	78,200					79,622						82,775						(10)(13)
NorthSea Therapeutics			Convertible Debt			December 2025			FIXED 6.00%			$	273					273						273						(5)(9)(10)
Phathom Pharmaceuticals, Inc.			Senior Secured			December 2027			Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 6.59% Exit Fee			$	153,201					155,420						158,117						(10)(12)(14)(15)(16) (17)(22)
Replimune Group, Inc.			Senior Secured			October 2027			Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee			$	31,769					32,076						33,784						(10)(12)(13)(14)
SynOx Therapeutics Limited			Senior Secured			May 2027			Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee			$	4,500					4,431						4,431						(5)(10)
uniQure B.V.			Senior Secured			January 2027			Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee			$	35,000					35,962						37,135						(5)(10)(11)(12)
Viridian Therapeutics, Inc.			Senior Secured			October 2026			Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee			$	8,000					8,191						8,350						(10)(13)(17)
X4 Pharmaceuticals, Inc.			Senior Secured			July 2027			Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee			$	75,000					75,292						75,304						(11)(12)(13)
Subtotal: Drug Discovery & Development (57.90%)*																		1,051,331						1,072,243
Electronics & Computer Hardware
Locus Robotics Corp.			Senior Secured			June 2026			Prime + 4.50%, Floor rate 8.00%, 4.00% Exit Fee			$	18,281					18,498						18,846						(19)
Shield AI, Inc.			Senior Secured			February 2029			Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee			$	75,790					75,200						76,132						(12)(14)(17)
Subtotal: Electronics & Computer Hardware (5.13%)*																		93,698						94,978
Healthcare Services, Other
Blue Sprig Pediatrics, Inc.			Senior Secured			November 2026			1-month SOFR + 5.11%, Floor rate 6.00%, PIK Interest 4.45%			$	71,414					70,813						70,397						(11)(12)(13)(14)

See notes to consolidated financial statements

8

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
Carbon Health Technologies, Inc.			Senior Secured			June 2026			Prime - (1.50%), Floor rate 7.00%, PIK Interest 7.00%, 5.64% Exit Fee			$	49,524					$	51,125					$	49,393					(11)(13)(14)
			Convertible Debt			December 2025			FIXED 12.00%			$	202					202						202						(9)
Total Carbon Health Technologies, Inc.												$	49,726					51,327						49,595
Curana Health Holdings, LLC			Senior Secured			January 2028			Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee			$	27,500					27,630						28,053						(13)(17)(19)
Equality Health, LLC			Senior Secured			February 2026			Prime + 6.25%, Floor rate 9.50%, PIK Interest 1.55%			$	70,402					70,084						70,078						(11)(12)(14)
Main Street Rural, Inc.			Senior Secured			July 2027			Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee			$	38,500					38,859						39,132						(13)(15)(17)
Marathon Health, LLC			Senior Secured			February 2029			Prime - (0.90%), Floor rate 7.10%, PIK Interest 4.00%, 3.00% Exit Fee			$	157,577					156,581						157,857						(14)(16)(17)
Modern Life, Inc.			Senior Secured			February 2027			Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee			$	18,200					18,208						18,393						(13)
NeueHealth, Inc.			Senior Secured			June 2028			Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee			$	24,874					23,990						24,141						(12)(14)
Recover Together, Inc.			Senior Secured			July 2027			Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee			$	40,000					40,257						40,110						(13)(17)
Strive Health Holdings, LLC			Senior Secured			September 2027			Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee			$	12,000					12,015						12,359						(15)
Vida Health, Inc.			Senior Secured			July 2026			FIXED 8.50%, PIK Interest 2.05%, 4.95% Exit Fee			$	36,571					37,000						36,636						(11)(14)
WellBe Senior Medical, LLC			Senior Secured			May 2029			Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee			$	20,148					20,023						19,633						(14)(15)(17)
Subtotal: Healthcare Services, Other (30.59%)*																		566,787						566,384
Information Services
Checkr Group, Inc.			Senior Secured			August 2028			Prime + 1.45%, Floor rate 8.00%, PIK Interest 2.00%, 2.75% Exit Fee			$	48,354					48,371						50,620						(12)(14)(17)
Saama Technologies, LLC			Senior Secured			July 2027			Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee			$	19,679					19,591						20,300						(12)(14)(17)
Signal Media Limited			Senior Secured			June 2025			Prime + 5.50%, Floor rate 9.00%, Cap rate 12.00%, 3.45% Exit Fee			$	6,150					6,220						6,424						(5)(10)
Subtotal: Information Services (4.18%)*																		74,182						77,344
Medical Devices & Equipment
Senseonics Holdings, Inc.			Senior Secured			September 2027			Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee			$	30,625					30,650						31,136						(11)
Sight Sciences, Inc.			Senior Secured			July 2028			Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee			$	24,500					24,273						24,277						(17)
Subtotal: Medical Devices & Equipment (2.99%)*																		54,923						55,413
Software
3GTMS, LLC			Senior Secured			February 2025			3-month SOFR + 10.40%, Floor rate 11.30%			$	13,042					13,013						13,013						(11)(17)(18)
			Senior Secured			February 2025			3-month SOFR + 7.25%, Floor rate 8.15%			$	6,209					6,184						6,184						(17)(18)
Total 3GTMS, LLC												$	19,251					19,197						19,197
Alchemer LLC			Senior Secured			May 2028			1-month SOFR + 8.14%, Floor rate 9.14%			$	21,302					20,955						21,302						(13)(18)
Allvue Systems, LLC			Senior Secured			September 2029			3-month SOFR + 7.25%, Floor rate 8.25%			$	36,410					35,612						36,651						(17)
AlphaSense, Inc.			Senior Secured			June 2029			1-month SOFR + 6.25%, Floor rate 8.25%			$	20,000					19,808						19,808						(17)
Annex Cloud			Senior Secured			February 2027			1-month BSBY + 10.00%, Floor rate 11.00%			$	11,408					11,260						11,016						(13)
Armis, Inc.			Senior Secured			March 2028			Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee			$	50,477					50,154						50,974						(12)(14)(17)
			Senior Secured			March 2028			Prime + 1.25%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee			$	25,031					24,802						24,880						(14)(17)
Total Armis, Inc.												$	75,508					74,956						75,854
Automation Anywhere, Inc.			Senior Secured			September 2027			Prime + 4.25%, Floor rate 9.00%, 4.50% Exit Fee			$	19,600					19,587						20,354						(11)(19)
Babel Street			Senior Secured			December 2027			3-month SOFR + 8.01%, Floor rate 9.01%			$	65,500					64,138						64,956						(15)(17)(18)
Behavox Limited			Senior Secured			September 2027			Prime - (0.55%), Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee			$	7,000					6,972						6,972						(5)(10)(17)
Brain Corporation			Senior Secured			September 2028			Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee			$	31,849					31,468						31,614						(13)

See notes to consolidated financial statements

9

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
Catchpoint Systems, Inc.			Senior Secured			November 2025			1-month SOFR + 9.41%, Floor rate 11.81%			$	9,996					$	9,905					$	9,985					(18)
Ceros, Inc.			Senior Secured			September 2026			3-month SOFR + 8.99%, Floor rate 9.89%			$	22,762					22,483						22,261						(17)(18)
Constructor.io Corporation			Senior Secured			July 2027			1-month SOFR + 8.44%, Floor rate 9.44%			$	4,688					4,608						4,687						(13)(17)(18)
Convoy, Inc.			Senior Secured			March 2026			Prime + 3.20%, Floor rate 6.45%, PIK Interest 1.95%, 4.55% Exit Fee			$	31,049					30,916						—						(8)(14)(19)
Copper CRM, Inc			Senior Secured			March 2025			Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 4.50% Exit Fee			$	8,669					8,954						8,954						(11)(14)
Coronet Cyber Security Ltd.			Senior Secured			October 2028			Prime - (2.95%), Floor rate 3.55%, PIK Interest 5.85%			$	8,500					8,348						8,348						(17)
Cutover, Inc.			Senior Secured			October 2025			Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee			$	5,500					5,634						5,757						(5)(10)(12)
			Senior Secured			October 2025			Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee			£	1,250					1,597						1,774						(5)(10)
Total Cutover, Inc.																		7,231						7,531
Cybermaxx Intermediate Holdings, Inc.			Senior Secured			August 2026			6-month SOFR + 8.63%, Floor rate 9.38%, 0.58% Exit Fee			$	8,207					8,120						8,071						(13)(17)(18)
			Senior Secured			August 2026			6-month SOFR + 12.36%, Floor rate 13.11%, 0.58% Exit Fee			$	2,527					2,489						2,581						(13)(17)(18)
Total Cybermaxx Intermediate Holdings, Inc.												$	10,734					10,609						10,652
Dashlane, Inc.			Senior Secured			December 2027			Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee			$	45,350					46,088						47,370						(11)(13)(14)(19)
Dispatch Technologies, Inc.			Senior Secured			April 2028			3-month SOFR + 8.01%, Floor rate 8.76%			$	8,792					8,643						8,533						(17)(18)
Dragos, Inc.			Senior Secured			July 2027			Prime + 2.00%, Floor rate 8.75%, PIK Interest 2.00%, 1.00% Exit Fee			$	6,500					6,162						6,163						(17)
DroneDeploy, Inc.			Senior Secured			July 2026			Prime + 4.50%, Floor rate 8.75%, 4.00% Exit Fee			$	9,375					9,271						9,457						(13)(17)
Earnix, Inc.			Senior Secured			June 2029			Prime - (1.15%), Floor rate 5.35%, PIK Interest 4.45%			$	18,952					18,631						18,631						(14)(17)
Elation Health, Inc.			Senior Secured			March 2026			Prime + 4.25%, Floor rate 9.00%, PIK Interest 1.95%, 3.95% Exit Fee			$	12,815					12,699						13,074						(14)(17)(19)
Flight Schedule Pro, LLC			Senior Secured			October 2027			1-month SOFR + 7.80%, Floor rate 8.70%			$	6,907					6,758						6,955						(17)(18)
Fortified Health Security			Senior Secured			December 2027			1-month SOFR + 7.64%, Floor rate 8.54%			$	7,000					6,873						7,037						(11)(17)(18)
Harness, Inc.			Senior Secured			March 2029			Prime - (2.25%), Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee			$	17,849					17,650						17,887						(14)(17)(19)
iGrafx, LLC			Senior Secured			May 2027			1-month SOFR + 8.61%, Floor rate 9.51%, 0.47% Exit Fee			$	4,962					4,884						4,915						(18)
Ikon Science Limited			Senior Secured			October 2024			3-month SOFR + 9.26%, Floor rate 10.00%			$	5,950					5,947						5,947						(5)(10)(17)(18)
Khoros (p.k.a Lithium Technologies)			Senior Secured			January 2025			PIK 3-month SOFR + 4.50%, Floor rate 5.50%			$	61,341					61,317						20,723						(8)(14)
Leapwork ApS			Senior Secured			February 2026			Prime + 0.25%, Floor rate 7.00%, PIK Interest 1.95%, 2.70% Exit Fee			$	3,871					3,901						3,999						(5)(10)(12)(14)(17)
LinenMaster, LLC			Senior Secured			August 2028			1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%			$	15,342					15,090						15,495						(12)(14)(17)
Loftware, Inc.			Senior Secured			March 2028			3-month SOFR + 7.88%, Floor rate 8.88%			$	27,206					26,696						27,646						(17)(18)
LogicSource			Senior Secured			July 2027			1-month SOFR + 8.93%, Floor rate 9.93%			$	13,178					12,993						13,178						(17)(18)
LogRhythm, Inc.			Senior Secured			July 2029			3-month SOFR + 7.50%, Floor rate 8.50%			$	25,000					24,277						24,277						(17)
Marigold Group, Inc. (p.k.a. Campaign Monitor Limited)			Senior Secured			November 2026			PIK Interest 6-month SOFR + 10.55%, Floor rate 11.55%			$	37,413					36,875						31,863						(13)(14)(19)
Mobile Solutions Services			Senior Secured			December 2025			6-month SOFR + 9.31%, Floor rate 10.06%			$	18,366					18,205						17,609						(18)
New Relic, Inc.			Senior Secured			November 2030			3-month SOFR + 6.75%, Floor rate 7.75%			$	20,890					20,412						20,291						(17)
Omeda Holdings, LLC			Senior Secured			July 2027			3-month SOFR + 8.05%, Floor rate 9.05%			$	7,688					7,524						7,687						(11)(17)(18)
Pindrop Security, Inc.			Senior Secured			June 2029			Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee			$	31,000					30,521						30,521						(15)(17)
Reveleer			Senior Secured			February 2027			Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee			$	36,191					36,071						36,095						(14)(15)

See notes to consolidated financial statements

10

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
Semperis Technologies Inc.			Senior Secured			April 2028			Prime - (1.75%), Floor rate 6.75%, PIK Interest 3.25%			$	15,124					$	15,016					$	15,016					(14)(17)(19)
ShadowDragon, LLC			Senior Secured			December 2026			3-month SOFR + 8.92%, Floor rate 9.82%			$	6,000					5,909						5,977						(17)(18)
Simon Data, Inc.			Senior Secured			March 2027			Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.95% Exit Fee			$	13,022					13,051						13,125						(12)(14)
Sisense Ltd.			Senior Secured			July 2027			Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee			$	33,894					34,126						34,298						(5)(10)(14)
Streamline Healthcare Solutions			Senior Secured			March 2028			3-month SOFR + 7.25%, Floor rate 8.25%			$	17,600					17,306						17,763						(11)(13)(17)(18)
Sumo Logic, Inc.			Senior Secured			May 2030			3-month SOFR + 6.50%, Floor rate 7.50%			$	23,000					22,504						23,212						(17)
Suzy, Inc.			Senior Secured			August 2027			Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee			$	16,264					16,071						16,605						(14)(15)(17)
ThreatConnect, Inc.			Senior Secured			May 2026			3-month SOFR + 9.15%, Floor rate 10.00%			$	10,794					10,658						10,794						(17)(18)
Tipalti Solutions Ltd.			Senior Secured			April 2027			Prime + 0.45%, Floor rate 7.95%, PIK Interest 2.00%, 3.75% Exit Fee			$	42,455					41,989						43,092						(5)(10)(14)
Zappi, Inc.			Senior Secured			December 2027			3-month SOFR + 8.03%, Floor rate 9.03%			$	12,761					12,540						12,786						(5)(10)(13)(17)(18)
Zimperium, Inc.			Senior Secured			May 2027			3-month SOFR + 8.31%, Floor rate 9.31%			$	14,790					14,602						14,459						(17)(18)
Subtotal: Software (53.06%)*																		1,048,267						982,622
Space Technologies
Voyager Space Holdings, Inc.			Senior Secured			July 2028			Prime + 1.25%, Floor rate 9.75%, PIK Interest 2.50%, 5.50% Exit Fee			$	45,153					44,839						44,839						(14)(15)
Subtotal: Space Technologies (2.42%)*																		44,839						44,839
Sustainable and Renewable Technology
Ampion, PBC			Senior Secured			May 2025			Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 3.95% Exit Fee			$	3,970					4,063						4,063						(13)(14)
Electric Hydrogen Co.			Senior Secured			May 2028			Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.89% Exit Fee			$	20,069					19,514						19,610						(14)(15)(19)
Pineapple Energy LLC			Senior Secured			June 2027			FIXED 10.00%			$	1,371					1,371						1,347						(19)
Subtotal: Sustainable and Renewable Technology (1.35%)*																		24,948						25,020
Total: Debt Investments (182.56%)*																		$	3,415,799					$	3,380,578

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Equity Investments
Biotechnology Tools
Alamar Biosciences, Inc.			Equity			2/21/2024			Preferred Series C			503,778						$	1,500					$	1,492
Subtotal: Biotechnology Tools (0.08%)*																		1,500						1,492
Consumer & Business Products
Fabletics, Inc.			Equity			4/30/2010			Common Stock			42,989						128						43
			Equity			7/16/2013			Preferred Series B			130,191						1,101						279
Total Fabletics, Inc.												173,180						1,229						322
Grove Collaborative, Inc.			Equity			4/30/2021			Common Stock			12,260						433						17						(4)
Savage X Holding, LLC			Equity			4/30/2010			Class A Units			172,328						13						482
Subtotal: Consumer & Business Products (0.04%)*																		1,675						821
Consumer & Business Services
Carwow LTD			Equity			12/15/2021			Preferred Series D-4			214,869						1,151						647						(5)(10)

See notes to consolidated financial statements

11

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Lyft, Inc.			Equity			12/26/2018			Common Stock			100,738						$	5,263					$	1,284					(4)
Nerdy Inc.			Equity			9/17/2021			Common Stock			100,000						1,000						98						(4)
OfferUp, Inc.			Equity			10/25/2016			Preferred Series A			286,080						1,663						439
			Equity			10/25/2016			Preferred Series A-1			108,710						632						167
Total OfferUp, Inc.												394,790						2,295						606
Oportun			Equity			6/28/2013			Common Stock			48,365						577						136						(4)
Reischling Press, Inc.			Equity			7/31/2020			Common Stock			3,095						40						—
Rhino Labs, Inc.			Equity			1/24/2022			Common Stock			7,063						1,000						—
Tectura Corporation			Equity			5/23/2018			Common Stock			414,994,863						900						6						(7)
			Equity			6/6/2016			Preferred Series BB			1,000,000						—						15						(7)
			Equity			12/29/2023			Preferred Series C			3,235,298						13,263						3,772						(7)
Total Tectura Corporation												419,230,161						14,163						3,793
Worldremit Group Limited			Equity			6/24/2024			Preferred Series X			6,641						639						660						(5)(10)
Subtotal: Consumer & Business Services (0.39%)*																		26,128						7,224
Diversified Financial Services
Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC)			Equity			3/1/2018			Member Units			1						34,006						21,669						(7)(20)
Hercules Adviser LLC			Equity			3/26/2021			Member Units			1						35						31,433						(7)(23)
Newfront Insurance Holdings, Inc.			Equity			9/30/2021			Preferred Series D-2			210,282						403						327
Subtotal: Diversified Financial Services (2.89%)*																		34,444						53,429
Drug Delivery
Aytu BioScience, Inc.			Equity			3/28/2014			Common Stock			680						1,500						2						(4)
BioQ Pharma Incorporated			Equity			12/8/2015			Preferred Series D			165,000						500						—
PDS Biotechnology Corporation			Equity			4/6/2015			Common Stock			2,498						309						9						(4)
Talphera, Inc.			Equity			12/10/2018			Common Stock			8,836						1,329						8						(4)
Subtotal: Drug Delivery (0.00%)*																		3,638						19
Drug Discovery & Development
Akero Therapeutics, Inc.			Equity			3/8/2024			Common Stock			34,483						1,000						989						(4)(10)
Avalo Therapeutics, Inc.			Equity			8/19/2014			Common Stock			42						1,000						—						(4)
Axsome Therapeutics, Inc.			Equity			5/9/2022			Common Stock			127,021						4,165						11,415						(4)(10)(16)
Bicycle Therapeutics PLC			Equity			10/5/2020			Common Stock			98,100						1,871						2,220						(4)(5)(10)
BridgeBio Pharma, Inc.			Equity			6/21/2018			Common Stock			231,329						2,255						5,890						(4)
Cyclo Therapeutics, Inc.			Equity			4/6/2021			Common Stock			134						42						—						(4)(10)
Dare Biosciences, Inc.			Equity			1/8/2015			Common Stock			1,129						1,000						4						(4)
Dynavax Technologies			Equity			7/22/2015			Common Stock			20,000						550						223						(4)(10)
Gritstone Bio, Inc.			Equity			10/26/2022			Common Stock			442,477						1,000						257						(4)
Heron Therapeutics, Inc.			Equity			7/25/2023			Common Stock			364,963						500						726						(4)
Hibercell, Inc.			Equity			5/7/2021			Preferred Series B			3,466,840						4,250						253						(15)

See notes to consolidated financial statements

12

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
HilleVax, Inc.			Equity			5/3/2022			Common Stock			235,295						$	4,000					$	414					(4)
Kura Oncology, Inc.			Equity			6/16/2023			Common Stock			47,826						550						935						(4)(10)
Madrigal Pharmaceutical, Inc.			Equity			9/29/2023			Common Stock			5,100						773						1,082						(4)(10)
NorthSea Therapeutics			Equity			12/15/2021			Preferred Series C			983						2,000						1,334						(5)(10)
Phathom Pharmaceuticals, Inc.			Equity			6/9/2023			Common Stock			147,233						1,730						2,662						(4)(10)(16)
Rocket Pharmaceuticals, Ltd.			Equity			8/22/2007			Common Stock			944						1,500						18						(4)
Savara, Inc.			Equity			8/11/2015			Common Stock			11,119						203						47						(4)
Tarsus Pharmaceuticals, Inc.			Equity			5/5/2022			Common Stock			77,778						1,050						2,558						(4)(10)
uniQure B.V.			Equity			1/31/2019			Common Stock			17,175						332						85						(4)(5)(10)
Valo Health, LLC			Equity			12/11/2020			Preferred Series B			510,308						3,000						2,126
			Equity			10/31/2022			Preferred Series C			170,102						1,000						1,029
Total Valo Health, LLC												680,410						4,000						3,155
Verge Analytics, Inc.			Equity			9/6/2023			Preferred Series C			208,588						1,500						1,488
Viridian Therapeutics, Inc.			Equity			11/6/2023			Common Stock			32,310						400						735						(4)(10)
X4 Pharmaceuticals, Inc.			Equity			11/26/2019			Common Stock			1,566,064						2,945						1,048						(4)
Subtotal: Drug Discovery & Development (2.03%)*																		38,616						37,538
Electronics & Computer Hardware
Locus Robotics Corp.			Equity			11/17/2022			Preferred Series F			15,116						650						277
Skydio, Inc.			Equity			3/8/2022			Preferred Series E			248,900						1,500						566
Subtotal: Electronics & Computer Hardware (0.05%)*																		2,150						843
Healthcare Services, Other
23andMe, Inc.			Equity			3/11/2019			Common Stock			825,732						5,094						287						(4)
Carbon Health Technologies, Inc.			Equity			3/30/2021			Preferred Series C			217,880						1,687						6
Click Therapeutics, Inc.			Equity			5/20/2024			Common Stock			560,000						1,662						1,800						(15)
Curana Health Holdings, LLC			Equity			5/13/2024			Common Units			1,114,380						2,500						2,837
WellBe Senior Medical, LLC			Equity			6/10/2024			Common Units			181,163						1,600						1,720
Subtotal: Healthcare Services, Other (0.36%)*																		12,543						6,650
Information Services
Yipit, LLC			Equity			12/30/2021			Preferred Series E			41,021						3,825						3,907
Subtotal: Information Services (0.21%)*																		3,825						3,907
Manufacturing Technology
Xometry, Inc.			Equity			5/9/2018			Common Stock			52,126						47						958						(4)
Subtotal: Manufacturing Technology (0.05%)*																		47						958
Medical Devices & Equipment
Coronado Aesthetics, LLC			Equity			10/15/2021			Common Units			180,000						—						1						(7)
			Equity			10/15/2021			Preferred Series A-2			5,000,000						250						318						(7)
Total Coronado Aesthetics, LLC												5,180,000						250						319
Subtotal: Medical Devices & Equipment (0.02%)*																		250						319

See notes to consolidated financial statements

13

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Semiconductors
Achronix Semiconductor Corporation			Equity			7/1/2011			Preferred Series C			277,995						$	160					$	194
Subtotal: Semiconductors (0.01%)*																		160						194
Software
3GTMS, LLC			Equity			8/9/2021			Common Stock			1,000,000						1,000						745
Black Crow AI, Inc. affiliates			Equity			3/24/2021			Preferred Note			3						2,406						2,406						(21)
CapLinked, Inc.			Equity			10/26/2012			Preferred Series A-3			53,614						51						—
Contentful Global, Inc.			Equity			12/22/2020			Preferred Series C			41,000						138						323						(5)(10)
			Equity			11/20/2018			Preferred Series D			108,500						500						895						(5)(10)
Total Contentful Global, Inc.												149,500						638						1,218
DNAnexus, Inc.			Equity			3/21/2014			Preferred Series C			51,948						97						5
Docker, Inc.			Equity			11/29/2018			Common Stock			20,000						4,284						210
Druva Holdings, Inc.			Equity			10/22/2015			Preferred Series 2			458,841						1,000						2,617
			Equity			8/24/2017			Preferred Series 3			93,620						300						560
Total Druva Holdings, Inc.												552,461						1,300						3,177
HighRoads, Inc.			Equity			1/18/2013			Common Stock			190						307						—
Leapwork ApS			Equity			8/25/2023			Preferred Series B2			183,073						250						155						(5)(10)
Lightbend, Inc.			Equity			12/4/2020			Common Stock			38,461						265						25
Nextdoor.com, Inc.			Equity			8/1/2018			Common Stock			1,019,255						4,854						2,528						(4)
Palantir Technologies			Equity			9/23/2020			Common Stock			300,000						1,834						11,160						(4)
SingleStore, Inc.			Equity			11/25/2020			Preferred Series E			580,983						2,000						1,842
			Equity			8/12/2021			Preferred Series F			52,956						280						207
Total SingleStore, Inc.												633,939						2,280						2,049
Sirion Labs, Inc.			Equity			6/30/2024			Preferred Series F1			152,250						1,791						1,999						(5)(10)
Verana Health, Inc.			Equity			7/8/2021			Preferred Series E			952,562						2,000						318
Subtotal: Software (1.40%)*																		23,357						25,995
Space Technologies
Planet Labs, Inc.			Equity			6/21/2019			Common Stock			547,880						615						1,222						(4)
Subtotal: Space Technologies (0.07%)*																		615						1,222
Sustainable and Renewable Technology
Impossible Foods, Inc.			Equity			5/10/2019			Preferred Series E-1			188,611						2,000						112
Modumetal, Inc.			Equity			6/1/2015			Common Stock			1,035						500						—
NantEnergy, LLC			Equity			8/31/2013			Common Units			59,665						102						—
Pineapple Energy LLC			Equity			12/10/2020			Common Stock			20,299						3,153						3						(4)
Pivot Bio, Inc.			Equity			6/28/2021			Preferred Series D			593,080						4,500						2,309
Subtotal: Sustainable and Renewable Technology (0.13%)*																		10,255						2,424
Total: Equity Investments (7.72%)*																		$	159,203					$	143,035

See notes to consolidated financial statements

14

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Warrant Investments
Biotechnology Tools
Alamar Biosciences, Inc.			Warrant			6/21/2022			Preferred Series C			75,567						$	36					$	124
PathAI, Inc.			Warrant			12/23/2022			Common Stock			53,418						460						95						(12)
Subtotal: Biotechnology Tools (0.01%)*																		496						219
Communications & Networking
Aryaka Networks, Inc.			Warrant			6/28/2022			Common Stock			229,611						123						92						(12)
Subtotal: Communications & Networking (0.00%)*																		123						92
Consumer & Business Products
Gadget Guard, LLC			Warrant			6/3/2014			Common Stock			1,662,441						228						—
Whoop, Inc.			Warrant			6/27/2018			Preferred Series C			686,270						17						464
Subtotal: Consumer & Business Products (0.03%)*																		245						464
Consumer & Business Services
Carwow LTD			Warrant			12/14/2021			Common Stock			174,163						164						54						(5)(10)
			Warrant			2/13/2024			Preferred Series D-4			109,257						20						11						(5)(10)
Total Carwow LTD												283,420						184						65
Houzz, Inc.			Warrant			10/29/2019			Common Stock			529,661						20						—
Landing Holdings Inc.			Warrant			3/12/2021			Common Stock			11,806						116						140						(15)
Lendio, Inc.			Warrant			3/29/2019			Preferred Series D			127,032						39						22
Plentific Ltd			Warrant			10/3/2023			Ordinary Shares			27,298						60						38						(5)(10)
Provi			Warrant			12/22/2022			Common Stock			117,042						166						65						(15)
Rhino Labs, Inc.			Warrant			3/12/2021			Common Stock			13,106						470						—						(15)
SeatGeek, Inc.			Warrant			6/12/2019			Common Stock			1,379,761						842						4,464						(16)
Skyword, Inc.			Warrant			11/14/2022			Common Stock			1,607,143						57						13
			Warrant			8/23/2019			Preferred Series B			444,444						83						1
Total Skyword, Inc.												2,051,587						140						14
Snagajob.com, Inc.			Warrant			4/20/2020			Common Stock			600,000						16						—
			Warrant			6/30/2016			Preferred Series A			1,800,000						782						—
			Warrant			8/1/2018			Preferred Series B			1,211,537						62						—
Total Snagajob.com, Inc.												3,611,537						860						—
Thumbtack, Inc.			Warrant			5/1/2018			Common Stock			343,497						985						741
Veem, Inc.			Warrant			3/31/2022			Common Stock			98,428						126						9						(12)
Worldremit Group Limited			Warrant			2/11/2021			Preferred Series D			77,215						129						69						(5)(10)(12)
			Warrant			8/27/2021			Preferred Series E			1,868						26						—						(5)(10)
Total Worldremit Group Limited												79,083						155						69
Subtotal: Consumer & Business Services (0.30%)*																		4,163						5,627

See notes to consolidated financial statements

15

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Diversified Financial Services
Next Insurance, Inc.			Warrant			2/3/2023			Common Stock			522,930						$	214					$	498
Subtotal: Diversified Financial Services (0.03%)*																		214						498
Drug Delivery
BioQ Pharma Incorporated			Warrant			10/27/2014			Common Stock			459,183						1						—
Subtotal: Drug Delivery (0.00%)*																		1						—
Drug Discovery & Development
Akero Therapeutics, Inc.			Warrant			6/15/2022			Common Stock			32,128						330						547						(4)(10)
AmplifyBio, LLC			Warrant			12/27/2022			Class A Units			69,239						238						172						(15)
Axsome Therapeutics, Inc.			Warrant			9/25/2020			Common Stock			61,004						1,290						1,813						(4)(10)(12)(16)
bluebird bio, Inc.			Warrant			3/15/2024			Common Stock			2,224,137						1,744						514						(4)
Cellarity, Inc.			Warrant			12/8/2021			Preferred Series B			100,000						287						64						(15)
Century Therapeutics, Inc.			Warrant			9/14/2020			Common Stock			16,112						37						—						(4)
COMPASS Pathways plc			Warrant			6/30/2023			Ordinary Shares			75,376						278						136						(4)(5)(10)
Curevo, Inc.			Warrant			6/9/2023			Common Stock			95,221						233						149						(15)
Dermavant Sciences Ltd.			Warrant			5/31/2019			Common Stock			223,642						101						—						(5)(10)
enGene, Inc.			Warrant			12/22/2023			Common Stock			43,689						118						105						(4)(5)(10)
Fresh Tracks Therapeutics, Inc.			Warrant			2/18/2016			Common Stock			201						119						—						(4)
Heron Therapeutics, Inc.			Warrant			8/9/2023			Common Stock			238,095						228						233						(4)(15)
Kineta, Inc.			Warrant			12/20/2019			Common Stock			2,202						110						—						(4)
Kura Oncology, Inc.			Warrant			11/2/2022			Common Stock			14,342						88						92						(4)(10)(15)
Madrigal Pharmaceutical, Inc.			Warrant			5/9/2022			Common Stock			13,229						570						1,539						(4)(10)
Phathom Pharmaceuticals, Inc.			Warrant			9/17/2021			Common Stock			64,687						848						128						(4)(10)(12)(15)(16)
Redshift Bioanalytics, Inc.			Warrant			3/23/2022			Preferred Series E			475,510						20						23						(15)
Scynexis, Inc.			Warrant			5/14/2021			Common Stock			106,035						296						4						(4)
SynOx Therapeutics Limited			Warrant			4/18/2024			Preferred Series B			251,195						83						83						(5)(10)
TG Therapeutics, Inc.			Warrant			2/28/2019			Common Stock			264,226						1,284						3,514						(4)(10)
Valo Health, LLC			Warrant			6/15/2020			Common Units			102,216						256						102
X4 Pharmaceuticals, Inc.			Warrant			3/18/2019			Common Stock			1,392,787						510						137						(4)
Subtotal: Drug Discovery & Development (0.51%)*																		9,068						9,355
Electronics & Computer Hardware
908 Devices, Inc.			Warrant			3/15/2017			Common Stock			49,078						101						9						(4)
Locus Robotics Corp.			Warrant			6/21/2022			Common Stock			8,503						34						51
Skydio, Inc.			Warrant			11/8/2021			Common Stock			622,255						557						244
Subtotal: Electronics & Computer Hardware (0.02%)*																		692						304
Healthcare Services, Other
Curana Health Holdings, LLC			Warrant			1/4/2024			Common Units			447,410						156						562

See notes to consolidated financial statements

16

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Modern Life, Inc.			Warrant			3/30/2023			Common Stock			52,665						$	210					$	113
NeueHealth, Inc.			Warrant			6/21/2024			Common Stock			185,625						716						726						(4)(12)
Recover Together, Inc.			Warrant			7/3/2023			Common Stock			194,830						382						193
Strive Health Holdings, LLC			Warrant			9/28/2023			Common Units			51,760						83						121						(15)
Vida Health, Inc.			Warrant			3/28/2022			Preferred Series E			192,431						121						1
Subtotal: Healthcare Services, Other (0.09%)*																		1,668						1,716
Information Services
INMOBI Inc.			Warrant			11/19/2014			Common Stock			149,165						82						—						(5)(10)
NetBase Quid, Inc. (p.k.a NetBase Solutions)			Warrant			8/22/2017			Preferred Series 1			60,000						356						—
Signal Media Limited			Warrant			6/29/2022			Common Stock			129,638						57						15						(5)(10)
Subtotal: Information Services (0.00%)*																		495						15
Manufacturing Technology
Bright Machines, Inc.			Warrant			3/31/2022			Common Stock			392,308						537						1,006
MacroFab, Inc.			Warrant			3/23/2022			Common Stock			1,111,111						528						132
Subtotal: Manufacturing Technology (0.06%)*																		1,065						1,138
Media/Content/Info
Fever Labs, Inc.			Warrant			12/30/2022			Preferred Series E-1			369,370						67						55
Subtotal: Media/Content/Info (0.00%)*																		67						55
Medical Devices & Equipment
Outset Medical, Inc.			Warrant			9/27/2013			Common Stock			62,794						401						2						(4)
Senseonics Holdings, Inc.			Warrant			9/8/2023			Common Stock			1,032,718						277						88						(4)
Sight Sciences, Inc.			Warrant			1/22/2024			Common Stock			94,980						327						331						(4)
Tela Bio, Inc.			Warrant			3/31/2017			Common Stock			15,712						61						—						(4)
Subtotal: Medical Devices & Equipment (0.02%)*																		1,066						421
Semiconductors
Achronix Semiconductor Corporation			Warrant			6/26/2015			Preferred Series D-2			750,000						99						461
Subtotal: Semiconductors (0.02%)*																		99						461
Software
Aria Systems, Inc.			Warrant			5/22/2015			Preferred Series G			231,535						74						—
Automation Anywhere, Inc.			Warrant			9/23/2022			Common Stock			254,778						449						338
Bitsight Technologies, Inc.			Warrant			11/18/2020			Common Stock			29,691						284						417
Brain Corporation			Warrant			10/4/2021			Common Stock			435,396						215						90
CloudBolt Software, Inc.			Warrant			9/30/2020			Common Stock			211,342						117						—
Cloudian, Inc.			Warrant			11/6/2018			Common Stock			477,454						71						—
Cloudpay, Inc.			Warrant			4/10/2018			Preferred Series B			6,763						54						665						(5)(10)
Coronet Cyber Security Ltd.			Warrant			9/26/2024			Ordinary Shares			39,183						254						254
Couchbase, Inc.			Warrant			4/25/2019			Common Stock			105,350						462						728						(4)

See notes to consolidated financial statements

17

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Cutover, Inc.			Warrant			9/21/2022			Common Stock			102,898						$	26					$	44					(5)(10)(12)
Dashlane, Inc.			Warrant			3/11/2019			Common Stock			770,838						461						1,077
Demandbase, Inc.			Warrant			8/2/2021			Common Stock			727,047						545						135
Dragos, Inc.			Warrant			6/28/2023			Common Stock			57,528						1,576						867
DroneDeploy, Inc.			Warrant			6/30/2022			Common Stock			95,911						278						295
Earnix, Inc.			Warrant			6/6/2024			Common Stock			20,762						220						295
Elation Health, Inc.			Warrant			9/12/2022			Common Stock			362,837						583						226
First Insight, Inc.			Warrant			5/10/2018			Preferred Series B			75,917						96						24
Fulfil Solutions, Inc.			Warrant			7/29/2022			Common Stock			84,995						325						255
Harness, Inc.			Warrant			3/12/2024			Common Stock			193,618						534						554
Kore.ai, Inc.			Warrant			3/31/2023			Preferred Series C			64,293						208						196
Leapwork ApS			Warrant			1/23/2023			Common Stock			39,948						16						22						(5)(10)(12)
Lightbend, Inc.			Warrant			2/14/2018			Preferred Series LB-2			86,984						131						24
Mixpanel, Inc.			Warrant			9/30/2020			Common Stock			82,362						252						231
Pindrop Security, Inc.			Warrant			6/26/2024			Common Stock			134,542						494						427						(15)
Reltio, Inc.			Warrant			6/30/2020			Common Stock			69,120						215						595
Semperis Technologies Inc.			Warrant			4/23/2024			Common Stock			72,122						115						161
Simon Data, Inc.			Warrant			3/22/2023			Common Stock			77,934						96						63						(12)
SingleStore, Inc.			Warrant			4/28/2020			Preferred Series D			312,596						103						430
Sisense Ltd.			Warrant			6/8/2023			Ordinary Shares			321,956						174						54						(5)(10)
Suzy, Inc.			Warrant			8/24/2023			Common Stock			292,936						367						230						(15)
Tipalti Solutions Ltd.			Warrant			3/22/2023			Ordinary Shares			509,753						359						323						(5)(10)
VideoAmp, Inc.			Warrant			1/21/2022			Common Stock			152,048						1,275						203						(15)
Subtotal: Software (0.50%)*																		10,429						9,223
Space Technologies
Capella Space Corp.			Warrant			10/21/2021			Common Stock			176,200						207						21						(15)
Subtotal: Space Technologies (0.00%)*																		207						21
Sustainable and Renewable Technology
Ampion, PBC			Warrant			4/15/2022			Common Stock			18,472						52						51
Electric Hydrogen Co.			Warrant			3/27/2024			Common Stock			246,618						507						363						(15)
Halio, Inc.			Warrant			4/7/2015			Common Stock			144,914						63						—
Subtotal: Sustainable and Renewable Technology (0.02%)*																		622						414
Total: Warrant Investments (1.62%)*																		$	30,720					$	30,023
Total Investments in Securities (191.90%)*																		$	3,605,722					$	3,553,636
Investment Funds & Vehicles Investments
Drug Discovery & Development
Forbion Growth Opportunities Fund I C.V.			Investment Funds & Vehicles			11/16/2020												2,847						5,123						(5)(10)(17)

See notes to consolidated financial statements

18

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Forbion Growth Opportunities Fund II C.V.			Investment Funds & Vehicles			6/23/2022												$	1,036					$	1,358					(5)(10)(17)
Subtotal: Drug Discovery & Development (0.35%)*																		3,883						6,481
Software
Liberty Zim Co-Invest L.P.			Investment Funds & Vehicles			7/21/2022												381						396						(5)(10)
Subtotal: Software (0.02%)*																		381						396
Total: Investment Funds & Vehicles Investments (0.37%)*																		$	4,264					$	6,877
Total Investments (192.27%)*																		$	3,609,986					$	3,560,513

Foreign Currency Forward Contracts
Foreign Currency			Settlement Date			Counterparty			Amount						Transaction			US $ Value at Settlement Date						Value
Great British Pound (GBP)			6/3/2025			Goldman Sachs Bank USA			£	20,511					Sold			$	26,178					$	(1,168)
Total Foreign Currency Forward ((0.06%))*																		$	26,178					$	(1,168)

*Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(1)Prime represents 8.00% as of September 30, 2024. 1-month SOFR, 3-month SOFR and 6-month SOFR represent 4.85%, 4.59%, and 4.25%, respectively, as of September 30, 2024.

(2)Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $121.3 million, $169.9 million and $48.6 million, respectively. The tax cost of investments is $3.6 billion.

(3)Preferred and common stock, warrants, and equity interest are generally non-income producing.

(4)Except for warrants in 22 publicly traded companies and common stock in 33 publicly traded companies, all investments are restricted as of September 30, 2024 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s valuation committee (the “Valuation Committee”) and approved by the board of directors (the “Board”).

(5)Non-U.S. company or the company’s principal place of business is outside the United States.

(6)Denotes that all or a portion of the investment in this portfolio company is held by Hercules SBIC V, L.P., the Company’s wholly owned small business investment company.

(7)Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.

(8)Debt is on non-accrual status as of September 30, 2024, and is therefore considered non-income producing.

(9)Denotes that all or a portion of the debt investment is convertible debt.

(10)Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(11)Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”).

(12)Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”).

(13)Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”).

(14)Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.

(15)Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company.

(16)Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of September 30, 2024.

(17)Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of September 30, 2024 (Refer to “Note 11 - Commitments and Contingencies”).

(18)Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition.

(19)Denotes second lien senior secured debt.

(20)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC.

See notes to consolidated financial statements

19

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

September 30, 2024 (unaudited)

(dollars in thousands)

(21)Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of September 30, 2024, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $2.4 million.

(22)Denotes the security holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the royalty contract are $12.0 million and $10.9 million, respectively.

(23)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1” for additional disclosure.

See notes to consolidated financial statements

20

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
Debt Investments
Biotechnology Tools
Alamar Biosciences, Inc.			Senior Secured			June 2026			Prime + 3.00%, Floor rate 6.50%, PIK Interest 1.00%, 5.95% Exit Fee			$	15,049					$	15,069					$	15,508					(13)(14)
PathAI, Inc.			Senior Secured			January 2027			Prime + 2.15%, Floor rate 9.15%, 9.81% Exit Fee			$	32,000					31,941						32,519						(12)
Subtotal: Biotechnology Tools (2.66%)*																		47,010						48,027
Communications & Networking
Aryaka Networks, Inc.			Senior Secured			July 2026			Prime + 3.25%, Floor rate 6.75%, PIK Interest 1.05%, 3.55% Exit Fee			$	25,153					24,943						26,000						(12)(14)(19)
Cytracom Holdings LLC			Senior Secured			February 2025			3-month SOFR + 9.72%, Floor rate 10.62%			$	3,267					3,239						3,272						(11)(17)(18)
Subtotal: Communications & Networking (1.62%)*																		28,182						29,272
Consumer & Business Services
Altumint, Inc.			Senior Secured			December 2027			Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee			$	10,000					9,905						9,905						(15)(17)
AppDirect, Inc.			Senior Secured			April 2026			Prime + 5.50%, Floor rate 8.75%, 7.12% Exit Fee			$	55,790					57,653						59,507						(12)
Carwow LTD			Senior Secured			December 2024			Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 4.95% Exit Fee			£	19,146					26,834						25,157						(5)(10)(14)
Houzz, Inc.			Convertible Debt			May 2028			PIK Interest 8.50%			$	23,340					23,340						23,244						(9)(14)
Jobandtalent USA, Inc.			Senior Secured			February 2025			1-month SOFR + 8.86%, Floor rate 9.75%, 3.00% Exit Fee			$	14,000					14,095						14,259						(5)(10)
Plentific Ltd			Senior Secured			October 2026			Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee			$	875					853						853						(5)(10)(17)
Provi			Senior Secured			December 2026			Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee			$	15,000					14,904						15,046						(15)
Rhino Labs, Inc.			Senior Secured			June 2024			Prime + 5.50%, Floor rate 8.75%, PIK Interest 2.25%			$	4,710					4,704						4,704						(14)(15)
Riviera Partners LLC			Senior Secured			April 2027			3-month SOFR + 8.26%, Floor rate 9.26%			$	36,868					36,339						34,659						(17)(18)
RVShare, LLC			Senior Secured			December 2026			3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%			$	28,876					28,404						28,888						(13)(14)(15)
SeatGeek, Inc.			Senior Secured			May 2026			Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee			$	25,199					25,126						25,869						(11)(14)(16)
			Senior Secured			July 2026			Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee			$	77,642					77,170						79,119						(12)(14)(16)
Total SeatGeek, Inc.												$	102,841					102,296						104,988
Skyword, Inc.			Senior Secured			November 2026			Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee			$	9,169					9,189						9,311						(13)(14)
Tectura Corporation			Senior Secured			July 2024			FIXED 8.25%			$	8,250					8,250						8,250						(7)
Thumbtack, Inc.			Senior Secured			April 2026			Prime + 4.95%, Floor rate 8.20%, PIK Interest 1.50%, 3.95% Exit Fee			$	10,258					10,317						10,639						(12)(14)(17)
Udacity, Inc.			Senior Secured			September 2024			Prime + 4.50%, Floor rate 7.75%, PIK Interest 2.00%, 3.00% Exit Fee			$	53,000					53,989						53,130						(12)(14)
Veem, Inc.			Senior Secured			March 2025			Prime + 4.00%, Floor rate 7.25%, PIK Interest 1.25%, 4.50% Exit Fee			$	5,107					5,176						5,230						(13)(14)
			Senior Secured			March 2025			Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.50%, 4.50% Exit Fee			$	5,110					5,189						5,286						(12)(14)
Total Veem, Inc.												$	10,217					10,365						10,516
Worldremit Group Limited			Senior Secured			February 2025			3-month SOFR + 9.40%, Floor rate 10.25%, 3.20% Exit Fee			$	88,250					89,318						89,653						(5)(10)(11)(12)(16) (19)
			Senior Secured			February 2025			1-month SOFR + 9.35%, Floor rate 10.25%, 3.20% Exit Fee			$	6,250					6,308						6,344						(5)(10)(16)(19)
Total Worldremit Group Limited												$	94,500					95,626						95,997
Subtotal: Consumer & Business Services (28.24%)*																		507,063						509,053
Diversified Financial Services
Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC)			Unsecured			September 2026			FIXED 11.50%			$	25,000					24,663						24,663						(7)(20)
			Unsecured			September 2026			FIXED 11.95%			$	10,000					9,815						9,815						(7)(20)
Total Gibraltar Acquisition, LLC												$	35,000					34,478						34,478

See notes to consolidated financial statements

21

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
Hercules Adviser LLC			Unsecured			June 2025			FIXED 5.00%			$	12,000					$	12,000					$	12,000					(7)(23)
Next Insurance, Inc.			Senior Secured			February 2028			Prime - (1.50%), Floor rate 4.75%, PIK Interest 5.50%			$	10,469					10,286						10,618						(14)(17)(19)
Subtotal: Diversified Financial Services (3.17%)*																		56,764						57,096
Drug Discovery & Development
Akero Therapeutics, Inc.			Senior Secured			January 2027			Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee			$	12,500					12,525						13,065						(10)(13)(17)
Aldeyra Therapeutics, Inc.			Senior Secured			October 2024			Prime + 3.10%, Floor rate 8.60%, 8.90% Exit Fee			$	15,000					15,152						15,152						(11)
Alladapt Immunotherapeutics Inc.			Senior Secured			September 2026			Prime + 3.65%, Floor rate 8.40%, Cap rate 10.90%, 5.30% Exit Fee			$	35,000					35,173						36,855						(13)
AmplifyBio, LLC			Senior Secured			January 2027			Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee			$	24,000					24,120						24,514						(15)
ATAI Life Sciences N.V.			Senior Secured			August 2026			Prime + 4.55%, Floor rate 8.55%, 6.95% Exit Fee			$	10,500					10,695						10,904						(5)(10)
Axsome Therapeutics, Inc.			Senior Secured			January 2028			Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee			$	143,350					143,646						150,255						(10)(11)(12)(16)
Bicycle Therapeutics PLC			Senior Secured			July 2025			Prime + 4.55%, Floor rate 8.05%, Cap rate 9.05%, 5.00% Exit Fee			$	11,500					11,880						11,783						(5)(10)(11)(12)
BiomX, INC			Senior Secured			September 2025			Prime + 5.70%, Floor rate 8.95%, 6.55% Exit Fee			$	6,448					6,807						6,790						(5)(10)(11)
Braeburn, Inc.			Senior Secured			October 2028			Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee			$	52,601					52,185						52,185						(14)
BridgeBio Pharma, Inc.			Senior Secured			November 2026			FIXED 9.00%, 2.00% Exit Fee			$	38,167					38,124						35,498						(12)(13)(14)
Cellarity, Inc.			Senior Secured			June 2026			Prime + 5.70%, Floor rate 8.95%, 3.75% Exit Fee			$	29,193					29,482						30,051						(13)(15)
COMPASS Pathways plc			Senior Secured			July 2027			Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee			$	24,144					23,798						24,601						(5)(10)(14)
Corium, Inc.			Senior Secured			September 2026			Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee			$	105,225					107,667						108,545						(13)(16)
Curevo, Inc.			Senior Secured			June 2027			Prime + 1.70%, Floor rate 9.70%, 6.95% Exit Fee			$	10,000					9,821						10,076						(15)
Eloxx Pharmaceuticals, Inc.			Senior Secured			April 2025			Prime + 6.25%, Floor rate 9.50%, 6.55% Exit Fee			$	3,099					3,789						3,731						(15)
enGene, Inc.			Senior Secured			January 2028			Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee			$	15,750					15,550						15,550						(5)(10)
G1 Therapeutics, Inc.			Senior Secured			November 2026			Prime + 5.65%, Floor rate 9.15%, 11.41% Exit Fee			$	38,750					39,679						40,421						(11)(12)(15)
Geron Corporation			Senior Secured			April 2025			Prime + 4.50%, Floor rate 9.00%, 6.55% Exit Fee			$	30,200					31,005						31,210						(10)(12)(13)
Gritstone Bio, Inc.			Senior Secured			July 2027			Prime + 3.15%, Floor rate 7.15%, Cap rate 8.65%, PIK Interest 2.00%, 5.75% Exit Fee			$	30,532					30,717						30,909						(13)(14)
Heron Therapeutics, Inc.			Senior Secured			February 2026			Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee			$	20,095					19,788						19,788						(14)(15)(17)
Hibercell, Inc.			Senior Secured			May 2025			Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee			$	12,535					13,117						13,181						(13)(15)
HilleVax, Inc.			Senior Secured			May 2027			Prime + 1.05%, Floor rate 4.55%, Cap rate 6.05%, PIK Interest 2.85%, 7.15% Exit Fee			$	20,524					20,685						20,335						(14)(15)
Kura Oncology, Inc.			Senior Secured			November 2027			Prime + 2.40%, Floor rate 8.65%, 15.13% Exit Fee			$	5,500					5,532						5,752						(10)(15)(17)
Locus Biosciences, Inc.			Senior Secured			July 2025			Prime + 6.10%, Floor rate 9.35%, 4.95% Exit Fee			$	5,399					5,651						5,686						(15)
Madrigal Pharmaceutical, Inc.			Senior Secured			May 2026			Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee			$	78,200					78,728						81,945						(10)
Phathom Pharmaceuticals, Inc.			Senior Secured			December 2027			Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.15%, 7.29% Exit Fee			$	129,699					130,934						128,326						(10)(12)(14)(15)(16) (17)(22)
Redshift Bioanalytics, Inc.			Senior Secured			January 2026			Prime + 4.25%, Floor rate 7.50%, 3.80% Exit Fee			$	5,000					5,047						5,119						(15)
Replimune Group, Inc.			Senior Secured			October 2027			Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee			$	31,416					31,450						32,702						(10)(12)(14)
Tarsus Pharmaceuticals, Inc.			Senior Secured			February 2027			Prime + 4.45%, Floor rate 8.45%, Cap rate 11.45%, 4.75% Exit Fee			$	12,375					12,488						12,916						(10)(13)(17)
TG Therapeutics, Inc.			Senior Secured			January 2026			Prime + 1.20%, Floor rate 8.95%, PIK Interest 2.25%, 5.69% Exit Fee			$	65,770					66,439						67,610						(10)(11)(12)(14)

See notes to consolidated financial statements

22

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
uniQure B.V.			Senior Secured			January 2027			Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee			$	70,000					$	71,157					$	73,318					(5)(10)(11)(12)
Valo Health, LLC			Senior Secured			May 2024			Prime + 6.45%, Floor rate 9.70%, 3.85% Exit Fee			$	2,396					2,808						2,808						(11)(13)
Verona Pharma, Inc.			Senior Secured			December 2028			1-month SOFR + 5.85%, Floor rate 11.19%, Cap rate 13.19%, 3.50% Exit Fee			$	15,750					15,646						15,646						(5)(10)
Viridian Therapeutics, Inc.			Senior Secured			October 2026			Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee			$	8,000					8,057						8,023						(10)(13)
X4 Pharmaceuticals, Inc.			Senior Secured			October 2026			Prime + 3.15%, Floor rate 10.15%, 3.80% Exit Fee			$	55,000					54,680						55,417						(11)(12)(13)
Subtotal: Drug Discovery & Development (66.60%)*																		1,184,022						1,200,667
Electronics & Computer Hardware
Locus Robotics Corp.			Senior Secured			June 2026			Prime + 4.50%, Floor rate 8.00%, 4.00% Exit Fee			$	18,281					18,348						18,982						(19)
Subtotal: Electronics & Computer Hardware (1.05%)*																		18,348						18,982
Healthcare Services, Other
Better Therapeutics, Inc.			Senior Secured			August 2025			Prime + 5.70%, Floor rate 8.95%, 5.95% Exit Fee			$	10,865					11,285						8,455						(15)
Blue Sprig Pediatrics, Inc.			Senior Secured			November 2026			1-month SOFR + 5.11%, Floor rate 6.00%, PIK Interest 4.45%			$	69,032					68,277						68,393						(11)(13)(14)
Carbon Health Technologies, Inc.			Senior Secured			March 2025			Prime + 5.60%, Floor rate 8.85%, 4.61% Exit Fee			$	46,125					47,193						46,242						(11)(13)
Equality Health, LLC			Senior Secured			February 2026			Prime + 6.25%, Floor rate 9.50%, PIK Interest 1.55%			$	54,425					54,142						54,697						(11)(12)(14)
Main Street Rural, Inc.			Senior Secured			July 2027			Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee			$	24,500					24,476						24,929						(15)(17)
Modern Life, Inc.			Senior Secured			February 2027			Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee			$	13,000					12,888						13,111						(13)(17)
Recover Together, Inc.			Senior Secured			July 2027			Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee			$	35,000					34,683						34,683
Strive Health Holdings, LLC			Senior Secured			September 2027			Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee			$	12,000					11,868						11,868						(15)
Vida Health, Inc.			Senior Secured			March 2026			9.20% + Lower of (Prime - 3.25%) or 1.00%, Floor rate 9.20%, Cap rate 10.20%, 4.95% Exit Fee			$	36,500					36,352						36,145						(11)
Subtotal: Healthcare Services, Other (16.56%)*																		301,164						298,523
Information Services
Capella Space Corp.			Senior Secured			November 2025			Prime + 5.00%, Floor rate 8.25%, PIK Interest 1.10%, 7.00% Exit Fee			$	20,477					21,166						21,351						(14)(15)
Checkr Group, Inc.			Senior Secured			August 2028			Prime + 1.45%, Floor rate 8.00%, PIK Interest 2.00%, 2.75% Exit Fee			$	47,621					47,460						49,382						(14)(17)
Saama Technologies, LLC			Senior Secured			July 2027			Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee			$	11,725					11,627						11,876						(14)(17)
Signal Media Limited			Senior Secured			June 2025			Prime + 5.50%, Floor rate 9.00%, Cap rate 12.00%, 3.45% Exit Fee			$	5,400					5,364						5,392						(5)(10)
Yipit, LLC			Senior Secured			September 2026			1-month SOFR + 8.45%, Floor rate 9.35%			$	31,875					31,482						31,875						(17)(18)
Subtotal: Information Services (6.65%)*																		117,099						119,876
Manufacturing Technology
Bright Machines, Inc.			Senior Secured			May 2025			Prime + 4.00%, Floor rate 9.50%, 5.00% Exit Fee			$	7,827					8,064						8,006						(13)
Subtotal: Manufacturing Technology (0.44%)*																		8,064						8,006
Media/Content/Info
Fever Labs, Inc.			Senior Secured			September 2026			Prime + 3.50%, Floor rate 9.00%, 4.00% Exit Fee			$	6,667					6,672						6,768						(19)
			Senior Secured			September 2025			Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee			$	1,167					1,178						1,188						(19)
			Senior Secured			December 2025			Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee			$	1,333					1,342						1,351						(19)
			Senior Secured			March 2026			Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee			$	1,500					1,501						1,509						(19)

See notes to consolidated financial statements

23

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
			Senior Secured			June 2026			Prime + 3.50%, Floor rate 9.00%, 3.00% Exit Fee			$	1,667					$	1,647					$	1,653					(19)
Total Fever Labs, Inc.												$	12,334					12,340						12,469
Subtotal: Media/Content/Info (0.69%)*																		12,340						12,469
Medical Devices & Equipment
Senseonics Holdings, Inc.			Senior Secured			September 2027			Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee			$	21,875					21,572						21,572						(17)
Subtotal: Medical Devices & Equipment (1.20%)*																		21,572						21,572
Software
3GTMS, LLC			Senior Secured			February 2025			3-month SOFR + 9.70%, Floor rate 10.60%			$	13,110					13,029						13,103						(11)(17)(18)
			Senior Secured			February 2025			3-month SOFR + 6.88%, Floor rate 7.78%			$	1,990					1,988						1,986						(17)(18)
Total 3GTMS, LLC												$	15,100					15,017						15,089
Agilence, Inc.			Senior Secured			October 2026			1-month BSBY + 9.00%, Floor rate 10.00%			$	9,212					9,040						9,212						(12)(17)(18)
Alchemer LLC			Senior Secured			May 2028			1-month SOFR + 8.14%, Floor rate 9.14%			$	20,908					20,508						21,297						(13)(17)(18)
Allvue Systems, LLC			Senior Secured			September 2029			6-month SOFR + 7.25%, Floor rate 8.25%			$	36,410					35,530						35,530						(17)
Annex Cloud			Senior Secured			February 2027			1-month BSBY + 9.41%, Floor rate 10.41%			$	9,823					9,649						9,761						(13)(17)
Automation Anywhere, Inc.			Senior Secured			September 2027			Prime + 4.25%, Floor rate 9.00%, 4.50% Exit Fee			$	19,600					19,345						20,269						(11)(17)(19)
Babel Street			Senior Secured			December 2027			3-month SOFR + 7.89%, Floor rate 8.89%			$	45,000					43,983						44,928						(15)(17)(18)
Brain Corporation			Senior Secured			April 2026			Prime + 3.70%, Floor rate 9.20%, PIK Interest 1.00%, 3.95% Exit Fee			$	30,415					30,678						30,989						(13)(14)(15)(17)
Campaign Monitor Limited			Senior Secured			November 2025			3-month SOFR + 9.05%, Floor rate 9.90%			$	33,000					32,706						33,000						(13)(19)
Catchpoint Systems, Inc.			Senior Secured			November 2025			3-month SOFR + 9.41%, Floor rate 11.81%			$	10,073					9,931						9,940						(18)
Ceros, Inc.			Senior Secured			September 2026			6-month SOFR + 8.99%, Floor rate 9.89%			$	22,867					22,498						23,075						(17)(18)
Constructor.io Corporation			Senior Secured			July 2027			1-month SOFR + 8.44%, Floor rate 9.44%			$	4,688					4,592						4,790						(13)(17)(18)
Convoy, Inc.			Senior Secured			March 2026			Prime + 3.20%, Floor rate 6.45%, PIK Interest 1.95%, 4.55% Exit Fee			$	31,049					30,916						—						(8)(14)(19)
Copper CRM, Inc			Senior Secured			March 2025			Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 3.96% Exit Fee			$	9,141					9,307						9,153						(11)(14)
Cutover, Inc.			Senior Secured			October 2025			Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee			$	5,500					5,544						5,715						(5)(10)(12)(17)
Cybermaxx Intermediate Holdings, Inc.			Senior Secured			August 2026			6-month SOFR + 8.63%, Floor rate 9.38%			$	7,955					7,830						7,778						(13)(17)
			Senior Secured			August 2026			6-month SOFR + 12.36%, Floor rate 13.11%			$	2,546					2,494						2,556						(17)
Total Cybermaxx Intermediate Holdings, Inc.												$	10,501					10,324						10,334
Dashlane, Inc.			Senior Secured			December 2027			Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 7.26% Exit Fee			$	42,863					43,087						43,087						(11)(13)(17)(19)
Dispatch Technologies, Inc.			Senior Secured			April 2028			3-month SOFR + 8.01%, Floor rate 8.76%			$	8,125					7,949						8,127						(17)(18)
DroneDeploy, Inc.			Senior Secured			July 2026			Prime + 4.50%, Floor rate 8.75%, 4.00% Exit Fee			$	6,250					6,083						6,153						(17)
Eigen Technologies Ltd.			Senior Secured			April 2025			Prime + 5.10%, Floor rate 8.35%, 2.95% Exit Fee			$	3,750					3,801						3,730						(5)(10)
Elation Health, Inc.			Senior Secured			March 2026			Prime + 4.25%, Floor rate 9.00%, PIK Interest 1.95%, 3.95% Exit Fee			$	12,629					12,253						12,692						(14)(17)(19)
Enmark Systems, Inc.			Senior Secured			September 2026			3-month SOFR + 6.73%, Floor rate 7.73%, PIK Interest 2.13%			$	8,363					8,230						8,363						(11)(14)(17)(18)
Flight Schedule Pro, LLC			Senior Secured			October 2027			1-month SOFR + 7.80%, Floor rate 8.70%			$	6,587					6,420						6,553						(17)(18)
Fortified Health Security			Senior Secured			December 2027			1-month SOFR + 7.64%, Floor rate 8.54%			$	7,000					6,851						6,910						(11)(17)(18)
iGrafx, LLC			Senior Secured			May 2027			1-month SOFR + 8.66%, Floor rate 9.56%			$	5,000					4,901						4,901						(18)

See notes to consolidated financial statements

24

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Maturity Date			Interest Rate and Floor (1)			Principal Amount						Cost (2)						Value						Footnotes
Ikon Science Limited			Senior Secured			October 2024			3-month SOFR + 9.26%, Floor rate 10.00%			$	6,213					$	6,148					$	6,148					(5)(10)(17)(18)
Khoros (p.k.a Lithium Technologies)			Senior Secured			January 2025			3-month SOFR + 4.50%, Floor rate 5.50%, PIK Interest 4.50%			$	57,770					57,730						56,293						(14)
Leapwork ApS			Senior Secured			February 2026			Prime + 0.25%, Floor rate 7.25%, PIK Interest 1.95%, 2.70% Exit Fee			$	3,813					3,810						3,907						(5)(10)(12)(14)(17)
LinenMaster, LLC			Senior Secured			August 2028			1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%			$	15,083					14,799						14,799						(14)(17)
Loftware, Inc.			Senior Secured			March 2028			3-month SOFR + 7.88%, Floor rate 8.88%			$	26,469					25,897						26,566						(17)(18)
LogicSource			Senior Secured			July 2027			3-month SOFR + 8.93%, Floor rate 9.93%			$	13,300					13,074						13,493						(17)(18)
Mobile Solutions Services			Senior Secured			December 2025			6-month SOFR + 9.31%, Floor rate 10.06%			$	18,366					18,116						18,176						(18)
New Relic, Inc.			Senior Secured			November 2030			3-month SOFR + 6.75%, Floor rate 7.75%			$	20,890					20,375						20,375						(17)
Omeda Holdings, LLC			Senior Secured			July 2027			3-month SOFR + 8.05%, Floor rate 9.05%			$	7,706					7,508						7,702						(11)(17)(18)
Onna Technologies, Inc.			Senior Secured			March 2026			Prime + 1.35%, Floor rate 8.85%, PIK Interest 1.75%, 4.45% Exit Fee			$	3,853					3,814						3,810						(14)
Salary.com, LLC			Senior Secured			September 2027			3-month SOFR + 8.00%, Floor rate 9.00%			$	22,185					21,814						22,048						(18)
ShadowDragon, LLC			Senior Secured			December 2026			1-month SOFR + 9.01%, Floor rate 9.91%			$	6,000					5,883						5,921						(17)(18)
Simon Data, Inc.			Senior Secured			March 2027			Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.92% Exit Fee			$	15,065					14,982						15,037						(12)(14)
Sisense Ltd.			Senior Secured			July 2027			Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee			$	34,830					34,584						34,881						(5)(10)(14)
Streamline Healthcare Solutions			Senior Secured			March 2028			3-month SOFR + 7.25%, Floor rate 8.25%			$	13,200					12,953						13,327						(17)(18)
Sumo Logic, Inc.			Senior Secured			May 2030			3-month SOFR + 6.50%, Floor rate 7.50%			$	23,000					22,460						23,105						(17)
Suzy, Inc.			Senior Secured			August 2027			Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee			$	12,064					11,837						11,837						(14)(15)(17)
ThreatConnect, Inc.			Senior Secured			May 2026			6-month SOFR + 9.25%, Floor rate 10.00%			$	10,920					10,730						10,920						(17)(18)
Tipalti Solutions Ltd.			Senior Secured			April 2027			Prime + 0.45%, Floor rate 7.95%, PIK Interest 2.00%, 3.75% Exit Fee			$	10,649					10,578						10,835						(5)(10)(14)(17)
Zappi, Inc.			Senior Secured			December 2027			3-month SOFR + 8.03%, Floor rate 9.03%			$	9,000					8,816						8,967						(5)(10)(13)(17)(18)
Zimperium, Inc.			Senior Secured			May 2027			3-month SOFR + 8.31%, Floor rate 9.31%			$	16,313					16,057						16,394						(17)(18)
Subtotal: Software (40.39%)*																		751,108						728,139
Sustainable and Renewable Technology
Ampion, PBC			Senior Secured			May 2025			Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 3.78% Exit Fee			$	3,926					3,952						3,939						(13)(14)
Pineapple Energy LLC			Senior Secured			June 2027			FIXED 10.00%			$	1,682					1,682						1,678						(19)
Subtotal: Sustainable and Renewable Technology (0.31%)*																		5,634						5,617
Total: Debt Investments (169.59%)*																		$	3,058,370					$	3,057,299

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Equity Investments
Consumer & Business Products
Fabletics, Inc.			Equity			4/30/2010			Common Stock			42,989						$	128					$	96
			Equity			7/16/2013			Preferred Series B			130,191						1,101						700
Total Fabletics, Inc.												173,180						1,229						796
Grove Collaborative, Inc.			Equity			4/30/2021			Common Stock			12,260						433						21						(4)
Savage X Holding, LLC			Equity			4/30/2010			Class A Units			172,328						13						863

See notes to consolidated financial statements

25

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
TFG Holding, Inc.			Equity			4/30/2010			Common Stock			173,180						$	89					$	584
Subtotal: Consumer & Business Products (0.13%)*																		1,764						2,264
Consumer & Business Services
Carwow LTD			Equity			12/15/2021			Preferred Series D-4			199,742						1,151						679						(5)(10)
DoorDash, Inc.			Equity			12/20/2018			Common Stock			56,996						657						5,636						(4)
Lyft, Inc.			Equity			12/26/2018			Common Stock			100,738						5,263						1,510						(4)
Nerdy Inc.			Equity			9/17/2021			Common Stock			100,000						1,000						343						(4)
OfferUp, Inc.			Equity			10/25/2016			Preferred Series A			286,080						1,663						377
			Equity			10/25/2016			Preferred Series A-1			108,710						632						143
Total OfferUp, Inc.												394,790						2,295						520
Oportun			Equity			6/28/2013			Common Stock			48,365						577						189						(4)
Reischling Press, Inc.			Equity			7/31/2020			Common Stock			3,095						39						—
Rhino Labs, Inc.			Equity			1/24/2022			Common Stock			7,063						1,000						559
Tectura Corporation			Equity			5/23/2018			Common Stock			414,994,863						900						4						(7)
			Equity			6/6/2016			Preferred Series BB			1,000,000						—						12						(7)
			Equity			12/29/2023			Preferred Series C			3,235,298						13,263						3,251						(7)
Total Tectura Corporation												419,230,161						14,163						3,267
Subtotal: Consumer & Business Services (0.70%)*																		26,145						12,703
Diversified Financial Services
Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC)			Equity			3/1/2018			Member Units			1						34,006						28,034						(7)(20)
Hercules Adviser LLC			Equity			3/26/2021			Member Units			1						35						28,713						(7)(23)
Newfront Insurance Holdings, Inc.			Equity			9/30/2021			Preferred Series D-2			210,282						403						325
Subtotal: Diversified Financial Services (3.17%)*																		34,444						57,072
Drug Delivery
Aytu BioScience, Inc.			Equity			3/28/2014			Common Stock			680						1,500						2						(4)
BioQ Pharma Incorporated			Equity			12/8/2015			Preferred Series D			165,000						500						—
PDS Biotechnology Corporation			Equity			4/6/2015			Common Stock			2,498						309						12						(4)
Talphera, Inc. (p.k.a. AcelRx Pharmaceuticals, Inc.)			Equity			12/10/2018			Common Stock			8,836						1,329						7						(4)
Subtotal: Drug Delivery (0.00%)*																		3,638						21
Drug Discovery & Development
Avalo Therapeutics, Inc.			Equity			8/19/2014			Common Stock			42						1,000						—						(4)
Axsome Therapeutics, Inc.			Equity			5/9/2022			Common Stock			127,021						4,165						10,110						(4)(10)(16)
Bicycle Therapeutics PLC			Equity			10/5/2020			Common Stock			98,100						1,871						1,774						(4)(5)(10)
BridgeBio Pharma, Inc.			Equity			6/21/2018			Common Stock			231,329						2,255						9,339						(4)
Cyclo Therapeutics, Inc. (p.k.a. Applied Molecular Transport)			Equity			4/6/2021			Common Stock			134						42						—						(4)(10)
Dare Biosciences, Inc.			Equity			1/8/2015			Common Stock			13,550						1,000						4						(4)

See notes to consolidated financial statements

26

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Dynavax Technologies			Equity			7/22/2015			Common Stock			20,000						$	550					$	280					(4)(10)
Gritstone Bio, Inc.			Equity			10/26/2022			Common Stock			442,477						1,000						903						(4)
Heron Therapeutics, Inc.			Equity			7/25/2023			Common Stock			364,963						500						620						(4)
Hibercell, Inc.			Equity			5/7/2021			Preferred Series B			3,466,840						4,250						1,834						(15)
HilleVax, Inc.			Equity			5/3/2022			Common Stock			235,295						4,000						3,777						(4)
Humanigen, Inc.			Equity			3/31/2021			Common Stock			43,243						800						—						(4)(10)
Kura Oncology, Inc.			Equity			6/16/2023			Common Stock			47,826						550						688						(4)(10)
Madrigal Pharmaceutical, Inc.			Equity			9/29/2023			Common Stock			5,100						773						1,180						(4)(10)
NorthSea Therapeutics			Equity			12/15/2021			Preferred Series C			983						2,000						1,427						(5)(10)
Phathom Pharmaceuticals, Inc.			Equity			6/9/2023			Common Stock			147,233						1,730						1,344						(4)(10)(16)
Rocket Pharmaceuticals, Ltd.			Equity			8/22/2007			Common Stock			944						1,500						28						(4)
Savara, Inc.			Equity			8/11/2015			Common Stock			11,119						203						52						(4)
Sio Gene Therapies, Inc.			Equity			2/2/2017			Common Stock			16,228						1,269						6						(4)
Tarsus Pharmaceuticals, Inc.			Equity			5/5/2022			Common Stock			155,555						2,100						3,150						(4)(10)
uniQure B.V.			Equity			1/31/2019			Common Stock			17,175						332						116						(4)(5)(10)
Valo Health, LLC			Equity			12/11/2020			Preferred Series B			510,308						3,000						2,911
			Equity			10/31/2022			Preferred Series C			170,102						1,000						1,187
Total Valo Health, LLC												680,410						4,000						4,098
Verge Analytics, Inc.			Equity			9/6/2023			Preferred Series C			208,588						1,500						1,753
Viridian Therapeutics, Inc.			Equity			11/6/2023			Common Stock			32,310						400						704						(4)(10)
X4 Pharmaceuticals, Inc.			Equity			11/26/2019			Common Stock			1,566,064						2,945						1,313						(4)
Subtotal: Drug Discovery & Development (2.47%)*																		40,735						44,500
Electronics & Computer Hardware
Locus Robotics Corp.			Equity			11/17/2022			Preferred Series F			15,116						650						407
Skydio, Inc.			Equity			3/8/2022			Preferred Series E			248,900						1,500						544
Subtotal: Electronics & Computer Hardware (0.05%)*																		2,150						951
Healthcare Services, Other
23andMe, Inc.			Equity			3/11/2019			Common Stock			825,732						5,094						754						(4)
Carbon Health Technologies, Inc.			Equity			3/30/2021			Preferred Series C			217,880						1,688						206
Subtotal: Healthcare Services, Other (0.05%)*																		6,782						960
Information Services
Planet Labs, Inc.			Equity			6/21/2019			Common Stock			547,880						615						1,353						(4)
Yipit, LLC			Equity			12/30/2021			Preferred Series E			41,021						3,825						4,890
Subtotal: Information Services (0.35%)*																		4,440						6,243
Medical Devices & Equipment
Coronado Aesthetics, LLC			Equity			10/15/2021			Common Units			180,000						—						2						(7)

See notes to consolidated financial statements

27

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
			Equity			10/15/2021			Preferred Series A-2			5,000,000						$	250					$	260					(7)
Total Coronado Aesthetics, LLC												5,180,000						250						262
Subtotal: Medical Devices & Equipment (0.01%)*																		250						262
Semiconductors
Achronix Semiconductor Corporation			Equity			7/1/2011			Preferred Series C			277,995						160						394
Subtotal: Semiconductors (0.02%)*																		160						394
Software
3GTMS, LLC			Equity			8/9/2021			Common Stock			1,000,000						1,000						863
Black Crow AI, Inc. affiliates			Equity			3/24/2021			Preferred Note			3						2,406						2,406						(21)
CapLinked, Inc.			Equity			10/26/2012			Preferred Series A-3			53,614						51						—
Contentful Global, Inc.			Equity			12/22/2020			Preferred Series C			41,000						138						303						(5)(10)
			Equity			11/20/2018			Preferred Series D			108,500						500						842						(5)(10)
Total Contentful Global, Inc.												149,500						638						1,145
Docker, Inc.			Equity			11/29/2018			Common Stock			20,000						4,284						636
Druva Holdings, Inc.			Equity			10/22/2015			Preferred Series 2			458,841						1,000						2,752
			Equity			8/24/2017			Preferred Series 3			93,620						300						587
Total Druva Holdings, Inc.												552,461						1,300						3,339
HighRoads, Inc.			Equity			1/18/2013			Common Stock			190						307						—
Leapwork ApS			Equity			8/25/2023			Preferred Series B2			183,073						250						231						(5)(10)
Lightbend, Inc.			Equity			12/4/2020			Common Stock			38,461						265						23
Nextdoor.com, Inc.			Equity			8/1/2018			Common Stock			1,019,255						4,854						1,927						(4)
Palantir Technologies			Equity			9/23/2020			Common Stock			568,337						3,474						9,758						(4)
SingleStore, Inc.			Equity			11/25/2020			Preferred Series E			580,983						2,000						1,721
			Equity			8/12/2021			Preferred Series F			52,956						280						196
Total SingleStore, Inc.												633,939						2,280						1,917
Verana Health, Inc.			Equity			7/8/2021			Preferred Series E			952,562						2,000						422
ZeroFox, Inc.			Equity			5/7/2020			Common Stock			289,992						101						252						(4)
Subtotal: Software (1.27%)*																		23,210						22,919
Sustainable and Renewable Technology
Fulcrum Bioenergy, Inc.			Equity			9/13/2012			Preferred Series C-1			187,265						711						529
Impossible Foods, Inc.			Equity			5/10/2019			Preferred Series E-1			188,611						2,000						479
Modumetal, Inc.			Equity			6/1/2015			Common Stock			1,035						500						—
NantEnergy, LLC			Equity			8/31/2013			Common Units			59,665						102						—
Pineapple Energy LLC			Equity			12/10/2020			Common Stock			304,487						3,153						180						(4)
Pivot Bio, Inc.			Equity			6/28/2021			Preferred Series D			593,080						4,500						2,684
Proterra, Inc.			Equity			5/28/2015			Common Stock			457,841						542						9						(4)
Subtotal: Sustainable and Renewable Technology (0.22%)*																		11,508						3,881
Total: Equity Investments (8.44%)*																		$	155,226					$	152,170

See notes to consolidated financial statements

28

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Warrant Investments
Biotechnology Tools
Alamar Biosciences, Inc.			Warrant			6/21/2022			Preferred Series B			46,197						$	36					$	20
PathAI, Inc.			Warrant			12/23/2022			Common Stock			53,418						460						334						(12)
Subtotal: Biotechnology Tools (0.02%)*																		496						354
Communications & Networking
Aryaka Networks, Inc.			Warrant			6/28/2022			Common Stock			229,611						123						128						(12)
Subtotal: Communications & Networking (0.01%)*																		123						128
Consumer & Business Products
Gadget Guard, LLC			Warrant			6/3/2014			Common Stock			1,662,441						228						—
The Neat Company			Warrant			8/13/2014			Common Stock			54,054						365						—
Whoop, Inc.			Warrant			6/27/2018			Preferred Series C			686,270						18						325
Subtotal: Consumer & Business Products (0.02%)*																		611						325
Consumer & Business Services
Carwow LTD			Warrant			12/14/2021			Common Stock			174,163						164						75						(5)(10)
Houzz, Inc.			Warrant			10/29/2019			Common Stock			529,661						20						—
Landing Holdings Inc.			Warrant			3/12/2021			Common Stock			11,806						116						298						(15)
Lendio, Inc.			Warrant			3/29/2019			Preferred Series D			127,032						39						33
Plentific Ltd			Warrant			10/3/2023			Ordinary Shares			19,499						48						51						(5)(10)
Provi			Warrant			12/22/2022			Common Stock			117,042						166						74						(15)
Rhino Labs, Inc.			Warrant			3/12/2021			Common Stock			13,106						470						4						(15)
SeatGeek, Inc.			Warrant			6/12/2019			Common Stock			1,379,761						842						3,065						(16)
Skyword, Inc.			Warrant			11/14/2022			Common Stock			1,607,143						57						58
			Warrant			8/23/2019			Preferred Series B			444,444						83						5
Total Skyword, Inc.												2,051,587						140						63
Snagajob.com, Inc.			Warrant			4/20/2020			Common Stock			600,000						16						—
			Warrant			6/30/2016			Preferred Series A			1,800,000						782						—
			Warrant			8/1/2018			Preferred Series B			1,211,537						62						—
Total Snagajob.com, Inc.												3,611,537						860						—
Thumbtack, Inc.			Warrant			5/1/2018			Common Stock			267,225						844						515						(12)
Udacity, Inc.			Warrant			9/25/2020			Common Stock			486,359						218						—						(12)
Veem, Inc.			Warrant			3/31/2022			Common Stock			98,428						126						16						(12)
Worldremit Group Limited			Warrant			2/11/2021			Preferred Series D			77,215						129						23						(5)(10)(12)(16)
			Warrant			8/27/2021			Preferred Series E			1,868						26						—						(5)(10)(16)
Total Worldremit Group Limited												79,083						155						23
Subtotal: Consumer & Business Services (0.23%)*																		4,208						4,217

See notes to consolidated financial statements

29

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Diversified Financial Services
Next Insurance, Inc.			Warrant			2/3/2023			Common Stock			522,930						$	214					$	554
Subtotal: Diversified Financial Services (0.03%)*																		214						554
Drug Delivery
Aerami Therapeutics Holdings, Inc.			Warrant			6/1/2016			Common Stock			67,069						—						—
BioQ Pharma Incorporated			Warrant			10/27/2014			Common Stock			459,183						2						—
PDS Biotechnology Corporation			Warrant			8/28/2014			Common Stock			3,929						390						—						(4)
Subtotal: Drug Delivery (0.00%)*																		392						—
Drug Discovery & Development
ADMA Biologics, Inc.			Warrant			2/24/2014			Common Stock			58,000						166						11						(4)
Akero Therapeutics, Inc.			Warrant			6/15/2022			Common Stock			22,949						175						335						(4)(10)
AmplifyBio, LLC			Warrant			12/27/2022			Class A Units			69,239						237						184						(15)
Axsome Therapeutics, Inc.			Warrant			9/25/2020			Common Stock			61,004						1,290						1,657						(4)(10)(12)(16)
Cellarity, Inc.			Warrant			12/8/2021			Preferred Series B			100,000						287						201						(15)
Century Therapeutics, Inc.			Warrant			9/14/2020			Common Stock			16,112						37						1						(4)
COMPASS Pathways plc			Warrant			6/30/2023			Ordinary Shares			75,376						278						285						(4)(5)(10)
Curevo, Inc.			Warrant			6/9/2023			Common Stock			95,221						233						251						(15)
Dermavant Sciences Ltd.			Warrant			5/31/2019			Common Stock			223,642						101						7						(5)(10)
enGene, Inc.			Warrant			12/22/2023			Common Stock			43,689						118						179						(4)(5)(10)
Evofem Biosciences, Inc.			Warrant			6/11/2014			Common Stock			3						266						—						(4)
Fresh Tracks Therapeutics, Inc. (p.k.a. Brickell Biotech, Inc.)			Warrant			2/18/2016			Common Stock			201						119						—						(4)
Heron Therapeutics, Inc.			Warrant			8/9/2023			Common Stock			238,095						228						223						(4)(15)
Kineta, Inc.			Warrant			12/20/2019			Common Stock			2,202						110						—						(4)
Kura Oncology, Inc.			Warrant			11/2/2022			Common Stock			14,342						88						63						(4)(10)(15)
Madrigal Pharmaceutical, Inc.			Warrant			5/9/2022			Common Stock			13,229						570						1,842						(4)(10)
Phathom Pharmaceuticals, Inc.			Warrant			9/17/2021			Common Stock			64,687						848						68						(4)(10)(12)(15)(16)
Redshift Bioanalytics, Inc.			Warrant			3/23/2022			Preferred Series E			475,510						20						6						(15)
Scynexis, Inc.			Warrant			5/14/2021			Common Stock			106,035						296						28						(4)
TG Therapeutics, Inc.			Warrant			2/28/2019			Common Stock			264,226						1,284						2,583						(4)(10)(12)
Valo Health, LLC			Warrant			6/15/2020			Common Units			102,216						256						153
X4 Pharmaceuticals, Inc.			Warrant			3/18/2019			Common Stock			1,392,787						510						225						(4)
Subtotal: Drug Discovery & Development (0.46%)*																		7,517						8,302
Electronics & Computer Hardware
908 Devices, Inc.			Warrant			3/15/2017			Common Stock			49,078						101						175						(4)
Locus Robotics Corp.			Warrant			6/21/2022			Common Stock			8,503						34						102
Skydio, Inc.			Warrant			11/8/2021			Common Stock			622,255						557						114
Subtotal: Electronics & Computer Hardware (0.02%)*																		692						391

See notes to consolidated financial statements

30

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Healthcare Services, Other
Modern Life, Inc.			Warrant			3/30/2023			Common Stock			37,618						$	164					$	165
Recover Together, Inc.			Warrant			7/3/2023			Common Stock			194,830						382						327
Strive Health Holdings, LLC			Warrant			9/28/2023			Common Units			51,760						83						95						(15)
Vida Health, Inc.			Warrant			3/28/2022			Common Stock			192,431						121						9
Subtotal: Healthcare Services, Other (0.03%)*																		750						596
Information Services
Capella Space Corp.			Warrant			10/21/2021			Common Stock			176,200						207						33						(15)
INMOBI Inc.			Warrant			11/19/2014			Common Stock			65,587						82						—						(5)(10)
NetBase Solutions, Inc.			Warrant			8/22/2017			Preferred Series 1			60,000						356						362
Signal Media Limited			Warrant			6/29/2022			Common Stock			113,828						49						91						(5)(10)
Subtotal: Information Services (0.03%)*																		694						486
Manufacturing Technology
Bright Machines, Inc.			Warrant			3/31/2022			Common Stock			392,308						537						279
MacroFab, Inc.			Warrant			3/23/2022			Common Stock			1,111,111						528						677
Xometry, Inc.			Warrant			5/9/2018			Common Stock			87,784						47						2,044						(4)
Subtotal: Manufacturing Technology (0.17%)*																		1,112						3,000
Media/Content/Info
Fever Labs, Inc.			Warrant			12/30/2022			Preferred Series E-1			369,370						67						235
Subtotal: Media/Content/Info (0.01%)*																		67						235
Medical Devices & Equipment
Intuity Medical, Inc.			Warrant			12/29/2017			Preferred Series B-1			3,076,323						294						—
Outset Medical, Inc.			Warrant			9/27/2013			Common Stock			62,794						401						78						(4)
Senseonics Holdings, Inc.			Warrant			9/8/2023			Common Stock			728,317						200						184						(4)
Tela Bio, Inc.			Warrant			3/31/2017			Common Stock			15,712						61						—						(4)
Subtotal: Medical Devices & Equipment (0.01%)*																		956						262
Semiconductors
Achronix Semiconductor Corporation			Warrant			6/26/2015			Preferred Series D-2			750,000						99						811
Subtotal: Semiconductors (0.04%)*																		99						811
Software
Aria Systems, Inc.			Warrant			5/22/2015			Preferred Series G			231,535						74						—
Automation Anywhere, Inc.			Warrant			9/23/2022			Common Stock			254,778						448						430
Bitsight Technologies, Inc.			Warrant			11/18/2020			Common Stock			29,691						284						666
Brain Corporation			Warrant			10/4/2021			Common Stock			194,629						165						47						(15)
CloudBolt Software, Inc.			Warrant			9/30/2020			Common Stock			211,342						117						12
Cloudian, Inc.			Warrant			11/6/2018			Common Stock			477,454						71						29
Cloudpay, Inc.			Warrant			4/10/2018			Preferred Series B			6,763						54						844						(5)(10)
Couchbase, Inc.			Warrant			4/25/2019			Common Stock			105,350						462						1,225						(4)

See notes to consolidated financial statements

31

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Cutover, Inc.			Warrant			9/21/2022			Common Stock			102,898						$	26					$	62					(5)(10)(12)
Dashlane, Inc.			Warrant			3/11/2019			Common Stock			770,838						461						258
Delphix Corp.			Warrant			10/8/2019			Common Stock			718,898						1,594						3,801
Demandbase, Inc.			Warrant			8/2/2021			Common Stock			727,047						545						396
DNAnexus, Inc.			Warrant			3/21/2014			Preferred Series C			909,091						97						47
Dragos, Inc.			Warrant			6/28/2023			Common Stock			49,309						1,452						1,207
DroneDeploy, Inc.			Warrant			6/30/2022			Common Stock			95,911						278						413
Eigen Technologies Ltd.			Warrant			4/13/2022			Common Stock			522						8						4						(5)(10)
Elation Health, Inc.			Warrant			9/12/2022			Common Stock			362,837						583						188
First Insight, Inc.			Warrant			5/10/2018			Preferred Series B			75,917						96						77
Fulfil Solutions, Inc.			Warrant			7/29/2022			Common Stock			84,995						325						456
Kore.ai, Inc.			Warrant			3/31/2023			Preferred Series C			64,293						208						243
Leapwork ApS			Warrant			1/23/2023			Common Stock			39,948						16						35						(5)(10)(12)
Lightbend, Inc.			Warrant			2/14/2018			Preferred Series D			89,685						131						49
Mixpanel, Inc.			Warrant			9/30/2020			Common Stock			82,362						252						306
Onna Technologies, Inc.			Warrant			7/5/2023			Common Stock			172,867						60						39
Poplicus, Inc.			Warrant			5/28/2014			Common Stock			132,168						—						—
Reltio, Inc.			Warrant			6/30/2020			Common Stock			69,120						215						447
Simon Data, Inc.			Warrant			3/22/2023			Common Stock			77,934						96						76						(12)
SingleStore, Inc.			Warrant			4/28/2020			Preferred Series D			312,596						103						386
Sisense Ltd.			Warrant			6/8/2023			Ordinary Shares			321,956						174						128						(5)(10)
Suzy, Inc.			Warrant			8/24/2023			Common Stock			292,936						367						354						(15)
The Faction Group LLC			Warrant			11/3/2014			Preferred Series AA			8,076						234						904
Tipalti Solutions Ltd.			Warrant			3/22/2023			Ordinary Shares			254,877						174						234						(5)(10)
VideoAmp, Inc.			Warrant			1/21/2022			Common Stock			152,048						1,275						186						(15)
Subtotal: Software (0.75%)*																		10,445						13,549
Surgical Devices
TransMedics Group, Inc.			Warrant			9/11/2015			Common Stock			14,440						39						676						(4)
Subtotal: Surgical Devices (0.04%)*																		39						676
Sustainable and Renewable Technology
Ampion, PBC			Warrant			4/15/2022			Common Stock			18,472						52						36
Halio, Inc.			Warrant			4/22/2014			Preferred Series A			325,000						155						36
			Warrant			4/7/2015			Preferred Series B			131,883						63						11
Total Halio, Inc.												456,883						218						47
Polyera Corporation			Warrant			3/24/2015			Preferred Series C			150,036						269						—
Subtotal: Sustainable and Renewable Technology (0.00%)*																		539						83
Total: Warrant Investments (1.88%)*																		$	28,954					$	33,969
Total Investments in Securities (179.92%)*																		$	3,242,550					$	3,243,438

See notes to consolidated financial statements

32

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

Portfolio Company			Type of Investment			Acquisition Date(4)			Series (3)			Shares						Cost (2)						Value						Footnotes
Investment Funds & Vehicles Investments
Drug Discovery & Development
Forbion Growth Opportunities Fund I C.V.			Investment Funds & Vehicles			11/16/2020												$	3,783					$	3,619					(5)(10)(17)
Forbion Growth Opportunities Fund II C.V.			Investment Funds & Vehicles			6/23/2022												319						611						(5)(10)(17)
Subtotal: Drug Discovery & Development (0.23%)*																		4,102						4,230
Software
Liberty Zim Co-Invest L.P.			Investment Funds & Vehicles			7/21/2022												381						378						(5)(10)
Subtotal: Software (0.02%)*																		381						378
Total: Investment Funds & Vehicles Investments (0.26%)*																		$	4,483					$	4,608
Total Investments before Cash and Cash Equivalents (180.18%)*																		$	3,247,033					$	3,248,046
Cash & Cash Equivalents
GS Financial Square Government Fund			Cash & Cash Equivalents						FGTXX/38141W273									$	56,000					$	56,000
Total: Investments in Cash & Cash Equivalents (3.11%)*																		$	56,000					$	56,000
Total: Investments after Cash & Cash Equivalents (183.28%)*																		$	3,303,033					$	3,304,046

Foreign Currency Forward Contracts
Foreign Currency			Settlement Date			Counterparty			Amount			Transaction						US $ Value at Settlement Date						Value
Great British Pound (GBP)			6/3/2024			Goldman Sachs Bank USA			£	19,288		Sold						$	23,810					$	(766)
Total: Total Foreign Currency Forward ((0.04))*																		$	23,810					$	(766)

*Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

(1)Prime represents 8.50% as of December 31, 2023. 1-month SOFR, 3-month SOFR, and 6-month SOFR represent 5.34%, 5.36%, and 5.35%, respectively, as of December 31, 2023.

(2)Gross unrealized appreciation, gross unrealized depreciation, and net unrealized appreciation for federal income tax purposes totaled $118.3 million, $115.9 million, and $2.4 million, respectively. The tax cost of investments is $3.2 billion.

(3)Preferred and common stock, warrants, and equity interests are generally non-income producing.

(4)Except for warrants in 24 publicly traded companies and common stock in 36 publicly traded companies, all investments are restricted as of December 31, 2023 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s Valuation Committee and approved by the Board.

(5)Non-U.S. company or the company’s principal place of business is outside the United States.

(6)[Reserved]

(7)Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.

(8)Debt is on non-accrual status as of December 31, 2023, and is therefore considered non-income producing.

(9)Denotes that all or a portion of the debt investment is convertible debt.

(10)Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.

(11)Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”).

(12)Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”).

(13)Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”).

See notes to consolidated financial statements

33

---

Table of Contents

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2023

(dollars in thousands)

(14)Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.

(15)Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company.

(16)Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of December 31, 2023.

(17)Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of December 31, 2023 (Refer to “Note 11 — Commitments and Contingencies”).

(18)Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition.

(19)Denotes second lien senior secured debt.

(20)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC.

(21)Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of December 31, 2023, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $2.4 million.

(22)Denotes the security holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the royalty contract are $12.0 million and $9.4 million, respectively.

(23)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1” for additional disclosure.

See notes to consolidated financial statements

34

---

Table of Contents

HERCULES CAPITAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business

Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. The Company sources its investments through its principal office located in San Mateo, CA, as well as through its additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, Denver, CO, and London, United Kingdom. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.

The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a Business Development Company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was subject to tax as a corporation under Subchapter C of the Internal Revenue Code of 1986, as amended (the “Code”). Effective January 1, 2006, the Company elected to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Code (see “Note 6 - Income Taxes”).

The Company is not registered with the Commodity Futures Trading Commission. The Company has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”), pursuant to Rule 4.5 under the CEA. The Company is not, therefore, subject to registration or regulation as a “commodity pool operator” under the CEA.

Hercules Capital IV, L.P. (“HC IV”) is our wholly owned Delaware limited partnership that was formed in December 2010. HC IV received a license to operate as a Small Business Investment Company (“SBIC”) under the authority of the Small Business Administration (“SBA”) on October 27, 2020. In September 2023, the Company formed Hercules SBIC V, L.P. (“SBIC V”) which received its SBIC license on July 9, 2024. SBICs are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. Hercules Technology SBIC Management, LLC, is a wholly owned limited liability company subsidiary of the Company, which was formed in November 2003 and serves as the general partner of HC IV and SBIC V.

The Company has also established certain wholly owned subsidiaries, all of which are structured as Delaware corporations or Limited Liability Companies (“LLCs”), to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Certain of the subsidiaries are taxable and not consolidated with Hercules for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments.

The Company formed Hercules Capital Management LLC and Hercules Adviser LLC in 2020 as wholly owned Delaware limited liability subsidiaries. The Company was granted no-action relief by the staff of the Securities and Exchange Commission (“SEC”) to allow Hercules Adviser LLC (the “Adviser Subsidiary”) to register as a registered investment adviser under the Investment Advisers Act of 1940, as amended (“Advisers Act”). The Adviser Subsidiary provides investment advisory and related services to investment vehicles (“Adviser Funds”) owned by one or more unrelated third-party investors (“External Parties”). The Adviser Subsidiary is owned by Hercules Capital Management LLC and collectively held and presented with Hercules Partner Holdings, LLC, which separately wholly owns the general partnership vehicles to each of the Adviser Funds.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements

35

---

Table of Contents

but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency.

As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946, Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated.

Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and all Variable Interest Entities (“VIE”) of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE.

To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE.

The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.

The Company's Consolidated Financial Statements included the accounts of the securitization trust, a VIE, formed in conjunction with the issuance of the 2031 Asset-Backed Notes (as defined in “Note 5 – Debt”). The assets of the Company's securitization VIE are restricted to be used to settle obligations of its consolidated securitization VIE, which are disclosed parenthetically on the Consolidated Statements of Assets and Liabilities. The liabilities are the only obligations of its consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to the Company's general credit.

36

---

Table of Contents

Fair Value Measurements

The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value.

The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

Valuation of Investments

The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, the Board has designated the Company’s Valuation Committee as the “valuation designee”. As of September 30, 2024, approximately 97.4% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Company's Valuation Committee and approved by the Board. Fair Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the valuation designee of the Board. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. The Company provides financing solutions to high-growth and innovative venture capital-backed and institutional-backed companies in technology-related industries including drug discovery and development, software, consumer & business services, and other healthcare services at all stages of development. Given the nature of investing in these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy established by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by the Company's Valuation Committee and approved by the Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

37

---

Table of Contents

In accordance with procedures established by its Board, the Company values investments on a quarterly basis following a multistep valuation process. The quarterly Board approved multi-step valuation process is described below:

(1)The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment;

(2)Preliminary valuation conclusions and business-based assumptions, along with any applicable fair value marks provided by an independent firm, are reviewed with the Company’s investment committee and certain member(s) of credit group as necessary;

(3)The Valuation Committee reviews the preliminary valuations recommended by the investment committee and certain member(s) of the credit group of each investment in the portfolio and determines the fair value of each investment in the Company’s portfolio in good faith and recommends the valuation determinations to the Audit Committee of the Board;

(4)The Audit Committee of the Board provides oversight of the quarterly valuation process in accordance with Rule 2a-5, which includes a review of the quarterly reports prepared by the Valuation Committee, reviews the fair valuation determinations made by the Valuation Committee, and approves such valuations for inclusion in public reporting and disclosures, as appropriate; and

(5)The Board, upon the recommendation of the Audit Committee, discusses valuations and approves the fair value of each investment in the Company’s portfolio.

Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by the Valuation Committee and approved by the Board.

As part of the overall process noted above, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Valuation Committee and subject to approval of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The change in fair value of each individual investment is recorded as an adjustment to the investment's fair value and the change is reflected in unrealized appreciation or depreciation.

Debt Investments

The Company principally invests in debt securities with a particular emphasis on Structured Debt. The Company uses the term “Structured Debt” to refer to a debt investment that is structured with an equity, warrant, option, or other right to purchase or convert into common or preferred stock. Given the nature of lending to venture capital-backed and institutional-backed companies in technology-related industries, substantially all of the Company’s debt investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. The Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives, and to the extent market quotations or other pricing indicators (i.e. broker quotes) are available, these investments are considered Level 1 or 2 assets in line with ASC Topic 820.

In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below.

The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers

38

---

Table of Contents

to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date.

The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. For syndicated debt investments, for which sufficient market data is available and liquidity, the Company values debt securities using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost.

When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recording warrant or other equity instruments is accreted into interest income over the life of the debt investment.

Equity Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors.

Investment Funds & Vehicles

The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate Net Asset Value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820.

39

---

Table of Contents

Derivative Instruments

The Company's derivative instruments include foreign currency forward contracts. The Company recognizes all derivative instruments as assets or liabilities at fair value in its consolidated financial statements. Derivative contracts entered into by the Company are not designated as hedging instruments, and as a result, the Company presents changes in fair value through net change in unrealized appreciation (depreciation) on non-control/non-affiliate investments in the Consolidated Statements of Operations. Realized gains and losses of the derivative instruments are included in net realized gains (losses) on non-control/non-affiliate investments in the Consolidated Statements of Operations. The net cash flows realized on settlement of derivatives are included in realized (gain) loss in the Consolidated Statements of Cash Flows.

Cash, Cash Equivalents, and Restricted Cash

Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. As of September 30, 2024, the Company held $102 thousand (Cost basis $102 thousand) of foreign cash. As of December 31, 2023, the Company held $804 thousand (Cost basis $842 thousand) of foreign cash. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions, including amounts held in a securitization trust by trustees related to its 2031 Asset-Backed Notes (refer to “Note 5 – Debt”).

Other Assets

Other assets generally consist of prepaid expenses, debt issuance costs on our Credit Facilities net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow and other investment related receivables.

Escrow Receivables

Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”.

Investment Income Recognition

The Company’s investment portfolio generates interest, fee, and dividend income. The Company records interest income on an accrual basis, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. The Company’s Structured Debt investments may generate OID. The OID received upfront typically represents the value of detachable equity, warrants, or another asset obtained in conjunction with the acquisition of debt securities. The OID is accreted into interest income over the term of the loan as a yield enhancement following the effective interest method. Additionally, certain debt investments in the Company’s portfolio earn PIK interest. The Company records PIK interest in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. Contractual PIK interest represents contractually deferred interest that is added to the loan balance as principal and is generally due at the end of the loan term.

The Company’s loan origination activities generate fee income, which is generally collected in advance and includes loan commitment, facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are

40

---

Table of Contents

capitalized and then amortized into income over the contractual life of the loan using the effective interest method. One-off fees for transaction and management services are generally recognized as income in the period when the services are rendered. The Company may also earn loan exit fees, which are contractual fees that are generally received upon the earlier of maturity or prepayment. The Company accretes loan exit fees into interest income following the effective interest method, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected.

From time to time, additional fees may be earned by the Company relating to specific loan modifications, prepayments, or other one-off events. These non-recurring fees are either amortized into fee income over the remaining term of the loan commencing in the quarter for loan modifications, or recognized currently as one-time fee income for items such as prepayment penalties, fees related to select covenant default waiver fees, and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding.

Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may determine to continue to accrue interest on a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.

Realized Gains or Losses

Realized gains or losses are measured by the difference between the net proceeds from the sale or other realization event and the cost basis of the investment using the specific identification method without regard to unrealized appreciation or depreciation previously recognized, and includes investments charged off during the period, net of recoveries.

Secured Borrowings

The Company follows the guidance in ASC Topic 860, Transfers and Servicing (“ASC Topic 860”), when accounting for participation and other partial loan sales. Certain loan sales do not qualify for sale accounting under ASC Topic 860 because these sales do not meet the definition of a “participating interest”, as defined in the guidance, in order for sale accounting treatment to be allowed. Participations or other partial loan sales which do not meet the definition of a participating interest, or which are not eligible for sale accounting treatment remain as an investment on the consolidated balance sheet as required under U.S. GAAP and the proceeds are recorded as a secured borrowing. Secured borrowings are carried at fair value.

Equity Offering Expenses

The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of registered securities.

Debt

The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, over the remaining life of the underlying debt obligations (see “Note 5 – Debt”). Accrued but unpaid interest is included within Accounts payable and accrued liabilities on the Consolidated Statements of Assets and Liabilities. In the event that the debt is extinguished, either partially or in full, before maturity, the Company recognizes the gain or loss in the Consolidated Statements of Operations within net realized gains (losses) as a “Loss on extinguishment of debt”.

Debt Issuance Costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30, Interest – Imputation of Interest, debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements.

Stock-Based Compensation

The Company has issued and may, from time to time, issue stock options, restricted stock, and other stock-based compensation awards to employees and directors. Management follows the guidance set forth under ASC Topic 718, to account for stock-based compensation awards granted. Under ASC Topic 718, compensation expense associated with

41

---

Table of Contents

stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment. This includes certain assumptions such as stock price volatility, forfeiture rate, expected outcome probability, and expected option life, as applicable to each award. In accordance with ASC Topic 480, certain stock awards are classified as a liability. The compensation expense associated with these awards is recognized in the same manner as all other stock-based compensation. The award liability is recorded as deferred compensation and included in Accounts payable and accrued liabilities.

Income Taxes

The Company accounts for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized.

Because taxable income as determined in accordance with U.S. federal tax regulations differ from U.S. GAAP, taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gains or losses are recognized at some time in the future for tax or U.S. GAAP purposes.

The Company has elected to be treated as a RIC under Subchapter M of the Code. To qualify as a RIC, the Company is required to meet certain income and asset tests in addition to distributing dividends of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions paid, to its stockholders. See “Certain United States Federal Income Tax Considerations” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 15, 2024 for additional information.

As a RIC, the Company is subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of its ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of its capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal income tax (such as the tax imposed on a RIC’s retained net capital gains).

The amount to be paid out as a distribution is determined by the Board each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company's earnings fall below the amount of the dividend distributions declared, however, a portion of the total amount of the Company's distributions for the fiscal year may be deemed a return of capital.

Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital. The Company intends to timely distribute to its stockholders substantially all of its annual taxable income for each year, except that it may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, it may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

Earnings Per Share (“EPS”)

Basic EPS is calculated by dividing net earnings applicable to common stockholders by the weighted average number of common shares outstanding. Common shares outstanding includes common stock and restricted stock for which no future service is required as a condition to the delivery of the underlying common stock. Diluted EPS includes the

42

---

Table of Contents

determinants of basic EPS and, in addition, reflects the dilutive effect of the common stock deliverable pursuant to stock options and to restricted stock for which future service is required as a condition to the delivery of the underlying common stock. In accordance with ASC 260-10-45-60A, the Company uses the two-class method in the computation of basic EPS and diluted EPS, if applicable.

Comprehensive Income

The Company reports all changes in comprehensive income in the Consolidated Statements of Operations. The Company did not have other comprehensive income for the three and nine months ended September 30, 2024 or 2023. The Company’s comprehensive income is equal to its net increase in net assets resulting from operations.

Distributions

Distributions to common stockholders are approved by the Board on a quarterly basis and the distribution payable is recorded on the ex-dividend date. The Company maintains an “opt out” dividend reinvestment plan that provides for reinvestment of the Company’s distribution on behalf of the Company’s stockholders, unless a stockholder elects to receive cash. As a result, if the Company declares a distribution, cash distributions will be automatically reinvested in additional shares of its common stock unless the stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash distributions.

Segments

The Company lends to and invests in portfolio companies in various technology-related industries including drug discovery and development, software, consumer & business services, and other healthcare services. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these loan and investment relationships has similar business and economic characteristics, they have been aggregated into a single reportable segment.

43

---

Table of Contents

3. Fair Value of Financial Instruments

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of September 30, 2024 and December 31, 2023.

(in thousands)						Balance as of September 30, 2024						Quoted Prices in Active Markets for Identical Assets (Level 1)						Significant Other Observable Inputs (Level 2)						Significant Unobservable Inputs (Level 3)
Description
Other assets and liabilities
Escrow and Other Investment Receivables						$	158					$	—					$	—					$	158
Accounts Payable and Accrued Liabilities						(1,770)						—						—						(1,770)
Investments
Senior Secured Debt						$	3,306,724					$	—					$	—					$	3,306,724
Unsecured Debt						73,854						—						—						73,854
Preferred Stock						47,342						—						—						47,342
Common Stock(2)						95,693						49,018						—						46,675
Warrants						30,023						—						10,647						19,376
						$	3,553,636					$	49,018					$	10,647					$	3,493,971
Investment Funds & Vehicles measured at Net Asset Value(3)						6,877
Total Investments, at fair value						$	3,560,513
Derivative Instruments(4)						(1,168)
Total Investments, at fair value including derivative instruments						$	3,559,345

(in thousands)						Balance as of December 31, 2023						Quoted Prices in Active Markets for Identical Assets (Level 1)						Significant Other Observable Inputs (Level 2)						Significant Unobservable Inputs (Level 3)
Description
Cash and cash equivalents
Money Market Fund(1)						$	56,000					$	56,000					$	—					$	—
Other assets
Escrow and Other Investment Receivables						$	10,888					$	—					$	—					$	10,888
Investments
Senior Secured Debt						$	2,987,577					$	—					$	—					$	2,987,577
Unsecured Debt						69,722						—						—						69,722
Preferred Stock						53,038						—						—						53,038
Common Stock(2)						99,132						57,342						—						41,790
Warrants						33,969						—						11,881						22,088
						$	3,243,438					$	57,342					$	11,881					$	3,174,215
Investment Funds & Vehicles measured at Net Asset Value(3)						4,608
Total Investments, at fair value						$	3,248,046
Derivative Instruments(4)						(766)
Total Investments including cash and cash equivalents and derivative instruments						$	3,303,280

(1)This investment is included in Cash and cash equivalents in the accompanying Consolidated Statements of Assets and Liabilities.

(2)Common Stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's Common Stock.

(3)In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statements of Assets and Liabilities.

(4)Derivative Instruments are carried at fair value and a level 2 security within the Company's fair value hierarchy.

44

---

Table of Contents

The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the nine months ended September 30, 2024 and 2023.

(in thousands)			Balance as of January 1, 2024						Net Realized Gains (Losses)(1)						Net Change in Unrealized Appreciation (Depreciation)(2)						Purchases(5)						Sales						Repayments(6)						Gross Transfers into Level 3(3)*						Gross Transfers out of Level 3(3)*						Balance as of September 30, 2024
Investments
Senior Secured Debt			$	2,987,577					$	(9,120)					$	(34,978)					$	1,099,563					$	—					$	(732,225)					$	—					$	(4,093)					$	3,306,724
Unsecured Debt			69,722						—						828						3,304						—						—						—						—						73,854
Preferred Stock			53,038						(711)						(9,013)						1,597						—						—						2,431						—						47,342
Common Stock			41,790						(1,351)						474						4,100						—						—						1,662						—						46,675
Warrants			22,088						(464)						(2,367)						2,948						(2,829)						—						—						—						19,376
Other Assets and Liabilities
Escrow and Other Investment Receivables			10,888						85						5,869						43						(18,497)						—						—						1,770						158
Accounts Payable and Accrued Liabilities			—						—						—						—						—						—						(1,770)						—						(1,770)
Total			$	3,185,103					$	(11,561)					$	(39,187)					$	1,111,555					$	(21,326)					$	(732,225)					$	2,323					$	(2,323)					$	3,492,359

(in thousands)			Balance as of January 1, 2023						Net Realized Gains (Losses)(1)						Net Change in Unrealized Appreciation (Depreciation)(2)						Purchases(5)						Sales						Repayments(6)						Gross Transfers into Level 3(4)*						Gross Transfers out of Level 3(4)*						Balance as of September 30, 2023
Investments
Senior Secured Debt			$	2,741,388					$	(5,400)					$	(22,135)					$	1,003,953					$	—					$	(695,856)					$	—					$	—					$	3,021,950
Unsecured Debt			54,056						—						4,958						10,916						—						—						—						—						69,930
Preferred Stock			41,488						(3,441)						1,392						2,851						—						—						—						—						42,290
Common Stock			25,059						—						10,684						4,500						(594)						—						—						—						39,649
Warrants			19,419						(3,443)						1,539						3,711						(1,108)						—						—						—						20,118
Other Assets
Escrow Receivable			875						80						—						—						(207)						—						—						—						748
Total			$	2,882,285					$	(12,204)					$	(3,562)					$	1,025,931					$	(1,909)					$	(695,856)					$	—					$	—					$	3,194,685

* The Company recognizes transfers as of the transaction date.

(1)Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations.

(2)Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations.

(3)Transfers out of Level 3 during the nine months ended September 30, 2024 related to the conversion of the Company's Level 3 debt investments in Better Therapeutics, Inc. and Eigen Technologies Ltd. into common stock and preferred stock Level 3 investments in acquiring companies.

(4)There were no transfers into or out of Level 3 during the nine months ended September 30, 2023.

(5)Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds.

(6)Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.

The following table presents the net unrealized appreciation (depreciation) recorded for debt, preferred stock, common stock, and warrant Level 3 investments relating to assets still held at the reporting date.

(in millions)			Nine Months Ended September 30,
			2024						2023
Debt Investments			$	(32.3)					$	(16.9)
Preferred Stock			(9.2)						(2.0)
Common Stock			(0.3)						10.7
Warrant Investments			(0.8)						(0.9)

45

---

Table of Contents

The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of September 30, 2024 and December 31, 2023. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.

Investment Type - Level 3 Debt Investments						Fair Value as of September 30, 2024 (in thousands)						Valuation Techniques/ Methodologies						Unobservable Input(1)						Range						Weighted Average(2)
Pharmaceuticals						$	990,349					Market Comparable Companies						Hypothetical Market Yield						9.90% - 16.55%						12.74%
																		Premium/(Discount)						(2.00)% - 4.00%						0.08%
Technology						1,202,375						Market Comparable Companies						Hypothetical Market Yield						10.08% - 19.19%						13.26%
																		Premium/(Discount)						(0.75)% - 3.00%						0.33%
						25,745						Convertible Note Analysis						Probability weighting of alternative outcomes						1.00% - 70.00%						50.64%
						52,586						Liquidation(3)						Probability weighting of alternative outcomes						5.00% - 100.00%						57.86%
Sustainable and Renewable Technology						20,957						Market Comparable Companies						Hypothetical Market Yield						12.13% - 15.66%						15.43%
																		Premium/(Discount)						0.25% - 3.00%						0.43%
Medical Devices						55,413						Market Comparable Companies						Hypothetical Market Yield						12.23% - 13.19%						12.65%
																		Premium/(Discount)						0.00% - 0.50%						0.28%
Lower Middle Market						601,995						Market Comparable Companies						Hypothetical Market Yield						8.66% - 19.68%						14.61%
																		Premium/(Discount)						(0.25)% - 3.25%						0.84%
Debt Investments for which Cost Approximates Fair Value
						240,443						Debt Investments originated within 6 months
						70,171						Imminent Payoffs(4)
						72,911						Debt Investments Maturing in Less than One Year
						47,633						Debt Investments in Wholly-Owned Subsidiaries
						$	3,380,578					Total Level 3 Debt Investments
Accounts Payable and Accrued Liabilities						(1,770)						Liquidation(3)						Probability weighting of alternative outcomes						10.00% - 50.00%						38.97%
						$	3,378,808					Total Level Three Debt Investments and Other Investment Receivables (Payables)

(1)The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment.

Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:

•Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries.

•Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, “Space Technologies”, and “Software” industries.

•Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry.

•Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries.

(2)The weighted averages are calculated based on the fair market value of each investment.

(3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables is the probability weighting of alternative outcomes.

(4)Imminent Payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.

46

---

Table of Contents

Investment Type - Level 3 Debt Investments						Fair Value as of December 31, 2023 (in thousands)						Valuation Techniques/ Methodologies						Unobservable Input(1)						Range						Weighted Average(2)
Pharmaceuticals						$	971,775					Market Comparable Companies						Hypothetical Market Yield						10.91% - 21.43%						13.46%
																		Premium/(Discount)						(1.00)% - 3.50%						0.04%
						8,455						Liquidation(3)						Probability weighting of alternative outcomes						10.00% - 50.00%						41.83%
Technology						1,181,823						Market Comparable Companies						Hypothetical Market Yield						11.30% - 20.74%						15.03%
																		Premium/(Discount)						(1.00)% - 5.00%						0.47%
						23,244						Convertible Note Analysis						Probability weighting of alternative outcomes						1.00% - 50.00%						39.32%
						—						Liquidation(3)						Probability weighting of alternative outcomes						100.00% - 100.00%						100.00%
Sustainable and Renewable Technology						1,678						Market Comparable Companies						Hypothetical Market Yield						10.75% - 10.75%						10.75%
																		Premium/(Discount)						0.75% - 0.75%						0.75%
Lower Middle Market						322,162						Market Comparable Companies						Hypothetical Market Yield						12.54% - 20.15%						14.13%
																		Premium/(Discount)						(0.75)% - 2.25%						0.56%
Debt Investments for which Cost Approximates Fair Value
						431,512						Debt Investments originated within 6 months
						54,430						Imminent Payoffs(4)
						62,220						Debt Investments Maturing in Less than One Year
						$	3,057,299					Total Level 3 Debt Investments
Other Investment Receivables						9,648						Liquidation(3)						Probability weighting of alternative outcomes						10.00% - 50.00%						41.83%
						$	3,066,947					Total Level Three Debt Investments and Other Investment Receivables

(1)The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment.

Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:

•Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries.

•Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, and “Software” industries.

•Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry.

•Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries.

(2)The weighted averages are calculated based on the fair market value of each investment.

(3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables is the probability weighting of alternative outcomes.

(4)Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.

47

---

Table of Contents

Investment Type - Level 3 Equity and Warrant Investments

Fair Value as of September 30, 2024 (in thousands)

Valuation Techniques/ Methodologies

Unobservable Input(1)

Range

Weighted Average(5)

Equity Investments

$

43,990

Market Comparable Companies

Revenue Multiple(2)

0.4x - 14.8x

13.4x

Tangible Book Value Multiple(2)

1.6x - 1.6x

1.6x

Discount for Lack of Marketability(3)

13.48% - 92.82%

36.18%

13,781

Market Adjusted OPM Backsolve

Market Equity Adjustment(4)

(83.75)% - 30.35%

(8.48)%

33,234

Discounted Cash Flow

Discount Rate(7)

11.52% - 33.40%

31.14%

3,012

Other(6)

Warrant Investments

15,466

Market Comparable Companies

Revenue Multiple(2)

0.9x - 11.9x

4.1x

Discount for Lack of Marketability(3)

12.93% - 33.96%

24.63%

3,910

Market Adjusted OPM Backsolve

Market Equity Adjustment(4)

(62.04)% - 30.35%

(1.40)%

Total Level 3 Equity and Warrant Investments

$

113,393

(1)The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes.

(2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.

(3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event.

(5)Weighted averages are calculated based on the fair market value of each investment.

(6)The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices.

(7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.

Investment Type - Level 3 Equity and Warrant Investments

Fair Value as of December 31, 2023 (in thousands)

Valuation Techniques/ Methodologies

Unobservable Input(1)

Range

Weighted Average(5)

Equity Investments

$

52,094

Market Comparable Companies

EBITDA Multiple(2)

12.3x - 12.3x

12.3x

Revenue Multiple(2)

0.3x - 20.1x

7.2x

Tangible Book Value Multiple(2)

1.8x - 1.8x

1.8x

Discount for Lack of Marketability(3)

7.11% - 92.72%

31.57%

11,096

Market Adjusted OPM Backsolve

Market Equity Adjustment(4)

(86.14)% - 32.69%

7.47%

28,713

Discounted Cash Flow

Discount Rate(7)

19.88% - 31.97%

30.51%

2,925

Other(6)

Warrant Investments

19,014

Market Comparable Companies

EBITDA Multiple(2)

12.3x -12.3x

12.3x

Revenue Multiple(2)

0.9x - 10.2x

4.2x

Discount for Lack of Marketability(3)

6.21% - 33.12%

21.70%

3,074

Market Adjusted OPM Backsolve

Market Equity Adjustment(4)

(70.67)% - 34.86%

13.17%

—

Other(6)

Total Level 3 Equity and Warrant Investments

$

116,916

(1)The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes.

48

---

Table of Contents

(2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.

(3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event.

(5)Weighted averages are calculated based on the fair market value of each investment.

(6)The fair market value of these investments is derived based on recent market transactions.

(7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.

The Company believes that the carrying amounts of its financial instruments, other than investments and debt, which consist of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The debt obligations of the Company are recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding debt obligations are based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument.

As of September 30, 2024 and December 31, 2023, the 2033 Notes were trading on the New York Stock Exchange (“NYSE”) at $25.63 and $25.25 per unit at par value. The par value at underwriting for the 2033 Notes was $25.00 per unit. Based on market quotations on or around September 30, 2024 and December 31, 2023, the 2031 Asset-Backed Notes were quoted for 0.970 and 0.950. The fair values of the SBA debentures, February 2025 Notes, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026, and January 2027 Notes are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms. The fair values of the outstanding debt under the MUFG Bank Facility and the SMBC Facility are equal to their outstanding principal balances as of September 30, 2024 and December 31, 2023.

The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of September 30, 2024 and December 31, 2023:

(in thousands)						September 30, 2024
Description						Carrying Value						Approximate Fair Value						Identical Assets (Level 1)						Observable Inputs (Level 2)						Unobservable Inputs (Level 3)
SBA Debentures						$	170,763					$	155,728					$	—					$	—					$	155,728
February 2025 Notes						49,952						49,902						—						—						49,902
June 2025 Notes						69,879						69,890						—						—						69,890
June 2025 3-Year Notes						49,887						50,560						—						—						50,560
March 2026 A Notes						49,866						48,691						—						—						48,691
March 2026 B Notes						49,854						48,726						—						—						48,726
September 2026 Notes						323,075						301,311						—						—						301,311
January 2027 Notes						346,932						327,712						—						—						327,712
2031 Asset-Backed Notes						148,985						145,500						—						145,500						—
2033 Notes						39,016						41,008						—						41,008						—
MUFG Bank Facility						240,000						240,000						—						—						240,000
SMBC Facility						201,000						201,000						—						—						201,000
Total						$	1,739,209					$	1,680,028					$	—					$	186,508					$	1,493,520

49

---

Table of Contents

(in thousands)						December 31, 2023
Description						Carrying Value						Approximate Fair Value						Identical Assets (Level 1)						Observable Inputs (Level 2)						Unobservable Inputs (Level 3)
SBA Debentures						$	170,323					$	142,011					$	—					$	—					$	142,011
July 2024 Notes						104,828						105,755						—						—						105,755
February 2025 Notes						49,866						49,144						—						—						49,144
June 2025 Notes						69,757						67,198						—						—						67,198
June 2025 3-Year Notes						49,771						48,983						—						—						48,983
March 2026 A Notes						49,795						47,702						—						—						47,702
March 2026 B Notes						49,776						47,759						—						—						47,759
September 2026 Notes						322,339						288,711						—						—						288,711
January 2027 Notes						345,935						315,832						—						—						315,832
2031 Asset-Backed Notes						148,544						142,500						—						142,500						—
2033 Notes						38,935						40,400						—						40,400						—
MUFG Bank Facility						61,000						61,000						—						—						61,000
SMBC Facility						94,000						94,000						—						—						94,000
Total						$	1,554,869					$	1,450,995					$	—					$	182,900					$	1,268,095

4. Investments

Control and Affiliate Investments

As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments. For purposes of determining the classification of its investments, the Company has included consideration of any voting securities or board appointment rights held by the Adviser Funds.

The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and nine months ended September 30, 2024 and 2023.

(in thousands)																		Three Months Ended September 30, 2024																								Nine Months Ended September 30, 2024
Portfolio Company(1)						Type						Fair Value as of September 30, 2024						Interest & Dividend Income						Fee Income						Net Change in Unrealized Appreciation (Depreciation)						Realized Gain (Loss)						Interest & Dividend Income						Fee Income						Net Change in Unrealized Appreciation (Depreciation)						Realized Gain (Loss)
Control Investments
Coronado Aesthetics, LLC						Control						$	319					$	—					$	—					$	133					$	—					$	—					$	—					$	57					$	—
Gibraltar Acquisition LLC(2)						Control						57,302						1,359						36						(74)						—						3,926						108						(6,365)						—
Hercules Adviser LLC(3)						Control						43,433						1,954						—						705						—						5,457						—						2,720						—
Tectura Corporation						Control						12,043						174						—						509						—						518						—						526						—
Total Control Investments												$	113,097					$	3,487					$	36					$	1,273					$	—					$	9,901					$	108					$	(3,062)					$	—

50

---

Table of Contents

(in thousands)																		Three Months Ended September 30, 2023																								Nine Months Ended September 30, 2023
Portfolio Company(1)						Type						Fair Value as of September 30, 2023						Interest Income						Fee Income						Net Change in Unrealized Appreciation (Depreciation)						Realized Gain (Loss)						Interest Income						Fee Income						Net Change in Unrealized Appreciation (Depreciation)						Realized Gain (Loss)
Control Investments
Coronado Aesthetics, LLC						Control						$	247					$	—					$	—					$	(50)					$	—					$	—					$	—					$	(72)					$	—
Gibraltar Acquisition, LLC(2)						Control						55,992						772						22						(1,726)						—						2,299						60						4,676						—
Hercules Adviser LLC(3)						Control						40,668						153						—						1,507						—						455						—						9,515						—
Tectura Corporation						Control						6,243						174						—						(830)						—						516						—						(1,799)						—
Total Control Investments												$	103,150					$	1,099					$	22					$	(1,099)					$	—					$	3,270					$	60					$	12,320					$	—

(1)In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2024 and September 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”.

(2)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.

(3)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1” for additional disclosure.

Portfolio Composition

The following table shows the fair value of the Company’s portfolio of investments by asset class as of September 30, 2024 and December 31, 2023:

(in thousands)			September 30, 2024												December 31, 2023
			Investments at Fair Value						Percentage of Total Portfolio						Investments at Fair Value						Percentage of Total Portfolio
Senior Secured Debt			$	3,306,724					92.9		%				$	2,987,577					92.0		%
Unsecured Debt			73,854						2.1		%				69,722						2.2		%
Preferred Stock			47,342						1.3		%				53,038						1.6		%
Common Stock			95,693						2.7		%				99,132						3.1		%
Warrants			30,023						0.8		%				33,969						1.0		%
Investment Funds & Vehicles			6,877						0.2		%				4,608						0.1		%
Total			$	3,560,513					100.0		%				$	3,248,046					100.0		%

A summary of the Company’s investment portfolio, at value, by geographic location as of September 30, 2024 and December 31, 2023 is shown as follows:

(in thousands)			September 30, 2024												December 31, 2023
			Investments at Fair Value						Percentage of Total Portfolio						Investments at Fair Value						Percentage of Total Portfolio
United States			$	3,219,874					90.4		%				$	2,861,615					88.1		%
United Kingdom			174,566						4.9		%				222,136						6.9		%
Israel			77,767						2.2		%				52,868						1.6		%
Netherlands			59,562						1.7		%				89,995						2.8		%
Canada			16,441						0.5		%				15,730						0.5		%
Ireland			4,513						0.1		%				—						0.0		%
Denmark			4,176						0.1		%				4,173						0.1		%
Singapore			1,999						0.1		%				—						0.0		%
Germany			1,219						0.0		%				1,144						0.0		%
Other			396						0.0		%				385						0.0		%
Total			$	3,560,513					100.0		%				$	3,248,046					100.0		%

51

---

Table of Contents

The following table shows the fair value of the Company’s portfolio by industry sector as of September 30, 2024 and December 31, 2023:

(in thousands)			September 30, 2024												December 31, 2023
			Investments at Fair Value						Percentage of Total Portfolio						Investments at Fair Value						Percentage of Total Portfolio
Drug Discovery & Development			$	1,125,617					31.6		%				$	1,257,699					38.7		%
Software			1,018,236						28.6		%				764,985						23.6		%
Healthcare Services, Other			574,750						16.1		%				300,079						9.3		%
Consumer & Business Services			355,831						10.0		%				525,973						16.2		%
Diversified Financial Services			112,709						3.2		%				114,722						3.5		%
Electronics & Computer Hardware			96,125						2.7		%				20,324						0.6		%
Information Services			81,266						2.3		%				126,605						3.9		%
Medical Devices & Equipment			56,153						1.6		%				22,096						0.7		%
Space Technologies			46,082						1.3		%				—						0.0		%
Biotechnology Tools			35,311						1.0		%				48,381						1.5		%
Sustainable and Renewable Technology			27,858						0.8		%				9,581						0.3		%
Communications & Networking			26,465						0.7		%				29,400						0.9		%
Manufacturing Technology			2,096						0.1		%				11,006						0.3		%
Consumer & Business Products			1,285						0.0		%				2,589						0.1		%
Semiconductors			655						0.0		%				1,205						0.0		%
Media/Content/Info			55						0.0		%				12,704						0.4		%
Drug Delivery			19						0.0		%				21						0.0		%
Surgical Devices			—						0.0		%				676						0.0		%
Total			$	3,560,513					100.0		%				$	3,248,046					100.0		%

No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of September 30, 2024 or December 31, 2023.

Concentrations of Credit Risk

As of September 30, 2024, the Company’s customers are primarily privately held companies and public companies which are active in the “Drug Discovery & Development”, “Software”, “Healthcare Services, Other”, “Consumer & Business Services”, and “Diversified Financial Services” sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property.

Industry and sector concentrations vary as new loans are recorded and loans are paid off. Investment income, consisting of interest, fees, and recognition of gains on equity and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Investment income recognized in any given year can be highly concentrated among several portfolio companies.

As of September 30, 2024 and December 31, 2023, the Company’s ten largest portfolio companies represented approximately 30.6% and 29.7% of the total fair value of the Company’s investments in portfolio companies, respectively. As of September 30, 2024 and December 31, 2023, the Company had five and five portfolio companies, respectively, that represented 5% or more of the Company’s net assets. As of September 30, 2024 and December 31, 2023, the Company had four and five equity investments, respectively, that represented 5% or more of the total fair value of the Company’s equity investments. These equity investments represented approximately 52.9% and 56.5% of the total fair value of the Company’s equity investments as of September 30, 2024 and December 31, 2023, respectively.

Investment Collateral

In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative

52

---

Table of Contents

pledge covering a company’s intellectual property. The Company's investments were collateralized as follows as of September 30, 2024 and December 31, 2023:

			Percentage of debt investments (at fair value), as of
			September 30, 2024						December 31, 2023
Senior Secured First Lien
All assets including intellectual property			63.1		%				52.3		%
All assets with negative pledge on intellectual property			16.1		%				24.0		%
“Last-out” with security interest in all of the assets			10.3		%				12.5		%
Total senior secured first lien position			89.5		%				88.8		%
Second lien			8.3		%				8.9		%
Unsecured			2.2		%				2.3		%
Total debt investments at fair value			100.0		%				100.0		%

Derivative Instruments

The Company enters into forward currency contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies. The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of September 30, 2024 and December 31, 2023:

(in thousands)									Fair Value
Derivative Instrument			Statement Location						September 30, 2024						December 31, 2023
Foreign currency forward contract			Other assets						$	—					$	—
Foreign currency forward contract			Accounts payable and accrued liabilities						1,168						766
			Total						$	1,168					$	766

Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three and nine months ended September 30, 2024 and 2023 are in the following locations in the Consolidated Statements of Operations:

(in thousands)									Three Months Ended September 30,												Nine Months Ended September 30,
Derivative Instrument			Statement Location						2024						2023						2024						2023
Foreign currency forward contract			Net realized gain (loss) - Non-control / Non-affiliate investments						$	—					$	—					$	(849)					$	—
Foreign currency forward contract			Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments						(1,356)						784						(402)						230
			Total						$	(1,356)					$	784					$	(1,251)					$	230

Investment Income

The Company’s investment portfolio generates interest, fee, and dividend income. The composition of the Company’s interest income and fee income is as follows:

(in thousands)			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Contractual interest income			$	90,288					$	89,747					$	268,441					$	258,685
Exit fee interest income			12,047						10,904						34,519						34,340
PIK interest income			12,706						6,652						37,870						17,999
Dividend income			2,100						—						5,800						—
Other investment income(1)			1,909						3,036						5,728						8,198
Total interest and dividend income			$	119,050					$	110,339					$	352,358					$	319,222

(1)Other investment income includes OID interest income and interest recorded on other assets.

53

---

Table of Contents

(in thousands)			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Recurring fee income			$	2,423					$	2,243					$	7,081					$	6,418
Fee income - expired commitments			413						300						1,790						651
Accelerated fee income - early repayments			3,362						3,862						10,578						11,774
Total fee income			$	6,198					$	6,405					$	19,449					$	18,843

As of September 30, 2024 and December 31, 2023, unamortized capitalized fee income was recorded as follows:

(in millions)			September 30, 2024						December 31, 2023
Offset against debt investment cost			$	36.7					$	32.9
Deferred obligation contingent on funding or other milestone			9.7						9.4
Total Unamortized Fee Income			$	46.4					$	42.3

As of September 30, 2024 and December 31, 2023, loan exit fees receivable were recorded as follows:

(in millions)			September 30, 2024						December 31, 2023
Included within debt investment cost			$	37.0					$	35.9
Deferred receivable related to expired commitments			3.4						4.3
Total Exit Fees Receivable			$	40.4					$	40.2

5. Debt

As of September 30, 2024 and December 31, 2023, the Company had the following available and outstanding debt:

(in thousands)			September 30, 2024																		December 31, 2023
			Total Available						Principal						Carrying Value(1)						Total Available						Principal						Carrying Value(1)
SBA Debentures(2)(4)			$	350,000					$	175,000					$	170,763					$	175,000					$	175,000					$	170,323
July 2024 Notes			—						—						—						105,000						105,000						104,828
February 2025 Notes			50,000						50,000						49,952						50,000						50,000						49,866
June 2025 Notes			70,000						70,000						69,879						70,000						70,000						69,757
June 2025 3-Year Notes			50,000						50,000						49,887						50,000						50,000						49,771
March 2026 A Notes			50,000						50,000						49,866						50,000						50,000						49,795
March 2026 B Notes			50,000						50,000						49,854						50,000						50,000						49,776
September 2026 Notes			325,000						325,000						323,075						325,000						325,000						322,339
January 2027 Notes			350,000						350,000						346,932						350,000						350,000						345,935
2031 Asset-Backed Notes			150,000						150,000						148,985						150,000						150,000						148,544
2033 Notes			40,000						40,000						39,016						40,000						40,000						38,935
MUFG Bank Facility(2)			400,000						240,000						240,000						400,000						61,000						61,000
SMBC Facility(2)(3)			400,000						201,000						201,000						400,000						94,000						94,000
Total			$	2,285,000					$	1,751,000					$	1,739,209					$	2,215,000					$	1,570,000					$	1,554,869

(1)Except for the SMBC Facility and MUFG Bank Facility, all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date.

(2)Availability subject to the Company meeting the borrowing base requirements.

(3)“Total Available” includes $175.0 million of available commitment through the letter of credit facility as of September 30, 2024 and December 31, 2023.

(4)As of September 30, 2024, the total available debt under the SBA Debentures was $350.0 million, of which $175.0 million was available to HC IV and $175.0 million was available to SBIC V. As of December 31, 2023, the total available debt under the SBA debentures was $175.0 million, all of which was available to HC IV.

54

---

Table of Contents

Debt issuance costs, net of accumulated amortization, were as follows as of September 30, 2024 and December 31, 2023:

(in thousands)						September 30, 2024						December 31, 2023
SBA Debentures						$	4,237					$	4,677
July 2024 Notes						—						172
February 2025 Notes						48						134
June 2025 Notes						121						243
June 2025 3-Year Notes						113						229
March 2026 A Notes						134						205
March 2026 B Notes						146						224
September 2026 Notes						1,925						2,661
January 2027 Notes						3,068						4,065
2031 Asset-Backed Notes						1,015						1,456
2033 Notes						984						1,065
MUFG Bank Facility(1)						2,220						3,540
SMBC Facility(1)						1,235						1,775
Total						$	15,246					$	20,446

(1)The MUFG Bank Facility and SMBC Facility, are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30.

For the three and nine months ended September 30, 2024, the components of interest expense, related fees, and cash paid for interest expense for debt were as follows:

(in thousands)						Three Months Ended September 30, 2024																														Nine Months Ended September 30, 2024
Description						Interest expense(1)						Amortization of debt issuance cost (loan fees)						Unused facility and other fees (loan fees)						Total interest expense and fees						Cash paid for interest expense						Interest expense(1)						Amortization of debt issuance cost (loan fees)						Unused facility and other fees (loan fees)						Total interest expense and fees						Cash paid for interest expense
SBA Debentures						$	1,149					$	147					$	—					$	1,296					$	2,300					$	3,424					$	439					$	—					$	3,863					$	4,575
July 2024 Notes						202						24						—						226						2,504						2,706						172						—						2,878						5,008
February 2025 Notes						535						29						—						564						1,070						1,605						86						—						1,691						2,140
June 2025 Notes						755						40						—						795						—						2,263						121						—						2,384						1,508
June 2025 3-Year Notes						750						38						—						788						—						2,250						116						—						2,366						1,500
March 2026 A Notes						563						24						—						587						1,125						1,688						71						—						1,759						2,250
March 2026 B Notes						568						25						—						593						1,138						1,706						77						—						1,783						2,276
September 2026 Notes						2,174						205						—						2,379						4,266						6,523						612						—						7,135						8,531
January 2027 Notes						3,080						208						—						3,288						5,906						9,236						622						—						9,858						11,812
2031 Asset-Backed Notes						1,903						100						—						2,003						1,856						5,710						300						—						6,010						5,568
2033 Notes						625						27						—						652						625						1,875						81						—						1,956						1,875
MUFG Bank Facility						4,105						443						329						4,877						3,875						8,181						1,328						1,572						11,081						7,596
SMBC Facility						3,961						180						174						4,315						4,020						9,989						540						599						11,128						9,582
Total						$	20,370					$	1,490					$	503					$	22,363					$	28,685					$	57,156					$	4,565					$	2,171					$	63,892					$	64,221

(1)Interest expense includes amortization of original issue discounts for the three months ended September 30, 2024 of $42 thousand, $126 thousand, and $47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Interest expense includes amortization of original issue discounts for the nine months ended September 30, 2024 of $125 thousand, $377 thousand, and $141 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively.

55

---

Table of Contents

For the three and nine months ended September 30, 2023, the components of interest expense, related fees, and cash paid for interest expense for debt were as follows:

(in thousands)						Three Months Ended September 30, 2023																														Nine Months Ended September 30, 2023
Description						Interest expense(1)						Amortization of debt issuance cost (loan fees)						Unused facility and other fees (loan fees)						Total interest expense and fees						Cash paid for interest expense						Interest expense(1)						Amortization of debt issuance cost (loan fees)						Unused facility and other fees (loan fees)						Total interest expense and fees						Cash paid for interest expense
SBA Debentures						$	1,150					$	146					$	—					$	1,296					$	2,300					$	3,412					$	436					$	—					$	3,848					$	4,562
July 2024 Notes						1,252						74						—						1,326						2,505						3,756						222						—						3,978						5,009
February 2025 Notes						535						29						—						564						1,070						1,605						86						—						1,691						2,140
June 2025 Notes						754						40						—						794						—						2,263						121						—						2,384						1,509
June 2025 3-Year Notes						750						39						—						789						—						2,250						117						—						2,367						1,500
March 2026 A Notes						563						24						—						587						1,125						1,688						71						—						1,759						2,250
March 2026 B Notes						569						26						—						595						1,138						1,706						78						—						1,784						2,275
September 2026 Notes						2,174						203						—						2,377						4,266						6,523						611						—						7,134						8,532
January 2027 Notes						3,079						207						—						3,286						5,906						9,236						621						—						9,857						11,812
2031 Asset-Backed Notes						1,902						101						—						2,003						1,857						5,709						301						—						6,010						5,570
2033 Notes						625						27						—						652						625						1,875						81						—						1,956						1,875
MUFG Bank Facility						1,247						443						709						2,399						1,240						4,323						1,327						2,017						7,667						4,673
SMBC Facility						1,828						180						276						2,284						1,715						5,891						513						715						7,119						5,703
Total						$	16,428					$	1,539					$	985					$	18,952					$	23,747					$	50,237					$	4,585					$	2,732					$	57,554					$	57,410

(1)Interest expense includes amortization of original issue discounts for the three months ended September 30, 2023 of $42 thousand, $126 thousand, and $47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Interest expense includes amortization of original issue discounts for the nine months ended September 30, 2023, of $125 thousand, $377 thousand, and $141 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively.

The overall weighted average cost of debt for the Company was approximately 5.1% and 4.8% for the three months ended September 30, 2024 and 2023, respectively and 5.0% and 4.8% for the nine months ended September 30, 2024 and 2023, respectively. The weighted average cost of debt includes interest and fees on the Company's debt but excludes the impact of fee accelerations due to the extinguishment of debt, as applicable. As of September 30, 2024 and December 31, 2023, the Company was in compliance with the terms of all borrowing arrangements. There are no sinking fund requirements for any of the Company’s debt.

SBA Debentures

The Company held the following SBA debentures outstanding principal balances as of September 30, 2024 and December 31, 2023:

(in thousands) Issuance/Pooling Date						Maturity Date						Interest Rate(1)						September 30, 2024						December 31, 2023
March 26, 2021						September 1, 2031						1.58%						$	37,500					$	37,500
June 25, 2021						September 1, 2031						1.58%						16,200						16,200
July 28, 2021						September 1, 2031						1.58%						5,400						5,400
August 20, 2021						September 1, 2031						1.58%						5,400						5,400
October 21, 2021						March 1, 2032						3.21%						14,000						14,000
November 1, 2021						March 1, 2032						3.21%						21,000						21,000
November 15, 2021						March 1, 2032						3.21%						5,200						5,200
November 30, 2021						March 1, 2032						3.21%						20,800						20,800
December 20, 2021						March 1, 2032						3.21%						10,000						10,000
December 23, 2021						March 1, 2032						3.21%						10,000						10,000
December 28, 2021						March 1, 2032						3.21%						5,000						5,000
January 14, 2022						March 1, 2032						3.21%						4,500						4,500
January 21, 2022						March 1, 2032						3.21%						20,000						20,000
Total SBA Debentures																		$	175,000					$	175,000

(1)Interest rates are determined initially at issuance and reset to a fixed rate at the debentures pooling date. The rates are inclusive of annual SBA charges.

SBICs are subject to a variety of regulations and oversight by the SBA concerning the size and nature of the companies in which they may invest as well as the structures of those investments. The SBA as part of its oversight

56

---

Table of Contents

periodically examines and audits to determine SBICs compliance with SBA regulations. Our SBIC was in compliance with all SBIC terms, including those pertaining to the SBA Debentures as of September 30, 2024 and December 31, 2023.

HC IV received its license to operate as an SBIC on October 27, 2020. The license has a 10-year term. Through the license, HC IV has access to $175.0 million of capital through the SBA debenture program, subject to maintaining certain conditions. As of September 30, 2024 and December 31, 2023, HC IV has issued a total of $175.0 million in SBA guaranteed debentures.

On July 9, 2024, SBIC V received its license to operate as an SBIC. This is Hercules' fourth SBIC license, through which the Company has access to $175.0 million of SBA debentures, subject to meeting certain conditions. The license has a 10-year term and SBA debentures bear fixed interest based on the treasury rate plus a spread applicable for the period the debentures are drawn. As of the latest debenture pooling date in September 2024, SBA debentures were issued with an interest rate of approximately 4.509%. The actual rates may vary depending on the timing of drawdown and pooling period.

The following table summarizes information related to our SBICs as of September 30, 2024 and December 31, 2023.

						September 30, 2024									December 31, 2023
Description						HC IV			SBIC V						HC IV			SBIC V
Number of investments held						28			1						25			—
Fair value of investments (in millions)						$	352.4		$	11.2					$	331.5		$	—
Percentage of fair value of investments based on the Company's total investment portfolio						9.9		%	0.3		%				10.2		%	0.0		%
Tangible assets (in millions)						$	369.7		$	13.3					$	341.8		$	—
Percentage of tangible assets based on the Company's total assets						10.1		%	0.4		%				10.0		%	0.0		%

2024 Notes

On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.77% interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the July 2024 Notes is due semiannually. The July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. On July 16, 2024, the Company fully repaid the aggregate outstanding $105.0 million principal and $2.5 million of accrued interest pursuant to the terms of the July 2024 Notes.

February 2025 Notes

On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of 4.28% interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the February 2025 Notes is due semiannually. The February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

June 2025 Notes

On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of 4.31% interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 Notes is due semiannually. The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

June 2025 3-Year Notes

On June 23, 2022, the Company issued $50.0 million in aggregate principal amount of 6.00% interest-bearing unsecured notes due June 23, 2025 (the “June 2025 3-Year Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 3-Year Notes is due semiannually. The June 2025 3-Year Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

March 2026 A Notes

On November 4, 2020, the Company issued $50.0 million in aggregate principal amount of 4.50% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the March 2026 A Notes is due

57

---

Table of Contents

semiannually. The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

March 2026 B Notes

On March 4, 2021, the Company issued $50.0 million in aggregate principal amount of 4.55% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering. Interest on the March 2026 B Notes is due semiannually. The March 2026 B Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

September 2026 Notes

On September 16, 2021, the Company issued $325.0 million in aggregate principal amount of 2.625% interest-bearing unsecured notes due September 16, 2026 (the “September 2026 Notes”), unless repurchased in accordance with the terms of the Seventh Supplemental Indenture, dated September 16, 2021. Interest on the September 2026 Notes is payable semi-annually in arrears on March 16 and September 16 of each year. The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

January 2027 Notes

On January 20, 2022, the Company issued $350.0 million in aggregate principal amount of 3.375% interest-bearing unsecured notes due January 20, 2027 (the “January 2027 Notes”), unless repurchased in accordance with the terms of the Eight Supplemental Indenture, dated January 20, 2022. Interest on the January 2027 Notes is payable semi-annually in arrears on January 20 and July 20 of each year. The January 2027 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the January 2027 Notes Indenture.

2031 Asset-Backed Notes

On June 22, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company issued $150.0 million in aggregate principal amount of 4.95% interest-bearing asset-backed notes due on July 20, 2031 (the “2031 Asset-Backed Notes”). The 2031 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2022-1 LLC (the “2022 Securitization Issuer”) pursuant to a note purchase agreement, dated as of June 22, 2022, by and among the Company, Hercules Capital Funding 2022-1 LLC, as trust depositor, the 2022 Securitization Issuer, and U.S. Bank Trust Company, N. A., as trustee, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2031 Asset-Backed Notes will be paid, to the extent of funds available.

Under the terms of the 2031 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2031 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2031 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. As of September 30, 2024 and December 31, 2023, there was approximately $5.1 million and $17.1 million, respectively, of funds segregated as restricted cash related to the 2031 Asset-Backed Notes. The reinvestment period for 2031 Asset-Backed Notes ended on July 20, 2024, and as a result all principal payments received from portfolio companies will no longer be eligible for reinvestment and will be utilized to pay down the outstanding principal amount.

2033 Notes

On September 24, 2018, the Company issued $40.0 million in aggregate principal amount of 6.25% interest-bearing unsecured notes due October 30, 2033 (the “2033 Notes”), unless repurchased in accordance with the terms of the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018. Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year. The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes indenture after October 30, 2023.

Credit Facilities

As of September 30, 2024 and December 31, 2023, the Company has two available credit facilities, the MUFG Bank Facility and the SMBC Facility (together, the “Credit Facilities”). For the nine months ended September 30, 2024 and year

58

---

Table of Contents

ended December 31, 2023, the weighted average interest rate was 7.79% and 7.41%, respectively, and the average debt outstanding under the Credit Facilities was $311.0 million and $192.3 million, respectively.

MUFG Bank Facility

On January 13, 2023, the Company entered into a third amended credit facility agreement, which amends the agreement dated as of June 10, 2022. The Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into the credit facility (the “MUFG Bank Facility”) with MUFG Bank Ltd. as the arranger and administrative agent, and the lenders party to the MUFG Bank Facility from time to time.

Under the MUFG Bank Facility, the lenders have made commitments of $400.0 million, which may be further increased via an accordion feature up to an aggregate $600.0 million, funded by existing or additional lenders and with the agreement of MUFG Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the MUFG Bank Facility to increase available borrowings. Debt under the MUFG Bank Facility generally bears interest at a rate per annum equal to SOFR plus 2.75% for SOFR loans. The MUFG Bank Facility matures on January 13, 2026, plus a twelve-month amortization period, unless sooner terminated in accordance with its terms. The MUFG Bank Facility is secured by all of the assets of Hercules Funding IV. The MUFG Bank Facility requires payment of a non-use fee during the revolving credit availability period.

The MUFG Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio and a minimum tangible net worth with respect to Hercules Funding IV. The MUFG Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy.

SMBC Facility

On June 14, 2022, the Company entered into a second amendment to a revolving credit agreement, which amends the revolving credit agreement, dated as of November 9, 2021, with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”), as administrative agent, and the lenders and issuing banks to the SMBC Facility. As of September 30, 2024, the SMBC Facility provides for borrowings in U.S. dollars and certain agreed upon foreign currencies of up to $225.0 million, from which the Company may access subject to certain conditions. The SMBC Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $500.0 million, funded by existing or additional lenders and with the agreement of SMBC Bank and subject to other customary conditions. Availability under the SMBC Facility will terminate on November 7, 2025, and the outstanding loans under the SMBC Facility will mature on November 9, 2026. Borrowings under the SMBC Facility are subject to compliance with a borrowing base and an aggregate portfolio balance. The Company’s obligations under the SMBC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and the subsidiary guarantors thereunder.

Additionally in January 2023, the Company entered into a Letter of Credit Facility Agreement (the “SMBC LC Facility”) with Sumitomo Mitsui Banking Corporation that provides for a letter of credit facility with a final maturity date ending on January 13, 2026 and a commitment amount of $175.0 million as amended. Further, the SMBC LC Facility includes an accordion provision to increase the commitment up to $400.0 million, subject to certain conditions. The Company’s obligations under the SMBC LC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and is primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and any subsidiary guarantors thereunder.

Interest under the SMBC Facility is determined by the nature and denomination of the borrowing. Interest rates are determined by the appropriate benchmark rate (SOFR, EURIBOR, Prime, CORRA, or TIBOR) as applicable for the type of borrowing plus an applicable margin adjustment which can range from 0.875% to 2.0% per annum subject to certain conditions. In addition to interest, the SMBC Facility is subject to a non-usage fee of 0.375% per annum (based on the immediately preceding period’s average usage) on the unused portion of the commitment under the SMBC Facility during the revolving period. The Company is required to pay letter of credit participation fees and a fronting fee on the average daily amount of any lender’s exposure with respect to any letters of credit issued under the SMBC Facility.

The SMBC Facility contains customary events of default with customary cure and notice provisions, including, without limitation, nonpayment, misrepresentation of representations and warranties in a material respect, breach of covenant, cross-default and cross-acceleration to other indebtedness and bankruptcy. The SMBC Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, including covenants relating to minimum stockholders' equity, asset coverage ratios, and our status as a RIC.

59

---

Table of Contents

6. Income Taxes

The determination of taxable income pursuant to U.S. federal income tax regulations differs from U.S. GAAP. As a result, permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. During the year ended December 31, 2023, the Company reclassified $0.8 million from accumulated net realized gains (losses) to additional paid-in capital for book purposes primarily related to net realized gains from portfolio companies which are held in taxable subsidiaries and are not consolidated with the Company for income tax purposes.

Taxable income and taxable net realized gains (losses) for the three and nine months ended September 30, 2024 and 2023 appears as follows:

(in millions, except per share data)						Three Months Ended September 30,									Nine Months Ended September 30,
Description						2024			2023						2024			2023
Taxable income						$	75.8		$	72.7					$	230.0		$	197.7
Taxable income per share						$	0.47		$	0.50					$	1.44		$	1.40
Taxable net realized gains (losses)						$	8.7		$	6.8					$	18.1		$	34.2
Taxable net realized gains (losses) per share						$	0.05		$	0.04					$	0.11		$	0.24
Weighted average shares outstanding						161.0			146.9						159.7			141.2

The aggregate gross unrealized appreciation of the Company’s investments over cost for U.S. federal income tax purposes appears as follows:

(in millions)
			September 30, 2024						December 31, 2023
Aggregate Gross Unrealized Appreciation			$	121.3					$	118.3
Aggregate Gross Unrealized Depreciation			169.9						115.9
Net Unrealized Appreciation (Depreciation) over cost for U.S. federal income tax purposes			(48.6)						2.4
Aggregate cost of securities for U.S. federal income tax purposes (in billions)			3.6						3.2

For the three and nine months ended September 30, 2024, the Company paid zero and $5.2 million of income tax, including excise tax, and had $5.3 million of accrued, but unpaid tax expense as of September 30, 2024. For the three and nine months ended September 30, 2023, the Company paid approximately $0.1 million and $5.2 million of income tax, including excise tax, and had $5.3 million of accrued, but unpaid tax expense as of September 30, 2023.

Additionally, the Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements and are recorded at fair value. These taxable subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by these taxable subsidiaries generally would be subject to tax at normal U.S. federal tax rates based on its taxable income.

In accordance with ASC 740, the Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties, if any, related to unrecognized tax benefits as a component of provision for income taxes. Based on an analysis of the Company’s tax position, there are no uncertain tax positions that met the recognition or measurement criteria. The Company is currently not undergoing any tax examinations. The Company does not anticipate any significant increase or decrease in unrecognized tax benefits for the next twelve months. The 2020 - 2023 federal tax years for the Company remain subject to examination by the Internal Revenue Service. The 2019 – 2023 state tax years for the Company remain subject to examination by the state taxing authorities.

7. Stockholders’ Equity and Distributions

The Company has issued and outstanding 162,505,144 and 157,758,072 shares of common stock as of September 30, 2024 and December 31, 2023, respectively. The Company currently sell shares through its equity distribution agreement with JMP Securities LLC (“JMP”) and Jefferies LLC (“Jefferies”) (the “2023 Equity Distribution Agreement”) entered into on May 5, 2023. The 2023 Equity Distribution Agreement provides that the Company may offer and sell up to 25.0 million shares of its common stock from time to time through JMP or Jefferies, as the Company's sales agents. Sales of the Company's common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made

60

---

Table of Contents

directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. Additionally, on August 7, 2023, the Company sold 6.5 million shares of common stock through an upsized public offering pursuant to an underwriting agreement with Morgan Stanley & Co. LLC, UBS Securities, and Wells Fargo Securities, LLC as joint book-running managers to sell.

The Company issued and sold the following shares of common stock during the nine months ended September 30, 2024 and 2023:

(in millions, except per share data)
Nine Months Ended September 30,			Number of Shares Issued			Gross Proceeds						Underwriting Fees/Offering Expenses						Net Proceeds						Average Price/Share
2024			3.7			$	67.3					$	1.0					$	66.3					$	17.83
2023			16.2			$	243.6					$	5.3					$	238.3					$	14.69

The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of September 30, 2024, approximately 13.6 million shares remain available for issuance and sale under the current equity distribution agreement.

The Company currently pays quarterly distributions to its stockholders. The following table summarizes the Company’s distributions declared during the nine months ended September 30, 2024 and year ended December 31, 2023:

(in thousands, except per share data)
Distribution Type			Declared Date			Record Date			Payment Date			Per Share Amount						Total Amount
Base			February 9, 2023			March 2, 2023			March 9, 2023			$	0.39					$	53,749
Supplemental			February 9, 2023			March 2, 2023			March 9, 2023			$	0.08					$	11,025
Base			April 27, 2023			May 16, 2023			May 23, 2023			$	0.39					$	55,910
Supplemental			April 27, 2023			May 16, 2023			May 23, 2023			$	0.08					$	11,469
Base			July 28, 2023			August 18, 2023			August 25, 2023			$	0.40					$	60,445
Supplemental			July 28, 2023			August 18, 2023			August 25, 2023			$	0.08					$	12,089
Base			October 26, 2023			November 15, 2023			November 22, 2023			$	0.40					$	61,345
Supplemental			October 26, 2023			November 15, 2023			November 22, 2023			$	0.08					$	12,269
Total distributions declared during the year ended December 31, 2023												$	1.90					$	278,301
Base			February 8, 2024			February 28, 2024			March 6, 2024			$	0.40					$	63,359
Supplemental			February 8, 2024			February 28, 2024			March 6, 2024			$	0.08					$	12,672
Base			April 25, 2024			May 14, 2024			May 21, 2024			$	0.40					$	64,912
Supplemental			April 25, 2024			May 14, 2024			May 21, 2024			$	0.08					$	12,982
Base			July 25, 2024			August 13, 2024			August 20, 2024			$	0.40					$	64,953
Supplemental			July 25, 2024			August 13, 2024			August 20, 2024			$	0.08					$	12,990
Total distributions declared during the nine months ended September 30, 2024												$	1.44					$	231,868

During the nine months ended September 30, 2024, for income tax purposes, the distributions paid of $1.44 per share were comprised of ordinary income. As of September 30, 2024, the Company estimates that it has generated undistributed taxable earnings “spillover” of $0.94 per share. The undistributed taxable earnings spillover will be carried forward toward distributions to be paid in accordance with RIC requirements.

The Company has a distribution reinvestment plan, whereby the Company may buy shares of its common stock in the open market or issue new shares in order to satisfy dividend reinvestment requests. When the Company issues new shares in connection with the dividend reinvestment plan, the issue price is equal to the closing price of its common stock on the dividend record date. During the nine months ended September 30, 2024 and 2023, the Company issued 342,129 and 197,592 shares, respectively, of common stock to stockholders in connection with the dividend reinvestment plan.

8. Equity Incentive Plans

The Company grants equity-based awards to employees and non-employee directors for the purpose of attracting and retaining the services of its executive officers, key employees, and members of the Board. The Company’s equity-based awards are granted under the 2018 Equity Incentive Plan (the “2018 Plan”) for employees and 2018 Non-Employee Director Plan (the “Director Plan”) for non-employee directors. The 2018 Plan and the Director Plan were approved by stockholders on June 28, 2018 and, unless earlier terminated by the Board, terminate on May 12, 2028. Subject to certain adjustments and permitted reversions of shares, the maximum aggregate number of shares that may be authorized for issuance under awards granted under the 2018 Plan and Director Plan is 9,261,229 shares and 300,000 shares, respectively. In connection with the issuance of shares under the 2018 Plan and Director Plan, the Company has registered, in aggregate, 18.7 million and 300,000 shares of common stock, respectively. Outstanding awards issued under plans that precede the

61

---

Table of Contents

2018 Plan and Director Plan remain outstanding, unchanged and subject to the terms of such plans and their respective award agreements, until the vesting, expiration or lapse of such awards in accordance with their terms.

The Company has received exemptive relief from the SEC that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Plan. The exemptive order also allows participants in the Director Plan and the 2018 Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time of option exercise or vesting on restricted stock.

The Company has granted equity-based awards that have service and performance conditions. Certain of the Company’s equity-based awards are classified as liability awards in accordance with ASC Topic 718, Compensation – Stock Compensation. All of the Company’s equity-based awards require future service, and are expensed over the relevant service period. The Company does not estimate forfeitures, and reverses all unvested costs associated with equity-awards in the period they are forfeited. For the three months ended September 30, 2024, and 2023, the Company recognized $3.2 million and $3.3 million of stock-based compensation expense in the Consolidated Statements of Operations, respectively. For the nine months ended September 30, 2024, and 2023, the company recognized $9.7 million and $9.8 million of stock-based compensation expense in the Consolidated Statements of Operations, respectively. As of September 30, 2024, and 2023, approximately $20.0 million and $21.3 million of total unrecognized compensation costs expected to be recognized over the next 2.3 and 2.8 years, respectively.

Service-Vesting Awards

The Company grants equity-based awards which have service conditions, which generally begin to vest one-third after one year after the date of grant and ratably over the succeeding 2 years in accordance with the individual award terms. Certain awards have service conditions of longer duration and may begin to vest up to seven years after the date of grant. These equity-based awards which vest upon achievement of service conditions are collectively referred to as the “Service Vesting Awards”. The grant date fair value of Service Vesting Awards granted during the nine months ended September 30, 2024, and 2023, were approximately $14.7 million, and $18.3 million, respectively.

The Company has granted restricted stock equity awards in the form of restricted stock awards and restricted stock units. The Company determines the grant date fair values of restricted stock equity awards using the grant date stock close price. The activities for the Company's unvested restricted stock equity awards for each of the nine months ended September 30, 2024, and 2023, are summarized below:

			Nine Months Ended September 30,
			2024												2023
			Shares						Weighted Average Grant Date Fair Value per Share						Shares						Weighted Average Grant Date Fair Value per Share
Unvested Shares Beginning of Period			1,880,409						$	14.52					958,985						$	16.35
Granted			835,481						$	17.48					1,314,268						$	13.83
Vested			(687,360)						$	14.46					(526,292)						$	16.18
Forfeited			(38,128)						$	15.45					(11,572)						$	15.42
Unvested Shares End of Period			1,990,402						$	12.70					1,735,389						$	14.50

In addition to the restricted stock equity-based awards, the Company has also issued stock options to certain employees. The fair value of options granted during the nine months ended September 30, 2024 and 2023, was approximately $134,000 and $134,000, respectively. During the nine months ended September 30, 2024 and 2023, approximately $98,000, and $73,000, of share-based cost due to stock option grants was expensed, respectively.

Performance-Vesting Awards

The Company has granted equity-based awards, which have market and performance conditions in addition to a service condition (“Performance Awards”). The value of these awards may increase dependent on increases to the Company’s total stockholder return (“TSR”). The total compensation will be determined by the Company’s TSR relative to specified BDCs during a specified performance period. Depending on the results achieved during the specified performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the target shares granted. The Performance Awards typically vest after four years, and generally may not be disposed until one year post vesting. The Company determines the fair values of the Performance Awards at the grant date

62

---

Table of Contents

using a Monte-Carlo simulation multiplied by the target payout level and is recognized over the service period. For certain Performance Awards, distribution equivalent units (“Performance DEUs”) will accrue in the form of additional shares, but will not be paid unless the Performance Awards to which such Performance DEUs relate actually vest.

During the nine months ended September 30, 2024 and 2023, no Performance Awards were granted or vested. During the nine months ended September 30, 2024, no shares of Performance DEUs were issued or vested. During the nine months ended September 30, 2023, 54,858 Performance DEUs were issued with a grant date fair value of $0.7 million. As of September 30, 2024 and 2023, there were no unvested Performance Awards.

Liability Classified Awards

The Company has granted equity-based awards which are subject to both service and performance conditions. These awards are settled either in cash or a fixed dollar value of shares, subject to the terms of each individual award, and therefore classified as liability awards (the “Liability Awards”). As of September 30, 2024, all Liability Awards have vested and have been settled. Generally, if the performance conditions of these types of awards are not met, the total compensation expense related to the Liability Awards may be less than the maximum granted value of the awards. The Company records Liability Awards as deferred compensation within Accounts Payable and Accrued Liabilities included on the Consolidated Statements of Assets and Liabilities.

Certain Liability Awards are structured similar to the Performance Awards, and increase in value with corresponding increases to the Company’s TSR and vest after four years. The Company remeasures the value of these awards each period based on the Company’s TSR achieved to date. Certain other Liability Awards are linked to attainment of investment funding goals. The Company determines the fair value of these Liability Awards based on the expected probability of the performance conditions being met and recognized over the service period. The Company accrues for Liability Awards based on the expected probability that the performance conditions would be met, this assumption is re-evaluated each period, and may be adjusted to reflect changes in this assumption. Generally, the other Liability Awards vest over a three-year service term.

For the nine months ended September 30, 2024, there was approximately $0.5 million of compensation expense related to the Liability Awards recognized in the Consolidated Statements of Operations and no amounts remain outstanding. During the nine months ended September 30, 2024 and 2023, $3.1 million and no Liability Awards vested, respectively.

As of September 30, 2023, all Liability Awards were unvested and there was approximately $0.9 million of total unrecognized compensation costs expected to be recognized over a weighted average period of 0.6 years. For the nine months ended September 30, 2023, there was approximately $1.1 million of compensation expense related to the Liability Awards recognized in the Consolidated Statements of Operations and $2.2 million accrued within Accounts Payable and Accrued Liabilities in the Consolidated Statements of Assets and Liabilities.

63

---

Table of Contents

9. Earnings Per Share

Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:

(in thousands, except per share data)						Three Months Ended September 30,												Nine Months Ended September 30,
						2024						2023						2024						2023
Numerator
Net increase (decrease) in net assets resulting from operations						$	68,711					$	27,967					$	201,527					$	217,306
Less: Total distributions declared						(77,943)						(72,534)						(231,868)						(204,687)
Total Earnings (loss), net of total distributions						(9,232)						(44,567)						(30,341)						12,619
Earnings (loss), net of distributions attributable to common shares						(9,232)						(44,567)						(30,341)						12,486
Add: Distributions declared attributable to common shares						77,263						71,860						229,650						202,556
Numerator for basic and diluted change in net assets per common share						$	68,031					$	27,293					$	199,309					$	215,042
Denominator
Basic weighted average common shares outstanding						161,019						146,899						159,742						141,223
Common shares issuable						496						211						511						903
Weighted average common shares outstanding assuming dilution						161,515						147,110						160,253						142,126
Change in net assets per common share:
Basic						$	0.42					$	0.19					$	1.25					$	1.52
Diluted						$	0.42					$	0.19					$	1.24					$	1.51

In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per share.

The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and nine months ended September 30, 2024, and 2023, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows:

						Three Months Ended September 30,												Nine Months Ended September 30,
Anti-dilutive Securities						2024						2023						2024						2023
Unvested common stock options						832						347						1,212						1,782
Restricted stock units						—						—						—						5,810
Unvested restricted stock awards						152						395						398						40,034

As of September 30, 2024 and December 31, 2023, the Company was authorized to issue 200.0 million shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote.

On October 28, 2024, the Company filed Articles of Amendment (the “Charter Amendment”) with the Secretary of State of the State of Maryland. The Charter Amendment amended the Company’s Articles of Incorporation to increase the number of authorized shares of Company stock from 200.0 million shares to 300.0 million shares, as approved by the Company’s Board. The Charter Amendment is effective as of October 28, 2024.

64

---

Table of Contents

10. Financial Highlights

Following is a schedule of financial highlights for the nine months ended September 30, 2024 and 2023:

(in thousands, except per share data and ratios)			Nine Months Ended September 30,
			2024						2023
Per share data: (1)
Net asset value at beginning of period			$	11.43					$	10.53
Net investment income			1.53						1.54
Net realized gain (loss)			0.01						0.04
Net unrealized appreciation (depreciation)			(0.28)						(0.04)
Total from investment operations			1.26						1.54
Net increase (decrease) in net assets from capital share transactions(1)			0.10						0.25
Distributions of net investment income(6)			(1.45)						(1.45)
Stock-based compensation expense included in net investment income and other movements(2)			0.06						0.06
Net asset value at end of period			$	11.40					$	10.93
Ratios and supplemental data:
Per share market value at end of period			$	19.64					$	16.42
Total return(3)			26.84		%				36.09		%
Shares outstanding at end of period			162,505						151,179
Weighted average number of common shares outstanding			159,742						141,223
Net assets at end of period			$	1,851,810					$	1,652,057
Ratio of total expense to average net assets(4)			9.18		%				10.38		%
Ratio of net investment income before investment gains and losses to average net assets(4)			17.67		%				18.85		%
Portfolio turnover rate(5)			20.06		%				22.20		%
Weighted average debt outstanding			$	1,696,442					$	1,601,552
Weighted average debt per common share			$	10.62					$	11.34

(1)All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date.

(2)Adjusts for the impact of stock-based compensation expense, which is a non-cash expense and has no net impact to net asset value. Pursuant to ASC Topic 718, the expense is offset by a corresponding increase in paid-in capital. Additionally, adjusts for other items attributed to the difference between certain per share data based on the weighted-average basic shares outstanding and those calculated using the shares outstanding as of a period end or transaction date.

(3)The total return for the nine months ended September 30, 2024, and 2023 equals to the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors.

(4)The ratios are calculated based on weighted average net assets for the relevant period and are annualized.

(5)The portfolio turnover rate for the nine months ended September 30, 2024, and 2023 equals to the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized.

(6)Includes distributions on unvested restricted stock awards.

11. Commitments and Contingencies

The Company’s commitments and contingencies consist primarily of unfunded commitments to extend credit in the form of loans to the Company’s portfolio companies. As of September 30, 2024, a portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company’s credit agreements with its portfolio companies generally contain customary lending provisions which allow the Company relief from funding obligations for previously made unfunded commitments in instances where the underlying portfolio company experiences materially adverse events that affect the financial condition or business outlook for the portfolio company. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by future or unachieved milestones.

As of September 30, 2024, and December 31, 2023, the Company had approximately $489.0 million and $335.3 million, respectively, of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones. In order to draw a portion of the Company's available unfunded commitments, a portfolio company must submit to the Company a formal funding request that complies with the applicable advance notice and other operational requirements. The amounts disclosed exclude unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the

65

---

Table of Contents

reporting period; and (ii) related to the portion of portfolio company investments assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations embedded in the borrowing agreements.

As of September 30, 2024, and December 31, 2023, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows:

(in thousands)						Unfunded Commitments (1) as of
Portfolio Company						September 30, 2024						December 31, 2023
Debt Investments:
Earnix Ltd.						$	41,250					$	—
Arcus Biosciences, Inc.						37,500						—
Shield AI, Inc.						37,500						—
Thumbtack, Inc.						30,000						40,000
Armis, Inc.						25,000						—
Checkr Group, Inc.						23,625						23,625
Skydio, Inc.						22,500						22,500
Pindrop Security, Inc.						19,375						—
Braeburn Pharmaceuticals						17,500						—
Coronet Cyber Security Ltd.						17,000						—
Phathom Pharmaceuticals, Inc.						15,300						6,120
Akero Therapeutics, Inc.						15,000						15,000
Main Street Rural, Inc.						14,000						10,500
Harness, Inc.						11,550						—
Marathon Health, LLC						10,000						—
Viridian Therapeutics						10,000						—
Suzy, Inc.						8,000						12,000
WellBe Senior Medical, LLC						8,000						—
Geron Corporation						7,800						—
Semperis Technologies Inc.						7,500						—
Elation Health, Inc.						7,500						7,500
Curana Health Holdings, LLC						7,500						—
ATAI Life Sciences N.V.						7,000						—
Behavox Limited						7,000						—
Dragos						6,500						13,000
Leapwork ApS						6,345						3,900
enGene, Inc.						5,250						—
Babel Street						4,367						3,375
Heron Therapeutics, Inc.						4,000						4,000
AlphaSense Inc.						4,000						—
Saama Technologies, LLC						3,875						3,875
Allvue Systems, LLC						3,590						3,590
Sight Sciences, Inc.						3,500						—
LogRhythm, Inc.						3,142						—
Recover Together, Inc.						2,500						—
Dronedeploy, Inc.						3,125						6,250
Riviera Partners LLC						3,000						3,000
Zappi, Inc.						2,571						2,571
Loftware, Inc.						2,277						2,277

66

---

Table of Contents

(in thousands)						Unfunded Commitments (1) as of
Portfolio Company						September 30, 2024						December 31, 2023
Debt Investments:
Streamline Healthcare Solutions						$	2,200					$	2,200
New Relic, Inc.						2,176						2,176
Sumo Logic, Inc.						2,000						2,000
Ceros, Inc.						1,707						1,707
ThreatConnect, Inc.						1,600						1,600
LogicSource						1,209						1,209
3GTMS, LLC						1,155						1,182
Zimperium, Inc.						1,088						3,727
Flight Schedule Pro, LLC						1,080						639
Ikon Science Limited						1,050						1,050
LinenMaster, LLC						1,000						1,000
Fortified Health Security						840						840
Omeda Holdings, LLC						731						731
Dispatch Technologies, Inc.						688						625
Constructor.io Corporation						625						625
ShadowDragon, LLC						333						333
Cybermaxx Intermediate Holdings, Inc.						12						390
Automation Anywhere, Inc.						—						29,400
Tarsus Pharmaceuticals, Inc.						—						20,625
Kura Oncology, Inc.						—						19,250
Tipalti Solutions Ltd.						—						10,500
Next Insurance, Inc.						—						10,000
Senseonics Holdings, Inc.						—						8,750
Modern Life, Inc.						—						6,500
Brain Corporation						—						5,000
Cutover, Inc.						—						2,650
Plentific Ltd						—						2,625
Altumint, Inc.						—						2,500
Yipit, LLC						—						2,250
Dashlane, Inc.						—						2,137
Annex Cloud						—						1,750
Agilence, Inc.						—						800
Enmark Systems, Inc.						—						457
Alchemer LLC						—						445
Cytracom Holdings LLC						—						72
Total Unfunded Debt Commitments:						484,936						330,828
Investment Funds & Vehicles:(2)
Forbion Growth Opportunities Fund I C.V.						1,757						1,757
Forbion Growth Opportunities Fund II C.V.						2,277						2,748
Total Unfunded Commitments in Investment Funds & Vehicles:						4,034						4,505
Total Unfunded Commitments						$	488,970					$	335,333

(1)For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $152.2 million and $127.7 million of unfunded commitments as of September 30, 2024, and December 31, 2023, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”.

(2)For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.

67

---

Table of Contents

The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type:

(in thousands) Unfunded Commitments
						September 30, 2024						December 31, 2023
Expiring during:
2024						$	162,870					$	291,896
2025						236,470						3,004
2026						32,202						7,537
2027						15,071						14,078
2028						6,164						6,547
2029						27,983						3,590
2030						4,176						4,176
Total Unfunded Debt Commitments						484,936						330,828
Unfunded Commitments in Investment Funds & Vehicles:
Expiring during:
2030						1,757						1,757
2032						2,277						2,748
Total Unfunded Commitments in Investment Funds & Vehicles						4,034						4,505
Total Unfunded Commitments						$	488,970					$	335,333

The following tables provide the Company’s contractual obligations as of September 30, 2024 and December 31, 2023:

As of September 30, 2024:						Payments due by period (in thousands)
Contractual Obligations(1)						Total						Less than 1 year						1 - 3 years						3 - 5 years						After 5 years
Debt(2)(3)						$	1,751,000					$	170,000					$	1,216,000					$	—					$	365,000
Lease and License Obligations(4)						24,528						3,206						6,551						5,560						9,211
Total						$	1,775,528					$	173,206					$	1,222,551					$	5,560					$	374,211
As of December 31, 2023:						Payments due by period (in thousands)
Contractual Obligations(1)						Total						Less than 1 year						1 - 3 years						3 - 5 years						After 5 years
Debt(5)(3)						$	1,570,000					$	105,000					$	689,000					$	411,000					$	365,000
Lease and License Obligations(4)						26,741						2,539						6,629						6,248						11,325
Total						$	1,596,741					$	107,539					$	695,629					$	417,248					$	376,325

(1)Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds.

(2)Includes $175.0 million in principal outstanding under the SBA Debentures, $50.0 million of the February 2025 Notes, $70.0 million of the June 2025 Notes, $50.0 million of the June 2025 3-Year Notes, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $150.0 million of the 2031 Asset-Backed Notes, $40.0 million of the 2033 Notes, $325.0 million of the September 2026 Notes and $350.0 million of the January 2027 Notes as of September 30, 2024. There was also $201.0 million outstanding under the SMBC Facility and $240.0 million outstanding under the MUFG Bank Facility as of September 30, 2024.

(3)Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”.

(4)Facility leases and licenses including short-term leases.

(5)Includes $175.0 million in principal outstanding under the SBA Debentures, $105.0 million of the July 2024 Notes, $50.0 million of the February 2025 Notes, $70.0 million of the June 2025 Notes, $50.0 million of the June 2025 3-Year Notes, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $150.0 million of the 2031 Asset-Backed Notes, $40.0 million of the 2033 Notes, $325.0 million of the September 2026 Notes and $350.0 million of the January 2027 Notes as of December 31, 2023. There was also $94.0 million outstanding under the SMBC Facility and $61.0 million outstanding under the MUFG Bank Facility as of December 31, 2023.

Certain premises are leased or licensed under agreements which expire at various dates through July 2034. For the three months ended September 30, 2024 and 2023, total rent expense, including short-term leases, amounted to approximately $0.8 million and $0.9 million in each period, respectively. For the nine months ended September 30, 2024 and 2023, total rent expense, including short-term leases, amounted to approximately $2.7 million and $2.5 million in each period, respectively. The Company recognizes an operating lease liability and a ROU asset for all leases, with the exception of short-term leases. The lease payments on short-term leases are recognized as rent expense on a straight-line basis. The discount rate applied to measure each ROU asset and lease liability is based on the Company’s incremental weighted average cost of debt. The Company considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is appropriate to the intended use of the underlying lease. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset.

68

---

Table of Contents

The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of September 30, 2024, and 2023:

(in thousands)			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Total operating lease cost			$	762					$	691					$	2,091					$	1,995
Cash paid for amounts included in the measurement of lease liabilities			$	371					$	495					$	1,268					$	2,231

			As of September 30, 2024						As of December 31, 2023
Weighted-average remaining lease term (in years)			8.06						8.68
Weighted-average discount rate			6.85		%				6.79		%

The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of September 30, 2024:

(in thousands)			As of September 30, 2024
2024			$	598
2025			3,088
2026			3,179
2027			3,452
Thereafter			14,090
Total lease payments			24,407
Less: imputed interest & other items			(5,927)
Total operating lease liability			$	18,480

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

12. Related Party Transactions

As disclosed in “Note 1 - Description of Business”, the Adviser Subsidiary is the Company's wholly owned registered investment advisor business, composed of the collectively held and presented entities Hercules Adviser LLC, Hercules Capital Management, LLC, and Hercules Partner Holdings, LLC entities. The Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value. The Adviser Subsidiary has entered into investment management agreements with its privately offered Adviser Funds, and it receives management fees based on the assets under management of the Adviser Funds. In addition, the general partner interests (the “GP Interests”) held by Hercules Partner Holdings, LLC may receive incentive fees based on the performance of the Adviser Funds. Both the Adviser Subsidiary and Hercules Partner Holdings, LLC are owned by Hercules Capital Management LLC. During the three and nine months ended September 30, 2024, the Adviser Subsidiary declared and paid dividend distributions to the Company of $1.8 million and $5.0 million, respectively. No dividend distributions were made during the three and nine months ended September 30, 2023. Refer to “Note 4 – Investments” for information related to income, gains and losses recognized related to the Company’s investment.

The Company has a shared services agreement (“Sharing Agreement”) with the Adviser Subsidiary, through which the Adviser Subsidiary has access to the Company's human capital resources (including administrative functions) and other resources and infrastructure (including office space and technology). Under the terms of the Sharing Agreement, the Company allocates the related expenses of shared services to the Adviser Subsidiary based on direct time spent, investment activity, and proportion of assets under management depending on the nature of the expense. The Company’s total expenses for the three months ended September 30, 2024 and 2023, are net of expenses allocated to the Adviser Subsidiary of $2.2 million and $2.4 million, respectively. The Company's total expenses for the nine months ended September 30, 2024 and 2023, are net of expenses allocated to the Adviser Subsidiary of $7.9 million and $7.5 million, respectively. As of September 30, 2024 and December 31, 2023, there was less than $0.1 million and approximately $0.1 million receivable, respectively, from the Adviser Subsidiary.

69

---

Table of Contents

In addition, the Company may from time-to-time make investments alongside the Adviser Funds or assign a portion of investments to the Adviser Funds in accordance with the Company’s allocation policy. The assigned investment activities for the nine months ended September 30, 2024 and 2023, are summarized below:

(in millions)			Nine Months Ended September 30,
			2024						2023
Investment commitments assigned to or directly committed by the Adviser Funds			$	422.1					$	491.4
Investment fundings assigned to, directly originated or funded by the Adviser Funds			$	277.1					$	294.4
Amounts received by the Company from the Adviser Funds relating to assigned investments			$	6.0					$	12.1

13. Subsequent Events

Dividend Distribution Declaration

On October 24, 2024, the Board declared a cash distribution of $0.40 per share to be paid on November 20, 2024 to stockholders of record as of November 13, 2024. In addition to the cash distribution, and as part of the supplemental cash distribution of $0.32 per share to be paid in four quarterly distributions of $0.08 per share, the Board declared a supplemental cash distribution of $0.08 per share to be paid on November 20, 2024 to stockholders of record as of November 13, 2024. Including the $0.08 per share supplemental cash distributions paid to stockholders of record as of March 6, 2024, May 14, 2024 and August 13, 2024, the Board has declared the full $0.32 per share of supplemental cash distribution declared on February 8, 2024.

Authorized shares of Company stock

On October 28, 2024, the Company filed Charter Amendment with the Secretary of State of the State of Maryland. The Charter Amendment amended the Company’s Articles of Incorporation to increase the number of authorized shares of Company stock from 200.0 million shares to 300.0 million shares, as approved by the Company’s Board. The Charter Amendment is effective as of October 28, 2024.

70

---

Table of Contents

ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

The matters discussed in this report, as well as in future oral and written statements by management of Hercules Capital, Inc., that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:

•our current and future management structure;

•our future operating results;

•our business prospects and the prospects of our prospective portfolio companies;

•the impact of investments that we expect to make;

•our informal relationships with third parties including in the venture capital industry;

•the expected market for venture capital investments and our addressable market;

•the dependence of our future success on the general economy and its impact on the industries in which we invest;

•our ability to access debt markets and equity markets;

•the occurrence and impact of macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war) on us and our portfolio companies;

•the ability of our portfolio companies to achieve their objectives;

•our expected financings and investments;

•our regulatory structure and tax status as a RIC;

•our ability to operate as a BDC and our subsidiaries ability to operate as SBICs;

•the adequacy of our cash resources and working capital;

•the timing of cash flows, if any, from the operations of our portfolio companies;

•the timing, form and amount of any distributions;

•the impact of fluctuations in interest rates on our business;

•the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and

•our ability to recover unrealized depreciation on investments.

You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this report.

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this report. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under Item 1A— “Risk Factors” of Part II of this quarterly report on Form 10-Q, Item 1A— “Risk Factors” of our Annual Report on Form 10-K filed with the SEC on February 15, 2024 and under “Forward-Looking Statements” of this Item 2.

Use of Non-GAAP Measures

Throughout this MD&A, we present our financial condition and results of operations in the way we believe will be most meaningful and representative of our business results. Some of the measurements we use are “Non-GAAP financial measures” under SEC rules and regulations. GAAP is the acronym for “generally accepted accounting principles” in the United States. The Non-GAAP financial measures we present may not be comparable to similarly-named measures reported by other companies.

71

---

Table of Contents

Overview

We are a leading specialty finance company with a focus on providing financing solutions to high-growth and innovative venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. Our primary business objectives are to increase our net income, net investment income, and net asset value through our investments. We principally invest in debt securities and, to a lesser extent, equity securities, with a particular emphasis on Structured Debt. We use the term “Structured Debt” to refer to a debt investment that is structured with an equity, warrant, option, or other right to purchase or convert into common or preferred stock. We aim to achieve our business objectives by maximizing our portfolio total return through generation of current income from our debt investments and capital appreciation from our warrant and equity investments. We expect that our investments will generally range from $25.0 million to $100.0 million, although we may make investments in amounts above or below this range. Through generation of current income from our debt investments and capital appreciation from our warrant and equity investments, we aim to maximize our portfolio total return.

Since inception through September 30, 2024, we have originated more than $21.0 billion in commitments in over 660 companies. We, our subsidiaries or our affiliates, may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. As of September 30, 2024, Hercules and its Adviser Subsidiary actively manage approximately $4.6 billion of assets.

We are structured as an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a BDC under the 1940 Act. As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes securities of private U.S. companies, cash, cash equivalents, and high-quality debt investments that mature in one year or less. Consistent with requirements under the 1940 Act, we invest primarily in United States based companies and to a lesser extent in foreign companies. We source our investments through our principal office located in San Mateo, CA, as well as through our additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, Denver, CO, and London, United Kingdom.

We have elected to be treated for tax purposes as a RIC under the Code and operate in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC, among other requirements, we must maintain certain income, asset, and distribution requirements. As a RIC, we generally will not be subject to U.S. federal income tax on the income that we distribute (or are deemed to distribute) to our stockholders provided that we maintain our RIC status for a given year.

Portfolio and Investment Activity

The total fair value of our investment portfolio as of September 30, 2024 and December 31, 2023 was as follows:

(in millions)			Fair Value
			September 30, 2024						December 31, 2023
Debt			$	3,380.6					$	3,057.3
Equity			143.0						152.2
Warrants			30.0						33.9
Investment Funds & Vehicles			6.9						4.6
Total Investment Portfolio			$	3,560.5					$	3,248.0

Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. Not all debt commitments represent future cash requirements. Unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company, which is expected to affect our funding levels. These commitments are subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the following year from underwriting. From time to time, unfunded contractual commitments may expire without being drawn and thus do not represent future cash requirements.

Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing and some portion may be assigned or allocated to or directly originated by the Adviser Funds prior to or after closing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

72

---

Table of Contents

Our portfolio activity for the nine months ended September 30, 2024 and September 30, 2023 was comprised of the following:

(in millions)			September 30, 2024						September 30, 2023
Investment Commitments(1)
Investment Commitments Originated by Hercules Capital and the Adviser Funds			$	2,073.2					$	1,760.2
Less: Commitments assigned to or directly committed by the Adviser Funds			(422.1)						(491.4)
Net Total Investment Commitments			$	1,651.1					$	1,268.8
Gross Debt Commitments Originated by Hercules Capital and the Adviser Funds
New portfolio company			$	1,857.6					$	1,355.9
Existing portfolio company			207.6						393.2
Sub-total			2,065.2						1,749.1
Less: Debt commitments assigned to or directly committed by the Adviser Funds			(420.7)						(490.1)
Net Total Debt Commitments			$	1,644.5					$	1,259.0
Investment Fundings(2)
Gross Debt Fundings by Hercules Capital and the Adviser Funds
New portfolio company			$	992.0					$	682.4
Existing portfolio company			338.2						597.5
Sub-total			1,330.2						1,279.9
Less: Debt fundings assigned to or directly funded by the Adviser Funds			(275.7)						(293.1)
Net Total Debt Fundings			$	1,054.5					$	986.8
Equity Investments and Investment Funds and Vehicles Fundings by Hercules Capital and the Adviser Funds
New portfolio company			$	2.0					$	2.0
Existing portfolio company			6.5						9.7
Sub-total			$	8.5					$	11.7
Less: Equity fundings assigned to or directly funded by the Adviser Funds			(1.4)						(1.3)
Net Total Equity and Investment Funds and Vehicle Fundings			$	7.1					$	10.4
Total Unfunded Contractual Commitment(3)			$	489.0					$	400.6
Non-Binding Term Sheets
New portfolio company			$	178.5					$	40.0
Existing portfolio company			2.0						50.0
Total			$	180.5					$	90.0

(1)Includes restructured loans and renewals in addition to new commitments.

(2)Funded amounts include borrowings on revolving facilities.

(3)Amount represents unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. This excludes $152.2 million and $135.7 million of unfunded commitments as of September 30, 2024, and 2023, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds.

We receive principal payments on our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to period. During the nine months ended September 30, 2024, we received approximately $724.0 million in aggregate principal repayments. Approximately $27.2 million of the aggregate principal repayments related to scheduled principal payments and approximately $696.8 million were early principal repayments related to 43 portfolio companies.

73

---

Table of Contents

Total portfolio investment activity (inclusive of unearned income and excluding activity related to taxes payable and escrow receivables) as of and for the nine months ended September 30, 2024 and September 30, 2023 was as follows:

(in millions)						September 30, 2024						September 30, 2023
Beginning portfolio						$	3,248.0					$	2,963.9
New fundings and restructures						1,338.7						1,291.6
Fundings assigned to or directly funded by the Adviser Funds						(277.1)						(294.4)
Warrants not related to current period fundings						0.7						1.6
Principal repayments received on investments						(27.2)						(37.8)
Early payoffs						(696.8)						(647.4)
Proceeds from sale of equity and warrant investments						(23.4)						(34.9)
Accretion of loan discounts and paid-in-kind interest						65.0						43.5
Net acceleration of loan discounts and loan fees due to early payoffs or restructures						(8.2)						(10.2)
New loan fees						(11.5)						(11.0)
Gain (loss) on investments due to sales or write offs						2.7						2.2
Net change in unrealized appreciation (depreciation)						(50.4)						(5.7)
Ending portfolio						$	3,560.5					$	3,261.4

Additionally, we may hold investments in debt, warrant, or equity positions of portfolio companies that have filed a registration statement with the SEC in contemplation of a potential initial public offering. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely manner or at all.

The following table presents certain selected information regarding our debt investment portfolio as of September 30, 2024 and December 31, 2023. This includes information on index rate floors which we have in place on all of our floating rate debt investments:

			September 30, 2024						December 31, 2023
Number of portfolio companies with debt outstanding			122						125
Percentage of debt bearing a floating rate			97.3		%				95.9		%
Percentage of debt bearing a fixed rate			2.7		%				4.1		%
Weighted average core yield(1)(3)			13.3		%				14.3		%
Weighted average effective yield(2)(3)			14.4		%				15.3		%
Prime rate at the end of the period			8.00		%				8.50		%
Percentage of Prime rate linked debt investments			75.5		%				69.2		%
Weighted average floor rate bearing a Prime rate			6.9		%				5.7		%
Percentage of SOFR and BSBY rate linked debt investments			21.8		%				26.7		%
Weighted average floor rate bearing a SOFR or BSBY rate			1.0		%				1.1		%

(1)The core yield is a Non-GAAP financial measure. The core yield on our debt investments excludes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, other one-time events, and includes income from expired commitments. Please refer to the "Portfolio Yield" section below for further discussion of this measure.

(2)The effective yield on our debt investments includes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events. The effective yield is derived by dividing total investment income from debt investments by the weighted average earning investment portfolio assets outstanding during the year, excluding non-interest earning assets such as warrants and equity investments. Please refer to the "Portfolio Yield" section below for further discussion of this measure.

(3)The core and effective yields represent the weighted average yields for the three-month periods ended September 30, 2024 and December 31, 2023. Please refer to the "Portfolio Yield" section below for further discussion of these measures.

Macroeconomic Market Developments

The capital markets are subject to fluctuations caused by various external factors such as changes in the inflationary environment, interest rate movements, concerns over slowing economic growth and possible global recession, uncertainty and disruption caused by geopolitical events, including the conflicts in Ukraine, Russia, and the Middle East, among other factors. These macroeconomic developments are outside our control and could require us to adjust our plan of operations, and impact our financial position, results of operations or cash flows in the future. We monitor macroeconomic market developments and their related impact to our business, including impacts to our portfolio companies, employees, due diligence and underwriting processes, and the broader financial markets.

Our investment portfolio continues to be focused on industries and sectors that are generally expected to be more resilient to U.S. and global economic cycles. This includes being partially insulated from declining interest rates as all of our floating rate debt investments, which represent 97.3% and 95.9% of our debt portfolio as of September 30, 2024 and

74

---

Table of Contents

December 31, 2023, respectively, are subject to interest rate floors. While our portfolio is not immune to the impact of macroeconomic events, we and our portfolio are well positioned to manage the current environment. Given the unpredictability and fluidity of the macroeconomic market, neither our management nor our Board is able to predict the full impact of the macroeconomic events on our business, future results of operations, financial position, or cash flows.

Income from Portfolio

We primarily generate revenue in the form of interest income, from our investments in debt securities, and fee income, which is primarily comprised of commitment and facility fees. Interest income is recognized in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate income from dividends on either direct equity investments or equity interests obtained in connection with originating loans, such as options, warrants or conversion rights. We also generate revenue in the form of capital gains, if any, on warrants or other equity securities that we acquire from our portfolio companies.

As of September 30, 2024, our debt investments generally have a term of between two and five years and typically bear interest at a rate ranging from approximately 8.0% to approximately 17.7%. In addition to the cash yields received on our debt investments, in some instances, our debt investments may also include any of the following: exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt.

Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the investment. In addition, our loans may include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.

Loan origination and commitment fees are generally received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. As of September 30, 2024 and December 31, 2023, unamortized capitalized fee income was recorded as follows:

(in millions)			September 30, 2024						December 31, 2023
Offset against debt investment cost			$	36.7					$	32.9
Deferred obligation contingent on funding or other milestone			9.7						9.4
Total Unamortized Fee Income			$	46.4					$	42.3

Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. As of September 30, 2024 and December 31, 2023, loan exit fees receivable were recorded as follows:

(in millions)			September 30, 2024						December 31, 2023
Included within debt investment cost			$	37.0					$	35.9
Deferred receivable related to expired commitments			3.4						4.3
Total Exit Fees Receivable			$	40.4					$	40.2

Additionally, we have debt investments in our portfolio that earn PIK interest. The PIK interest, computed at the contractual rate specified in each loan agreement, is recorded as interest income and added to the principal balance of the loan on specified capitalization dates. To maintain our status as a RIC, the non-cash PIK income must be distributed to stockholders with other sources of income in the form of dividend distributions even though we have not yet collected any cash from the borrower. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments. During the three months ended September 30, 2024 and 2023, we recorded approximately $12.7 million and $6.7 million in PIK income, respectively. During the nine months ended September 30, 2024 and 2023, we recorded approximately $37.9 million and $18.0 million in PIK income, respectively.

Portfolio Yield

We report our financial results on a GAAP basis. We monitor the performance of our total investment portfolio and total debt portfolio using both GAAP and Non-GAAP financial measures. In particular, we evaluate performance through monitoring the portfolio yields as we consider them to be effective indicators, for both management and stockholders, of

75

---

Table of Contents

the financial performance of our total investment portfolio and total debt portfolio. The key metrics that we monitor with respect to yields are as described below:

•“Total Yield” - The total yield is derived by dividing GAAP basis “Total investment income” by the weighted average GAAP basis value of investment portfolio assets outstanding during the year, including non-interest earning assets such as warrants and equity investments at amortized cost.

•“Effective Yield” on total debt investments - The effective yield is derived by dividing GAAP basis “Total investment income” from debt investments(1) by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding during the year.

•“Core Yield” on total debt investments – The core yield is a Non-GAAP financial measure. The core yield is derived by dividing “Core investment income” from debt investments by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding during the year. “Core investment income” adjusts GAAP basis “Total investment income” from debt investments(1) to exclude fee and other income accelerations attributed to early payoffs, deal restructuring, loan modifications, and other one-time income events, but includes income from expired commitments.

			Three Months Ended September 30,
			2024						2023
Total Yield			13.8		%				14.7		%
Effective Yield(1)			14.4		%				15.5		%
Core Yield (Non-GAAP)(1)			13.3		%				14.2		%

(1)Yield calculated using “Total investment income” excluding bank interest, dividend income, and investment income from other assets for the three months ended September 30, 2024.

We believe that these measures are useful for our stockholders as it provides further insight into the yield of our portfolio to allow a more meaningful comparison with our competitors. As noted above, Core Yield, a Non-GAAP financial measure, is derived by dividing Core investment income, as defined above, by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding. The reconciliation to calculate “Core investment income” from GAAP basis 'Total investment income' are as follows:

(in thousands)						Three Months Ended September 30,
						2024						2023
GAAP Basis: Total investment income						$	125,248					$	116,744
Less: fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events except income from expired commitments						(9,160)						(9,378)
Non-GAAP Basis: Core investment income						$	116,088					$	107,366
Less: bank interest income, dividend income, and other investment income from other assets						(2,831)						(903)
Core investment income from debt portfolio						$	113,257					$	106,463

We believe the Core Yield is useful for our investors as it provides the yield at which our debt investments are originated and eliminates one-off items that can fluctuate significantly from period to period, thereby allowing for a more meaningful comparison over time.

Although the Core Yield, a Non-GAAP financial measure, is intended to enhance our stockholders’ understanding of our performance, the Core Yield should not be considered in isolation from or as an alternative to the GAAP financial metrics presented. The aforementioned Non-GAAP financial measure may not be comparable to similar Non-GAAP financial measures used by other companies.

Another financial measure that we monitor is the total return for our investors, which was approximately 26.8% and 36.1% during the nine months ended September 30, 2024 and 2023, respectively. The total return equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. The total return does not reflect any sales load that may be paid by investors. See “Note 10 – Financial Highlights” included in the notes to our consolidated financial statements appearing elsewhere in this report.

76

---

Table of Contents

Portfolio Composition

Our portfolio companies are primarily privately held companies and public companies which are active in sectors characterized by high margins, high growth rates, consolidation and product and market extension opportunities.

The following table presents the fair value of the Company’s portfolio by industry sector as of September 30, 2024 and December 31, 2023:

			September 30, 2024												December 31, 2023
(in thousands)			Investments at Fair Value						Percentage of Total Portfolio						Investments at Fair Value						Percentage of Total Portfolio
Drug Discovery & Development			$	1,125,617					31.6		%				$	1,257,699					38.7		%
Software			1,018,236						28.6		%				764,985						23.6		%
Healthcare Services, Other			574,750						16.1		%				300,079						9.3		%
Consumer & Business Services			355,831						10.0		%				525,973						16.2		%
All other industries(1)			486,079						13.7		%				399,310						12.2		%
Total			$	3,560,513					100.0		%				$	3,248,046					100.0		%

(1)See “Note 4 – Investments” for complete list of industry sectors and corresponding amounts of investments at fair value as a percentage of the total portfolio. As of September 30, 2024, the fair value as a percentage of total portfolio does not exceed 5.0% for any individual industry sector other than “Drug Discovery & Development”, “Software”, "Healthcare Services, Other", or “Consumer & Business Services”.

Industry and sector concentrations vary as new loans are recorded and loans are paid off. Investment income, consisting of interest, fees, and recognition of gains on equity and warrants or other equity interests, can fluctuate materially when a loan is paid off or a warrant or equity interest is sold. Investment income recognized in any given year can be highly concentrated in several portfolio companies.

For the nine months ended September 30, 2024 and the year ended December 31, 2023, our ten largest portfolio companies represented approximately 30.6% and 29.7% of the total fair value of our investments in portfolio companies, respectively. As of September 30, 2024 and December 31, 2023, we had five and five investments that represented 5% or more of our net assets, respectively. As of September 30, 2024 and December 31, 2023, the Company had four and five equity investments, respectively, that represented 5% or more of the total fair value of the Company’s equity investments. These equity investments represented approximately 52.9% and 56.5% of the total fair value of the Company’s equity investments as of September 30, 2024 and December 31, 2023, respectively.

As of September 30, 2024 and December 31, 2023, approximately 97.3% and 95.9% of the debt investment portfolio was priced at floating interest rates or floating interest rates with a Prime, SOFR, or BSBY-based interest rate floor, respectively. Changes in interest rates, including Prime, SOFR, or BSBY rates, may affect the interest income and the value of our investment portfolio for portfolio investments with floating rates.

Our investments in Structured Debt generally have detachable equity enhancement features in the form of warrants or other equity securities designed to provide us with an opportunity for capital appreciation. These features are treated as OID and are accreted into interest income over the term of the loan as a yield enhancement. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing round. As of September 30, 2024, we held warrants in 98 portfolio companies, with a fair value of approximately $30.0 million. The fair value of our warrant portfolio decreased by approximately $3.9 million, as compared to a fair value of $33.9 million as of December 31, 2023, primarily related to the decrease in fair value of the portfolio companies.

Our existing warrant holdings would require us to invest approximately $61.4 million to exercise such warrants as of September 30, 2024. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. As attractive investment opportunities arise, we may exercise certain of our warrants to purchase stock, and could ultimately monetize our investments. Of the warrants that we have monetized since inception, we have realized multiples in the range of approximately 1.02x to 42.71x based on the historical rate of return on our investments. We may also experience losses from our warrant portfolio in the event that warrants are terminated or expire unexercised.

77

---

Table of Contents

Portfolio Grading

We use an investment grading system, which grades each debt investment on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. The following table shows the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of September 30, 2024 and December 31, 2023, respectively:

(in thousands)						September 30, 2024																		December 31, 2023
Investment Grading						Number of Companies						Debt Investments at Fair Value						Percentage of Total Portfolio						Number of Companies						Debt Investments at Fair Value						Percentage of Total Portfolio
1						20						$	731,277					21.6		%				20						$	626,770					20.5		%
2						51						1,474,880						43.6		%				52						1,286,195						42.1		%
3						44						1,078,012						31.9		%				47						1,040,629						34.0		%
4						5						75,686						2.3		%				5						103,705						3.4		%
5						2						20,723						0.6		%				1						—						0.0		%
						122						$	3,380,578					100.0		%				125						$	3,057,299					100.0		%

As of September 30, 2024 and December 31, 2023, our debt investments had a weighted average investment grading of 2.24 and 2.24 on a cost basis, respectively. Changes in a portfolio company's investment grading may be a result of changes in portfolio company's performance and/or timing of expected liquidity events. For instance, we may downgrade a portfolio company if it is not meeting our financing criteria or are underperforming relative to their respective business plans. We may also downgrade a portfolio company as it approaches a point in time when it will require additional equity capital to continue operations. Conversely, we may upgrade a portfolio company's investment grading when it is exceeding our financial performance expectations and/or is expected to mature/repay in full due to a liquidity event. The overall downgrade of the portfolio's weighted average investment grading is reflective of the impact of current macroeconomic environment.

As macroeconomic events evolve and cause disruption in the capital markets and to businesses, we are continuing to monitor and work with the management teams and stakeholders of our portfolio companies to navigate the significant market, operational, and economic challenges created by these events. This includes remaining proactive in our assessments of credit performance to manage potential risks across our investment portfolio.

Non-accrual Investments

The following table shows the amortized cost of our performing and non-accrual investments as of September 30, 2024 and December 31, 2023:

(in millions)			September 30, 2024												December 31, 2023
			Amortized Cost						Percentage of Total Portfolio at Amortized Cost						Amortized Cost						Percentage of Total Portfolio at Amortized Cost
Performing			$	3,518					97.4		%				$	3,216					99.0		%
Non-accrual			92						2.6		%				31						1.0		%
Total Investments			$	3,610					100.0		%				$	3,247					100.0		%

Debt investments are placed on non-accrual status when it is probable that principal, interest, or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, we cease to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay our current and future contractual obligations. We may not apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.

78

---

Table of Contents

Results of Operations

Our condensed consolidated operating results for the three and nine months ended September 30, 2024 and 2023, were as follows:

(in thousands, except per share data)						Three Months Ended September 30,												Nine Months Ended September 30,
						2024						2023						2024						2023
Total investment income						$	125,248					$	116,744					$	371,807					$	338,065
Total expenses						42,084						39,950						127,123						120,072
Net investment income						83,164						76,794						244,684						217,993
Net realized gain (loss):						(559)						(2,587)						1,825						5,590
Net change in unrealized appreciation (depreciation):						(13,894)						(46,240)						(44,982)						(6,277)
Net increase (decrease) in net assets resulting from operations						$	68,711					$	27,967					$	201,527					$	217,306
Net investment income before gains and losses per common share:
Basic						$	0.51					$	0.52					$	1.52					$	1.53
Change in net assets resulting from operations per common share:
Basic						$	0.42					$	0.19					$	1.25					$	1.52
Diluted						$	0.42					$	0.19					$	1.24					$	1.51

Our operating results can vary substantially from period to period due to various factors, including changes in the level of investments held, changes in our investment yields, recognition of realized gains and losses, and changes in net unrealized appreciation and depreciation, among other factors. As a result, comparison of the net increase (decrease) in net assets resulting from operations may not be meaningful.

Investment Income

Total investment income for the three and nine months ended September 30, 2024 was approximately $125.2 million and $371.8 million, respectively as compared to approximately $116.7 million and $338.1 million, respectively for the three and nine months ended September 30, 2023. Investment income is primarily composed of interest income earned on our debt investments, fee income from commitments, facilities, and other loan related fees and dividend income distributions.

Interest and Dividend Income

The following table summarizes the components of interest and dividend income for the three and nine months ended September 30, 2024 and 2023:

(in thousands)			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Contractual interest income			$	90,288					$	89,747					$	268,441					$	258,685
Exit fee interest income			12,047						10,904						34,519						34,340
PIK interest income			12,706						6,652						37,870						17,999
Dividend income			2,100						—						5,800						—
Other investment income(1)			1,909						3,036						5,728						8,198
Total interest and dividend income			$	119,050					$	110,339					$	352,358					$	319,222

(1)Other investment income includes OID interest income and interest recorded on other assets.

Interest and dividend income for the three and nine months ended September 30, 2024 totaled approximately $119.0 million and $352.4 million as compared to approximately $110.3 million and $319.2 million for the three and nine months ended September 30, 2023. The increase in interest and dividend income for the three and nine months ended September 30, 2024 as compared to the period ended September 30, 2023 is primarily attributable to an increase in the weighted average principal, dividend income distributions, and partially offset by lower core yield.

79

---

Table of Contents

Interest income is comprised of recurring interest income from the contractual servicing of loans and non-recurring interest income that is related to the acceleration of income due to early loan repayments and other one-time events during the period.

The following table summarizes recurring and non-recurring interest income for the three and nine months ended September 30, 2024 and 2023:

(in thousands)			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Recurring interest income			$	113,252					$	104,823					$	337,863					$	300,810
Non-recurring interest income			5,798						5,516						14,495						18,412
Total interest income			$	119,050					$	110,339					$	352,358					$	319,222

A portion of interest income is earned in the form of PIK interest. The following table shows the PIK-related activity for the nine months ended September 30, 2024 and 2023, at cost:

(in thousands)			Nine Months Ended September 30,
			2024						2023
Beginning PIK interest receivable balance			$	38,030					25,713
PIK interest income during the period			37,870						17,999
PIK capitalized as principal or converted to equity or other assets			(618)						(375)
Payments received from PIK loans			(12,671)						(4,023)
Realized gain (loss)			—						(52)
Ending PIK interest receivable balance			$	62,611					39,262

The increase in PIK interest income during the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023 is due to an increase in the weighted average principal outstanding for debt investments which earn PIK interest. Payments on PIK loans are normally received only in the event of payoffs. The PIK receivable for September 30, 2024 and September 30, 2023 was approximately 2% and 1% of total debt investments, respectively.

Fee Income

Fee income from commitment, facility and loan related fees for the three and nine months ended September 30, 2024 totaled approximately $6.2 million and $19.4 million, respectively as compared to approximately $6.4 million and $18.8 million, respectively for the three and nine months ended September 30, 2023. Fee income was relatively consistent for the three months ended September 30, 2024 and 2023. The increase in fee income for the nine months ended September 30, 2024 and 2023 is primarily due to an increase in the weighted average principal and an increase in expired commitments.

Fee income is comprised of recurring fee income from commitment, facility, and loan related fees, fee income due to expired commitments, and acceleration of fee income due to early loan repayments during the period. The following table summarizes the components of fee income for the three and nine months ended September 30, 2024 and 2023:

(in thousands)			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Recurring fee income			$	2,423					$	2,243					$	7,081					$	6,418
Fee income - expired commitments			413						300						1,790						651
Accelerated fee income - early repayments			3,362						3,862						10,578						11,774
Total fee income			$	6,198					$	6,405					$	19,449					$	18,843

In certain investment transactions, we may earn income from advisory services; however, we had no income from advisory services in the three and nine months ended September 30, 2024 or 2023.

Operating Expenses

Our operating expenses are comprised of interest and fees on our debt borrowings, general and administrative expenses, taxes, and employee compensation and benefits. During the three and nine months ended September 30, 2024 and 2023, our net operating expenses totaled approximately $42.1 million and $40.0 million, respectively for the three-month periods, and approximately $127.1 million and $120.1 million, respectively for the nine-month periods.

Interest and Fees on our Debt

Interest and fees on our debt totaled approximately $22.4 million and $19.0 million for the three months ended September 30, 2024 and 2023, respectively, and approximately $63.9 million and $57.6 million for the nine months ended September 30, 2024 and 2023, respectively. Our higher weighted average borrowings outstanding and cost of debt during

80

---

Table of Contents

both the three and nine month periods ended September 30, 2024, resulted in an increase of interest and fee expenses as compared to the three and nine months ended September 30, 2023.

Our weighted average cost of debt was approximately 5.1% and 4.8% for the three months ended September 30, 2024 and 2023, respectively and 5.0% and 4.8%, for the nine months ended September 30, 2024 and 2023, respectively. The weighted average cost of debt includes interest and fees on our debt but excludes the impact of fee accelerations due to the extinguishment of debt, as applicable. The increase in the weighted average cost of debt during 2024 as compared to 2023, was attributable to increased usage of our Credit Facilities which are floating rate instruments and have a higher borrowing rate.

General and Administrative Expenses and Tax Expenses

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, rent, expenses associated with the workout of underperforming investments, and various other expenses. Our general and administrative expenses stayed flat at $4.6 million for the three months ended September 30, 2024 and 2023, respectively and increased to $14.1 million from $13.9 million for the nine months ended September 30, 2024 and 2023, respectively. The increase in general and administrative expenses for the nine months ended September 30, 2024 is primarily attributable to an increase in costs of office and technology expenses, and certain professional fees. Tax expenses were $2.0 million and $1.9 million during the three months ended September 30, 2024 and 2023, respectively and $4.5 million and $5.2 million for the nine months ended September 30, 2024 and 2023, respectively. Our tax expenses primarily relate to excise tax accruals.

Employee Compensation

Employee compensation and benefits totaled approximately $12.1 million and $42.9 million, for the three and nine months ended September 30, 2024 as compared to approximately $13.6 million and $41.1 million respectively, for the three and nine months ended September 30, 2023. The movement between the three and nine months ended September 30, 2024 and 2023 was primarily due to fluctuations in variable compensation.

Employee stock-based compensation totaled approximately $3.2 million and $9.7 million, for the three and nine months ended September 30, 2024 as compared to approximately $3.3 million and $9.8 million respectively, for the three and nine months ended September 30, 2023. There was no significant change between the comparative periods.

Expenses allocated to the Adviser Subsidiary

The shared services agreement with the Adviser Subsidiary (the “Sharing Agreement”), provides the Adviser Subsidiary access to our human capital resources, including deal professionals, finance, and administrative functions, as well as other resources including infrastructure assets such as office space and technology. Under the terms of the Sharing Agreement, we allocate the related expenses of shared services to the Adviser Subsidiary. Our total net operating expenses for the three months ended September 30, 2024 and 2023, are net of expenses allocated to the Adviser Subsidiary of $2.2 million and $2.4 million, respectively and $7.9 million and $7.5 million for the nine months ended September 30, 2024 and 2023, respectively. The decrease in expenses allocated to the Adviser Subsidiary for the three months ended September 30, 2024 compared to 2023 is due to lower allocations to the Adviser Funds. The increase in expenses allocated to the Adviser Subsidiary for the nine months ended September 30, 2024 compared to 2023 is due to a result of higher average assets under management and higher allocations to the Adviser Funds. As of September 30, 2024 and December 31, 2023, there was less than $0.1 million and approximately $0.1 million due from the Adviser Subsidiary, respectively.

Net Realized Gains and Losses and Net Change in Unrealized Appreciation and Depreciation

Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Realized loss on debt extinguishment relates to additional fees, costs, and accelerated recognition of remaining debt issuance costs, which are recognized in the event debt is extinguished before its stated maturity. The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

81

---

Table of Contents

A summary of net realized gains and losses for the three and nine months ended September 30, 2024 and 2023 is as follows:

(in thousands)			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Realized gains			$	2,790					$	3,693					$	17,766					$	23,533
Realized losses			(3,291)						(6,280)						(14,950)						(17,956)
Realized foreign exchange gains (losses)			(58)						—						(991)						13
Net realized gains (losses)			$	(559)					$	(2,587)					$	1,825					$	5,590

During the three and nine months ended September 30, 2024, we recognized a net realized loss of $0.6 million and a net realized gain of $1.8 million, respectively. The net realized gains (losses) were generated from gross realized gains of $2.8 million and $17.8 million respectively, for the three and nine month periods, primarily from the sale of our equity and warrant positions in Palantir Technologies, TransMedics Group, Inc., Tarsus Pharmaceuticals, Inc., DoorDash, Inc., and sale proceeds from the completed acquisition of Delphix Corp. Our gains were offset by gross realized losses of $3.3 million and $15.0 million, respectively, for the three and nine month periods, from the write-off of equity and warrant investments in Proterra, Inc., The Faction Group LLC, Udacity, Inc., Humanigen, Inc., Eigen Technologies Ltd., ADMA Biologics, Inc., Sio Gene Therapies, Inc., Fulcrum Bioenergy, Inc., PDS Biotechnology Corporation, Polyera Corporation, Intuity Medical, Inc., and The Neat Company which had no value after the respective portfolio companies were acquired or dissolved. Additionally, we realized a loss of $9.1 million from write-off of our debt investments relating to Better Therapeutics, Inc. and Eigen Technologies Ltd., net of recovered collections of $6.0 million.

During the three and nine months ended September 30, 2023, we recognized net realized loss of $2.6 million and a net realized gain of $5.5 million, respectively. The net realized gains (losses) were generated from gross realized gains of $3.7 million and $23.5 million, respectively, for the three and nine month periods, primarily from the sale of our equity and warrant positions in Palantir Technologies, Provention Bio, Inc., TransMedics Group, Inc., Sprinklr, Inc., and Zeta Global Corp. Our gains were offset by gross realized losses of $6.3 million and $18.0 million, respectively, for the three and nine month periods, primarily from the write-off of equity and warrant investments in Concert Pharmaceuticals, Inc. and Fungible, Inc. which had no value after the respective portfolio companies were acquired, the write-off of our equity investments in Gynesonics, Inc., Paratek Pharmaceuticals, Inc. and Flowonix Medical Inc. as a result of capital markets transactions. Additionally, we realized a net $5.4 million loss from write-off of our debt investments in Codiak Biosciences, Inc. and Esme Learning Solutions, Inc., net of recovered collections of $17.5 million.

The net change in unrealized appreciation and depreciation of our investments is derived from the changes in fair value of each investment determined in good faith by our Valuation Committee and approved by the Board. The following table summarizes the change in net unrealized appreciation or depreciation of investments for the three and nine months ended September 30, 2024 and 2023:

			Three Months Ended September 30,												Nine Months Ended September 30,
(in thousands)			2024						2023						2024						2023
Gross unrealized appreciation on portfolio investments			$	28,782					$	34,458					$	86,226					$	130,577
Gross unrealized depreciation on portfolio investments			(38,093)						(75,113)						(126,780)						(115,661)
Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event			(1,587)						(4,396)						(11,498)						(20,904)
Net change in unrealized appreciation (depreciation) on portfolio investments			(10,898)						(45,051)						(52,052)						(5,988)
Other net changes in unrealized appreciation (depreciation)(1)			(2,996)						(1,189)						7,070						(289)
Total net change in unrealized appreciation (depreciation) on investments			$	(13,894)					$	(46,240)					$	(44,982)					$	(6,277)

(1)Includes the net change in unrealized appreciation (depreciation) related to derivative instruments and other assets and liabilities.

During the three months ended September 30, 2024 and 2023, we recorded approximately $13.9 million and $46.2 million of net unrealized depreciation, respectively, on our investments. During the nine months ended September 30, 2024

82

---

Table of Contents

and 2023, we recorded approximately $45.0 million and $6.3 million of net unrealized depreciation on our investments, respectively.

The following tables summarize the key drivers of change in net unrealized appreciation (depreciation) of investments for the three and nine months ended September 30, 2024 and 2023:

			For the Three Months Ended September 30, 2024																		For the Nine Months Ended September 30, 2024
(in thousands)			Debt						Equity, Warrants and Investment Funds(1)						Total						Debt						Equity, Warrants and Investment Funds(1)						Total
Investment valuation appreciation (depreciation)			$	(15,641)					$	6,330					$	(9,311)					$	(34,786)					$	(5,768)					$	(40,554)
Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event			(2,957)						1,370						(1,587)						(784)						(10,714)						(11,498)
Other net changes in unrealized appreciation (depreciation)			1,718						(4,714)						(2,996)						1,420						5,650						7,070
Net change in unrealized appreciation (depreciation)			$	(16,880)					$	2,986					$	(13,894)					$	(34,150)					$	(10,832)					$	(44,982)

			For the Three Months Ended September 30, 2023																		For the Nine Months Ended September 30, 2023
(in thousands)			Debt						Equity, Warrants and Investment Funds(1)						Total						Debt						Equity, Warrants and Investment Funds(1)						Total
Investment valuation appreciation (depreciation)			$	(30,528)					$	(10,127)					$	(40,655)					$	264					$	14,652					$	14,916
Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event			(9,271)						4,875						(4,396)						(17,696)						(3,208)						(20,904)
Other net changes in unrealized appreciation (depreciation)			(1,053)						(136)						(1,189)						267						(556)						(289)
Net change in unrealized appreciation (depreciation)			$	(40,852)					$	(5,388)					$	(46,240)					$	(17,165)					$	10,888					$	(6,277)

(1)Includes the net change in unrealized appreciation (depreciation) related to derivative instruments and other assets and liabilities.

Income and Excise Taxes

We account for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

Because federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.

The Adviser Subsidiary

Hercules Capital Management LLC through the Adviser Subsidiary has entered into investment management agreements (the “IMAs”) with the Adviser Funds. Pursuant to the IMAs, the Adviser Subsidiary provides investment advisory and management services to the Adviser Funds in exchange for an asset-based fee. In addition, Hercules Capital Management LLC through its control of the GP Interests for each of the Adviser Funds may receive certain incentive fee allocations. The Adviser Funds are privately offered investment funds exempt from registration under the 1940 Act that invest in debt and equity investments in venture or institutionally backed technology related and life sciences companies.

83

---

Table of Contents

The Adviser Subsidiary receives fee income for the services provided to the Adviser Funds. The Adviser Subsidiary’s contribution to our net investment income is derived from dividend income declared by the Adviser Subsidiary and interest income earned on loans to the Adviser Subsidiary. For the three months ended September 30, 2024 and 2023, $1.8 million and no dividends, respectively, were declared by the Adviser Subsidiary. For the nine months ended September 30, 2024 and 2023, $5.0 million and no dividends, respectively, were declared by the Adviser Subsidiary.

Financial Condition, Liquidity, Capital Resources and Obligations

Our liquidity and capital resources are derived from our debt borrowings and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our debt and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. We may also raise additional equity or debt capital through registered offerings off a shelf registration, At-the-Market (“ATM”), and private offerings of securities, by securitizing a portion of our investments, or by borrowing from the SBA through our SBIC subsidiaries. This “Financial Condition, Liquidity, Capital Resources and Obligations” section should be read in conjunction with the “Macroeconomic Market Developments” section above.

During the nine months ended September 30, 2024, we principally funded our operations from (i) cash receipts from interest, dividend, and fee income from our investment portfolio, (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments, (iii) borrowings on our credit facilities, and (iv) equity offerings.

During the nine months ended September 30, 2024, our operating activities used $88.8 million of cash and cash equivalents, compared to $62.6 million used during the nine months ended September 30, 2023. The $26.2 million increase in cash used in operating activities was primarily due to a $64.5 million increase in net purchases of investments offset by a $36.8 million increase in principal, fee repayments, and proceeds from the sale of debt investments.

During the nine months ended September 30, 2024, our investing activities used approximately $700 thousand of cash, compared to $390 thousand used during the nine months ended September 30, 2023. The $310 thousand increase in cash used in investing activities was due to an increase in purchases of capital equipment.

During the nine months ended September 30, 2024, our financing activities provided $17.5 million of cash, compared to $74.3 million provided during the nine months ended September 30, 2023. The $56.8 million decrease in cash flows from financing activities was primarily due to a $172.0 million decrease in equity issued and a $23.8 million increase in dividend distributions, offset by an increase in net borrowing activity of $126.0 million. During the nine months ended September 30, 2024, we distributed dividends of $225.6 million compared to $201.8 million during the nine months ended September 30, 2023. We also reduced the usage of our ATM program, which provided (net of offering costs) approximately $66.3 million and down from $238.3 million, during the nine months ended September 30, 2024 and 2023, respectively.

As of September 30, 2024, our net assets totaled $1.9 billion, with a NAV per share of $11.40. We intend to continue to operate in order to generate cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.

Available liquidity and capital resources as of September 30, 2024

As of September 30, 2024, we had $572.3 million in available liquidity, including $38.9 million in cash, cash equivalents, and available borrowing capacity of approximately $23.4 million under the SMBC Facility, $175.0 million under our SMBC letter of credit facility, $160.0 million under the MUFG Bank Facility, and $175.0 million of SBA Debentures, subject to certain conditions. Additional liquidity is available through accordion provisions within the terms of our Credit Facilities, through which the available borrowing capacity can be increased by an aggregate $475.0 million, subject to certain conditions. Further, the SMBC letter of credit facility may also be increased by an additional $225.0 million (up to $400.0 million), subject to certain conditions. Total amounts outstanding as of September 30, 2024, were $441.0 million outstanding under our Credit Facilities, which are floating interest rate obligations, and the remaining $1,310.0 million of term debt outstanding, which are all fixed interest rate debt obligations.

Not considered above, as of September 30, 2024, we held $5.1 million of cash classified as restricted cash. Our restricted cash relates to amounts that are held as collateral securing certain of our financing transactions, including collections of interest and principal payments on assets that are securitized related to the 2031 Asset-Backed Notes. Based on current characteristics of the securitized debt investment portfolios, the restricted funds may be used to pay monthly interest and principal on the securitized debt with any excess distributed to us or available for our general operations. Refer

84

---

Table of Contents

to “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our debt obligations.

The 1940 Act permits BDCs to incur borrowings, issue debt securities, or issue preferred stock unless immediately after the borrowings or issuance the ratio of total assets (less total liabilities other than indebtedness) to total indebtedness plus preferred stock is less than 200% (or 150% if certain requirements are met). On September 4, 2018 and December 6, 2018, our Board, including a “required majority” (as such term is defined in Section 57(o) of the 1940 Act) and our stockholders, respectively, approved the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act. As of September 30, 2024, our asset coverage ratio under our regulatory requirements as a BDC was 217.1% excluding our SBA debentures. Our exemptive order from the SEC allows us to exclude all SBA leverage from our asset coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 150%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total asset coverage when including our SBA debentures was 205.7% as of September 30, 2024.

The 1940 Act prohibits us from selling shares of our common stock at a price below the current NAV per share of such stock, with certain exceptions. One such exception is prior stockholder approval of issuances below NAV provided that our Board makes certain determinations. On August 16, 2024, we obtained authorization from our stockholders to issue common stock at a price below our then-current NAV per share for a twelve-month period which will expire on August 16, 2025.

As detailed above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe we have ample liquidity to support our near-term capital requirements. As the impact of the macro-economic events, potential global recession, acts of terrorism, war, geopolitical events, and the related disruption to markets and business continues to impact the economy, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the current circumstances.

Equity Offerings

We may from time-to-time issue and sell shares of our common stock through public or ATM offerings. We currently sell shares through our equity distribution agreement with JMP Securities LLC (“JMP”) and Jefferies LLC (“Jefferies”) (the “2023 Equity Distribution Agreement”) entered into on May 5, 2023. The 2023 Equity Distribution Agreement provides that we may offer and sell up to 25.0 million shares of our common stock from time to time through JMP or Jefferies, as our sales agents. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. We generally use net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of September 30, 2024, approximately 13.6 million shares remain available for issuance and sale under the current equity distribution agreement.

During the three and nine months ended September 30, 2024, we issued and sold zero and 3.7 million shares of our common stock receiving total accumulated net proceeds of zero and $66.4 million, respectively. This is a decrease from the approximately $107.6 million and $238.3 million of accumulated net proceeds received from the issuance and sale of 6.5 million shares and 16.2 million shares, respectively, during the three and nine months ended September 30, 2023.

Commitments and Obligations

Our significant cash requirements generally relate to our debt obligations. As of September 30, 2024, we had $1,751.0 million of debt outstanding, $170.0 million within the next year, $1,216.0 million within 1 to 3 years, and $365.0 million beyond 3 years.

In addition to our debt obligations, in the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet.

Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made unfunded commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold.

85

---

Table of Contents

Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. As such, our disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones. Refer to “Note 11 – Commitments and Contingencies” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our unfunded commitments.

As of September 30, 2024, we had approximately $489.0 million of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones, as well as uncalled capital commitments to make investments in private equity funds. In order to draw a portion of the Company's available unfunded commitments, a portfolio company must submit to the Company a formal funding request that complies with the applicable advance notice and other operational requirements. The available unfunded commitments excludes unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) $152.2 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds.

Additionally, we had approximately $180.5 million of non-binding term sheet outstanding to five new companies and one existing company, which generally convert to contractual commitments within approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

The fair value of our unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations embedded in the borrowing agreements.

Critical Accounting Policies and Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.

For a description of our critical accounting policies, refer to “Note 2 – Summary of Significant Accounting Policies” included in the notes to our consolidated financial statements appearing elsewhere in this report. We consider the most significant accounting policies to be those related to our Valuation of Investments, Fair Valuation Measurements, Income Recognition, and Income Taxes. The valuation of investments is our most significant critical estimate. The most significant input to this estimate is the yield interest rate, which includes the hypothetical market yield plus premium or discount adjustment, used in determining the fair value of our debt investments. The following table shows the approximate increase (decrease) to the fair value of our debt investments from hypothetical change to the yield interest rates used for each valuation, assuming no other changes:

(in thousands)						Change in unrealized appreciation (depreciation)
Basis Point Change
(100)						$	48,570
(50)						$	26,165
50						$	(28,321)
100						$	(57,107)

For a further discussion and disclosure of key inputs and considerations related to this estimate, refer to “Note 3 – Fair Value of Financial Instruments” included in the notes to our consolidated financial statements appearing elsewhere in this report.

86

---

Table of Contents

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our investment income will be affected by changes in various interest rates, including Prime, SOFR, and BSBY rates, to the extent our debt investments include variable interest rates. As of September 30, 2024, approximately 97.3% of the loans in our portfolio had variable rates based on floating Prime, SOFR, or BSBY rates with a floor. The majority of our loans are linked to the Prime rate and comprise 75.5% of the loan portfolio, and have a weighted average Prime floor of 6.9% as of September 30, 2024. Our SOFR or BSBY indexed debt investments have weighted average index floors of approximately 1.0% as of September 30, 2024. Our debt borrowings under the Credit Facilities bear interest at a floating rate, all other outstanding debt borrowings bear interest at a fixed rate. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.

Based on our Consolidated Statements of Assets and Liabilities as of September 30, 2024, the following table shows the approximate annualized increase (decrease) in components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and debt:

(in thousands)						Interest Income						Interest Expense						Net Income						EPS
Basis Point Change
(200)						$	(32,024)					$	(8,196)					$	(23,828)					$	(0.15)
(100)						$	(17,644)					$	(4,098)					$	(13,546)					$	(0.08)
(75)						$	(13,426)					$	(3,073)					$	(10,353)					$	(0.06)
(50)						$	(9,286)					$	(2,049)					$	(7,237)					$	(0.04)
(25)						$	(4,873)					$	(1,024)					$	(3,849)					$	(0.02)
25						$	5,577					$	1,024					$	4,553					$	0.03
50						$	11,586					$	2,049					$	9,537					$	0.06
75						$	18,931					$	3,073					$	15,858					$	0.10

We generally do not engage in hedging activities. From time-to-time, we may hedge against interest rate fluctuations and foreign currency by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates and foreign currency, they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the nine months ended September 30, 2024, we have entered into a foreign currency forward to limit our foreign currency exposure with respect to the British Pound. For additional information refer to “Note 4 – Investments”, included in the notes to our consolidated financial statements appearing elsewhere in this report.

Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including our debt borrowings and use of our Credit Facilities that could affect the net increase in net assets resulting from operations, or net income. It also does not assume any repayments from our portfolio companies. Accordingly, no assurances can be given that actual results would not differ materially from the statement above.

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio. For additional information regarding the interest rate associated with each of our debt borrowings, refer to Item 2 - “Financial Condition, Liquidity and Capital Resources” in this quarterly report on Form 10-Q and “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report.

87

---

Table of Contents

ITEM 4.    CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company’s chief executive and chief financial officers, under the supervision and with the participation of the Company’s management, conducted an evaluation of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d- 15(e) under the Exchange Act. As of the end of the period covered by this quarterly report on Form 10-Q, the Company’s chief executive and chief financial officers have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in reports that the Company files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s chief executive and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

88

---

Table of Contents

PART II: OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.

ITEM 1A.    RISK FACTORS

In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 15, 2024 (the “Annual Report”).

Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.

Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected, and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies as of September 30, 2024 that represent greater than 5% of our net assets:     

(in thousands)			September 30, 2024
			Fair Value						Percentage of Net Assets
Axsome Therapeutics, Inc.			$	165,469					8.9		%
Phathom Pharmaceuticals, Inc.			$	160,907					8.7		%
Marathon Health, LLC			$	157,857					8.5		%
Corium, Inc.			$	110,394					6.0		%
SeatGeek, Inc.			$	109,152					5.9		%

•Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options.

•Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.

•Marathon Health, LLC is a provider of employer-sponsored healthcare platform intended to provide convenient and unhurried patient-centered care services.

•Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport.

•SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and theater events.

Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

89

---

Table of Contents

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

Dividend Reinvestment Plan

During the nine months ended September 30, 2024, we issued 342,129 shares of common stock to stockholders in connection with the dividend reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act. The aggregate value of the shares of our common stock issued under our dividend reinvestment plan was approximately $6.3 million.

ITEM 3.    DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.    MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5.    OTHER INFORMATION

Rule 10b5-1 Trading Plans

On June 27, 2024, Scott Bluestein, chief executive officer and director, adopted a written plan for the sale of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan covered the sale of up to 100,000 shares of the Company’s common stock over a period commencing after the later of (1) 91 days from the adoption date or (2) the earlier of (a) the third business day following the public disclosure of the Company’s financial results on Form 10-Q for the quarter ended June 30, 2024 or (b) 121 days after the adoption date, and terminated on December 15, 2024 or upon the earlier completion of all authorized transactions under the plan. On September 26, 2024, all authorized transactions were completed under the plan and the plan terminated.

During the third quarter ended September 30, 2024, no other directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

90

---

Table of Contents

ITEM 6.    EXHIBITS

Exhibit Number			Description
3(a)			Articles of Amendment and Restatement.(1)
3(b)			Articles of Amendment, dated March 6, 2007.(2)
3(c)			Articles of Amendment, dated April 5, 2011.(3)
3(d)			Articles of Amendment, dated April 3, 2015.(4)
3(e)			Articles of Amendment, dated February 23, 2016.(5)
3(f)*			Articles of Amendment, dated October 28, 2024.
3(g)			Amended and Restated Bylaws of Hercules Capital, Inc.(5)
31.1*			Chief Executive Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*			Chief Financial Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*			Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*			Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*			Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*			Inline XBRL Taxonomy Extension Schema Document.
101.CAL*			Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*			Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*			Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*			Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104			The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, has been formatted in Inline XBRL

_____________________________________

*Filed herewith.

(1)Previously filed as part of Pre-Effective Amendment No. 1, as filed on May 17, 2005 (File No. 333-122950) to the Registration Statement on Form N-2 of the Company.

(2)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 9, 2007.

(3)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on April 11, 2011.

(4)Previously filed as part of the Registration Statement on Form N-2 of the Company, as filed on April 20, 2015 (File No. 333-203511).

(5)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 20, 2020.

91

---

Table of Contents

Schedule 12 – 14

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

For the Nine Months Ended September 30, 2024 (unaudited)

(in thousands)						Investment(1)						Amount of Interest, Dividends, and Fees Credited to Income(2)						Realized Gain (Loss)						Fair Value as of December 31, 2023						Gross Additions(3)						Gross Reductions(4)						Net Change in Unrealized Appreciation/ (Depreciation)						Fair Value as of September 30, 2024
Portfolio Company
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC(8)						Preferred Stock						$	—					$	—					$	260					$	—					$	—					$	58					$	318
						Common Stock						—						—						2						—						—						(1)						1
Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC)(5)						Unsecured Debt						4,034						—						34,478						1,155						—						—						35,633
						Member Units						—						—						28,034						—						—						(6,365)						21,669
Hercules Adviser LLC(6)						Unsecured Debt						5,457						—						12,000						—						—						—						12,000
						Member Units						—						—						28,713						—						—						2,720						31,433
Total Majority Owned Control Investments												$	9,491					$	—					$	103,487					$	1,155					$	—					$	(3,588)					$	101,054
Other Control Investments
Tectura Corporation(7)						Senior Debt						$	518					$	—					$	8,250					$	—					$	—					$	—					$	8,250
						Preferred Stock						—						—						3,263						—						—						524						3,787
						Common Stock						—						—						4						—						—						2						6
Total Other Control Investments												$	518					$	—					$	11,517					$	—					$	—					$	526					$	12,043
Total Control Investments												$	10,009					$	—					$	115,004					$	1,155					$	—					$	(3,062)					$	113,097

(1)Stock and warrants are generally non-income producing and restricted.

(2)Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment.

(3)Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities.

(4)Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period.

(5)As of March 31, 2018, the Company's investment in Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) became classified as a control investment as a result of obtaining a controlling financial interest. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.

(6)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.

(7)As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018.

(8)As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company

92

---

Table of Contents

Schedule 12 – 14

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

For the Nine Months Ended September 30, 2023 (unaudited)

(in thousands)						Investment(1)						Amount of Interest and Fees Credited to Income(2)						Realized Gain (Loss)						Fair Value as of December 31, 2022						Gross Additions(3)						Gross Reductions(4)						Net Change in Unrealized Appreciation/ (Depreciation)						Fair Value as of September 30, 2023
Portfolio Company
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC(8)						Preferred Stock						$	—					$	—					$	313					$	—					$	—					$	(68)					$	245
						Common Stock						—						—						6						—						—						(4)						2
Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC)(5)						Unsecured Debt						2,359						—						21,700						9,872						—						2,867						34,439
						Member Units						—						—						15,244						4,500						—						1,809						21,553
Hercules Adviser LLC(6)						Unsecured Debt						455						—						12,000						—						—						—						12,000
						Member Units						—						—						19,153						—						—						9,515						28,668
Total Majority Owned Control Investments												$	2,814					$	—					$	68,416					$	14,372					$	—					$	14,119					$	96,907
Other Control Investments
Tectura Corporation(7)						Senior Debt						$	516					$	—					$	8,042					$	—					$	—					$	(1,799)					$	6,243
						Preferred Stock						—						—						—						—						—						—						—
						Common Stock						—						—						—						—						—						—						—
Total Other Control Investments												$	516					$	—					$	8,042					$	—					$	—					$	(1,799)					$	6,243
Total Control Investments												$	3,330					$	—					$	76,458					$	14,372					$	—					$	12,320					$	103,150

(1)Stock and warrants are generally non-income producing and restricted.

(2)Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment.

(3)Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities.

(4)Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period.

(5)As of March 31, 2018, the Company's investment in Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) became classified as a control investment as a result of obtaining a controlling financial interest. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.

(6)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to "Note 1" for additional disclosure.

(7)As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018.

(8)As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company.

93

---

Table of Contents

Schedule 12 – 14

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

As of September 30, 2024 (unaudited)

(in thousands)						Industry						Type of Investment(1)						Maturity Date						Interest Rate and Floor						Principal or Shares						Cost						Value(2)
Portfolio Company
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC						Medical Devices & Equipment						Preferred Series A Equity																		5,000,000						$	250					$	318
						Medical Devices & Equipment						Common Stock																		180,000						—						1
Total Coronado Aesthetics, LLC																																				$	250					$	319
Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC)(3)						Diversified Financial Services						Unsecured Debt						September 2026						FIXED 3.45%, PIK Interest 8.05%						$	26,033					25,774						25,774
						Diversified Financial Services						Unsecured Debt						September 2026						FIXED 11.95%						$	10,000					9,859						9,859
						Diversified Financial Services						Member Units																		1						34,006						21,669
Total Gibraltar Acquisition, LLC																																				$	69,639					$	57,302
Hercules Adviser LLC(4)						Diversified Financial Services						Unsecured Debt						June 2025						FIXED 5.00%						$	12,000					12,000						12,000
						Diversified Financial Services						Member Units																		1						35						31,433
Total Hercules Adviser LLC																																				$	12,035					$	43,433
Total Majority Owned Control Investments (5.46%)*																																				$	81,924					$	101,054
Other Control Investments
Tectura Corporation						Consumer & Business Services						Senior Secured Debt						January 2027						FIXED 8.25%						$	8,250					$	8,250					$	8,250
						Consumer & Business Services						Common Stock																		414,994,863						900						6
						Consumer & Business Services						Preferred Series BB Equity																		1,000,000						—						15
						Consumer & Business Services						Preferred Series C Equity																		3,235,298						13,263						3,772
Total Tectura Corporation																																				$	22,413					$	12,043
Total Other Control Investments (0.65%)*																																				$	22,413					$	12,043
Total Control Investments (6.11%)*																																				$	104,337					$	113,097

*Value as a percent of net assets

(1)Stock and warrants are generally non-income producing and restricted.

(2)All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

(3)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.

(4)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.

94

---

Table of Contents

Schedule 12 – 14

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES

As of and for the year ended December 31, 2023

(in thousands)						Industry						Type of Investment(1)						Maturity Date						Interest Rate and Floor						Principal or Shares						Cost						Value(2)
Portfolio Company
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC						Medical Devices & Equipment						Preferred Series A Equity																		5,000,000						$	250					$	260
						Medical Devices & Equipment						Common Stock																		180,000						—						2
Total Coronado Aesthetics, LLC																																				$	250					$	262
Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC)(3)						Diversified Financial Services						Unsecured Debt						September 2026						Interest rate FIXED 11.50%						$	25,000					24,663						24,663
						Diversified Financial Services						Unsecured Debt						September 2026						Interest rate FIXED 11.95%						$	10,000					9,815						9,815
						Diversified Financial Services						Member Units																		1						34,006						28,034
Total Gibraltar Acquisition, LLC																																				$	68,484					$	62,512
Hercules Adviser LLC(4)						Diversified Financial Services						Unsecured Debt						June 2025						Interest rate FIXED 5.00%						$	12,000					12,000						12,000
						Diversified Financial Services						Member Units																		1						35						28,713
Total Hercules Adviser LLC																																				$	12,035					$	40,713
Total Majority Owned Control Investments (5.74%)*																																				$	80,769					$	103,487
Other Control Investments
Tectura Corporation						Consumer & Business Services						Senior Secured Debt						July 2024						Interest rate FIXED 8.25%						$	8,250					$	8,250					$	8,250
						Consumer & Business Services						Common Stock																		414,994,863						900						4
						Consumer & Business Services						Preferred Series BB Equity																		1,000,000						—						12
						Consumer & Business Services						Preferred Series C Equity																		3,235,298						13,263						3,251
Total Tectura Corporation																																				$	22,413					$	11,517
Total Other Control Investments (0.64%)*																																				$	22,413					$	11,517
Total Control Investments (6.38%)*																																				$	103,182					$	115,004

*Value as a percent of net assets

(1)Stock and warrants are generally non-income producing and restricted.

(2)All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

(3)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment

Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance,

LLC, respectively.

(4)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.

95

---

Table of Contents

SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

						HERCULES CAPITAL, INC. (Registrant)
Dated: October 30, 2024						/S/ SCOTT BLUESTEIN
						Scott Bluestein
						President, Chief Executive Officer, and Chief Investment Officer
Dated: October 30, 2024						/S/ SETH H. MEYER
						Seth H. Meyer
						Chief Financial Officer, and Chief Accounting Officer

96